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In 1926, almost 90 years ago, the first case of what is now known as von Willebrand 
disease (VWD), was published in the Finish scientific journal Finnish society of Medicine 
[1,2]. Prof. dr. Erik von Willebrand described in this journal his first case of an inher-
itable bleeding disorder that he had observed in several members of a family from 
the Åland islands. The dominating symptoms of the disorder consisted of nose bleed-
ing, bleeding from the gums, bleeding from the female genital tract and bleeding from 
trivial wounds. His first case was that of a young girl, Hjördis. Already at a young age 
the girl had experienced several severe bleeding episodes. At the age of 13, she bled to 
death during her fourth menstrual period. Von Willebrand concluded that the fam-
ily suffered from a previously unknown hemophilia condition, which in contrast to 
hemophilia affected both sexes, and called it hereditary pseudohemophilia. In 1957 
Nilsson and co-workers concluded that the impaired clot formation was due to the 
lack of a plasma factor, the von Willebrand factor (VWF), which was present in both 
normal and in hemophilia A plasma [3,4]. 
Von Willebrand Disease
A decreased concentration or abnormal function of VWF is responsible for VWD, 
the most common inherited bleeding disorder with an estimated prevalence ranging 
from 0.035% to 1.3% of the population [5-7]. Prevalence based on the number of pa-
tients registered at specialized centers is much lower than estimates based on pop-
ulation screenings. Patients registered at hemostasis centers probably have a more 
symptomatic phenotype, while individuals identified during screenings only have a 
mild form of the disease [6,8]. VWD is a heterogeneous disorder, which resulted in 
the initial description of more than 20 subtypes. The current classification merged 
these into a total of 6 subgroups (Table 1) [9]. A reduced concentration of structurally 
normal VWF is classified as type 1 VWD. Qualitatively abnormal variants of VWF are 




Table 1. VWD Classification
VWD Subtype Description*
Type 1 Partial quantitative deficiency of VWF.
Type 2A Qualitative VWF defect resulting in a reduction of VWF-dependent platelet adhesion.
Type 2B Qualitative VWF defect resulting in increased VWF-dependent platelet adhesion.
Type 2M Qualitative VWF defect associated with specific defects in platelet/VWF interaction but with a normal range of multimers.
Type 2N Qualitative VWF defect resulting from defective VWF binding to factor VIII (FVIII) and consequently low levels of circulating 
FVIII.
Type 3 Clinically severe quantitative disorder resulting from a markedly reduced or absent platelet and plasma VWF (less than 5U/dL). 
Consequently, FVIII activity is also reduced.
*From the ISTH-SSC VWF Online Database [10] and the latest classification update [9].
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the VWF protein is classified as type 3 VWD. Treatment of VWD is based on increasing 
plasma levels of functional VWF. This may be achieved by infusion of exogenous VWF 
concentrate or by releasing endogenous VWF from the endothelial storage organelles 
Weibel-Palade bodies (WPB), via administration of DDAVP. Therefore treatment with 
DDAVP is only useful in type 1 VWD and in some cases of type 2 VWD.
Von Willebrand factor
VWF is a glycoprotein circulating in plasma as large multimers. When activated upon 
vascular damage VWF serves as an adhesion molecule for platelets thereby initiat-
ing platelet plug formation. VWF is also the carrier protein of coagulation factor VIII 
(FVIII)(Figure 1). VWF synthesis is restricted to endothelial cells and megakaryocytes 
[11,12]. Upon translocation to the endoplasmic reticulum, VWF dimerizes through the 
formation of C-terminal disulfide bonds at the CK-domains of the VWF monomers 
[13]. In the endoplasmic reticulum N-linked glycosylation is initiated. The dimers are 
transported to the Golgi apparatus where the N-linked glycosylation is completed and 
O-linked sugars are added [14]. In the trans Golgi network dimers form multimers via 
N-terminal disulfide bonds at the D’D3 domain and the VWF propeptide (VWFpp) is 




Figure 1. Schematic representation of the VWF monomer structure. The domain structure [32] and functional 
binding sites of VWF. The different types of structural domains are indicated by different colours. The signal 
peptide (SP) and propeptide are cleaved upon translocation into the endoplasmic reticulum and in the Golgi 
apparatus respectively. The locations of the intersubunit disulfide bonds (S-S) are shown in the CK and D3 
domains, which are important for the formation of VWF dimers and multimers, respectively. Locations of known 
binding sites are shown for VWF ligands as well as the cleavages sites for VWF proteases. FVIII, factor VIII; GP, 
glycoprotein; PSGL-1, P-selectin glycoprotein ligand-1; ADAMTS13, a distintegrin and metalloproteinase with a 
thrombospondin type 1 motif member 13; MMP9, matrix metalloprotease 9; IGFBP7, insulin-like growth factor-
binding protein 7.
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creted constitutively into the plasma, where it has a variable half-life of about 12 hours 
[16]. The remaining VWF is stored in cell-specific organelles; WPB in endothelial cells 
or α-granules in megakaryocytes. The highest molecular weight VWF multimers are 
stored and thus are released at sites of vascular damage in response to secretion stim-
uli like thrombin, stress, vasopressin or its synthetic analogue desmopressin (DDAVP) 
[17,18](Figure 2).
After secretion into the plasma the large VWF multimers are proteolytically cleaved 
by ADAMTS13 (A Disintegrin and Metalloproteinase with a Thrombospondin type 1 
motif). The ADAMTS13 cleavage site in the A2 domain of VWF is accessible only after 
partial unfolding of VWF, which is most likely induced by the shear stress exerted 
on VWF after binding to the endothelial surface [19] or exposed collagen [20]. The 




Figure 2. Schematic illustration of VWF metabolism. The structure of precursor VWF is indicated by different 
colors; red for signal peptide, blue for VWFpp (D1-D2 domains), green for D’D3 domains, white for A1-C6 domains 
and orange for CK domain. Important steps in VWF synthesis are removal of the signal peptide, dimerization and 
multimerization of proVWF and cleavage of the VWFpp resulting in mature multimers lacking VWFpp. Multimers 
are assembled in tubules and packed into WPB. WPB fuse with the plasma membrane upon stimulation of 
endothelial cells, allowing secretion of the ultra-large (UL) VWF strings. Under shear stress ULVWF can self-
associate, leading to enormous VWF strands. Blood platelets (red circles) adhere with high affinity to ULVWF. 
ADAMTS13 cleaves ULVWF, giving rise to plasma VWF. Proteolyzed VWF is then (mainly) cleared by specific 
liver-macrophages, the Kupffer cells. ER, endoplasmic reticulum; TGN, trans Golgi network.
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Intravenous injection of VWF in VWF deficient mice led to accumulation of the bulk 
of VWF in the liver. However, it was also found in a number of other organs, like the 
spleen, kidneys and lungs. When taking the size of the organs into account, VWF is 
taken up relatively efficient by both liver and spleen in particular [21]. Macrophages 
in both liver and spleen seem to contribute to the removal of VWF from the circula-
tion and several receptors are now identified which are capable of binding VWF, for 
example C-type lectin domain family 4 member M (CLEC4M), Sialic acid-binding im-
munoglobulin-type lectins 5 (Siglec-5), Low density lipoprotein receptor-related pro-
tein 1 (LRP1) and Asialoglycoprotein receptor (ASGPR). These ligands could therefore 
mediate the removal of VWF from the circulation [22](Figure 2). 
VWF is capable of inducing cell-signalling pathways beyond hemostasis and is asso-
ciated with several other pathophysiological processes. For example, VWF seems to 
actively participate in the inflammatory response. Platelet-decorated VWF strings re-
leased from endothelial cells can recruit leukocytes under conditions of high shear 
stress [23] and VWF promotes leukocyte extravasation [24]. VWF seems to negatively 
regulate angiogenesis [25], the process of formation of new blood vessels from 
pre-existing vessels. VWF seems to regulate angiogenesis via multiple intracellular 
and extracellular pathways involving the VWF ligands αvβ3 and angiopoietin-2. But 
other pathways may also be involved since galectin-3, osteoprotegerin and insulin-like 
growth factor binding protein 7 (IGFBP7), are also found to be involved in angiogen-
esis and are associated with VWF inside and outside the endothelium [26-28]. While 
VWF limits the Vascular Endothelial Growth Factor (VEGF)-induced proliferation of 
endothelial cells [25], the opposite effect is observed for smooth muscle cells [29], 
suggesting that VWF could play a role in the thickening of the vascular wall. Besides 
modulating proliferation of cells, VWF can also induce apoptosis. The interaction of 
VWF with the platelet receptor GPIbα induces apoptotic events in platelets [30]. This 
pro-apoptotic property of VWF seems not restricted to platelets only. Tumor cells 
have a higher metastatic potential in the absence of VWF. The inhibitory effect of VWF 
on tumor cell survival is probably via the interaction with the integrin αvβ3. Certain 
tumor cells have armed themselves against VWF via the production of ADAM28, a 
protease that cleaves VWF in a shear dependent manner [31]. So, apart from its role in 
hemostasis, it has recently become clear that VWF is a much more complex multifac-
eted protein than initially thought. Several aspects of the metabolism and function of 
VWF were studied in the different chapters of this thesis.
Outline of the Thesis
Part 1: Aspects of synthesis and secretion of VWF
Chapter 2 gives an overview of factors that influence VWF plasma levels. Besides mu-
tations within the VWF gene that can lead to impaired synthesis, secretion or clear-
ance, also other factors influencing plasma VWF levels are described, showing that 
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variants with impaired intrachain (p.Cys1130Phe and p.Cys2671Tyr) and interchain 
(p.Cys2773Ser) disulfide bonds on the biogenesis and exocytosis of WPB. We showed 
that natural mutations of cysteines involved in the formation of interchain disulfide 
bonds do not affect either the storage in WPB or secretion of von Willebrand factor, 
whereas mutations of cysteines forming intrachain disulfide bonds lead to reduced 
von Willebrand factor storage and secretion because the von Willebrand factor is re-
tained in the endoplasmic reticulum. Expression studies for storage and secretion 
of VWF with mutations in A domains are limited, we therefore studied in Chapter 
4 the storage and secretion properties of 6 different mutant VWF molecules charac-
terized by mutations within the A domains of VWF. Three mutations in the A1 do-
main (pSer1285Pro, p.Leu1307Pro and p.Arg1374His), two mutations in the A2 do-
main (p.Arg1583Trp and p.Tyr1584Cys) and one mutation in the A3 domain of VWF 
(p.Val1822Gly) were transiently transfected into HEK293 cells to analyze the biogene-
sis and exocytosis of WPB.
Part 2: Aspects of clearance of VWF
Individuals with blood group O have approximately 25% lower plasma VWF levels. The 
general assumption is that VWF covered with blood group O antigens (H-antigens), is 
cleared faster, via yet unknown mechanisms, compared to VWF with A or B antigens 
present. We therefore studied in Chapter 5 the clearance rates of VWF obtained from 
donors with either blood group A, B or O. However, we could not demonstrate the as-
sumed faster clearance of O-VWF, instead we showed that within one individual there 
is no difference in clearance between the different blood groups. We therefore think 
that the blood group O individuals clear VWF faster compared to non-O individuals, 
but that this faster clearance is independent of the blood group antigens present on 
VWF. Faster clearance of the VWF protein is one of the mechanisms leading to de-
creased VWF plasma levels and subsequently bleeding phenotypes. Mature VWF and 
VWF propeptide are released in equimolar amounts in the plasma, but the half-lives 
differ. The ratio between these two parameters can therefore be used to discriminate 
between normal and accelerated VWF clearance. In Chapter 6, by using the VWFpp/
VWF:Ag and FVIII:C/VWF:Ag ratios, we aimed to define the pathophysiology of 658 
type 1, 2 and 3 VWD patients included in the Willebrand in the Netherlands (WiN) 
cohort.
Part 3: Aspects of VWF beyond hemostasis
It has recently been shown that VWF can act as a negative regulator of angiogene-
sis. VWF is stored in endothelial cells in WPB together with angiopoietin-2, osteo-
protegerin and galectin-3. These proteins are known to mediate angiogenesis. We 
hypothesized in Chapter 7 that defects in VWF, potentially leading to impaired or 
loss of WPB formation, result in dysregulated release of angiogenic mediators in 
the circulation. Using the WiN cohort (see Chapter 6) plasma samples of 655 type 
1, 2 and 3 VWD patients were analyzed for their angiopoietin-1, angiopoietin-2, 
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Blood Outgrowth Endothelial Cells (BOECs) isolated from type 1 and 2 von Willebrand 
disease (VWD) patients showed enhanced in vitro angiogenesis compared with BOECs 
from healthy individuals. Characterisation of the angiogenic capacity of BOECs from 
VWD patients is however, limited and differences between the different types of VWD 
have not been investigated in detail. We therefore examined in Chapter 8 the angio-
genic capacity of BOECs from 11 patients diagnosed with type 1, type 2 and type 3 VWD. 
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Abstract
Von Willebrand Disease (VWD) is a bleeding disorder characterized by reduced plas-
ma von Willebrand factor (VWF) levels (VWD types 1 and 3) or functionally abnor-
mal VWF (VWD type 2). Type 1 VWD is the most frequent form and leads to mild or 
moderate bleeding tendencies. Low plasma levels in type 1 VWD patients are the re-
sult from mutations in the VWF gene, leading to decreased synthesis, impaired se-
cretion, increased clearance of VWF or a combination of these conditions. Several 
studies have shown that genetic changes within the VWF gene are common and are 
highly penetrant in the more severe type 1 VWD cases. However, in approximately 30 
to 40% of the index cases no (causative) mutations were found, suggesting that other 
factors outside the VWF gene can determine VWF plasma levels. Factors such as ABO 
blood group, platelet α2β1 polymorphisms, age, and hormonal alterations have major 
influences on VWF levels and/or bleeding phenotype. This illustrates that VWD is a 
complex multifactorial disease, with inter-relating genetic and environmental com-
ponents contributing to the variable phenotype of the disease. So despite the growing 
understanding of the pathophysiology of VWD, the diagnosis is often difficult because 
of the many factors influencing VWF levels. 
Introduction
Von Willebrand factor (VWF) is a glycoprotein circulating in plasma as large multim-
ers. When activated upon vascular damage VWF serves as an adhesion molecule for 
platelets thereby initiating platelet plug formation. VWF is also the carrier protein 
of coagulation factor VIII (FVIII). VWF synthesis is restricted to endothelial cells and 
megakaryocytes [1,2]. Upon translocation to the endoplasmic reticulum (ER), VWF 
dimerizes through the formation of C-terminal disulfide bonds at the CK-domains of 
the VWF monomers [3]. In the ER N-linked glycosylation is initiated. The dimers are 
transported to the Golgi apparatus where the N-linked glycosylation is completed and 
O-linked sugars are added [4]. In the trans Golgi network dimers form multimers via 
N-terminal disulfide bonds at the D’D3 domain and the propeptide is proteolytically 
removed [5]. Part of the synthesized VWF multimers is secreted constitutively into 
the plasma, where it has a variable half-life of about 12 hours. The remaining VWF 
is stored in cell-specific organelles; the Weibel-Palade bodies (WPB) in endothelial 
cells or α-granules in megakaryocytes. The highest molecular weight VWF multim-
ers are stored and thus are released at sites of vascular damage in response to secre-
tion stimuli like thrombin, stress, vasopressin or its synthetic analogue desmopressin 
(DDAVP). After secretion into the plasma the large VWF multimers are proteolytically 
cleaved by ADAMTS13 (A Disintegrin and Metalloproteinase with Thrombospondin 
motifs). The ADAMTS13 cleavage site in the A2 domain is accessible only after partial 
unfolding of VWF, which is most likely induced by the shear stress exerted on VWF 
after binding to the endothelial surface [6]. The mechanisms involved in clearance 
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mice led to accumulation of the bulk of VWF in the liver [7]. However, it was also 
found in a number of other organs, like the spleen, kidneys and lungs. When taking 
the size of the organs into account, VWF is taken up relatively efficient by both liver 
and spleen in particular.  Recently it was shown that the Ashwell receptor on hepato-
cytes is capable of binding VWF which lacks its sialic acid group [8]. Macrophages in 
both liver and spleen seem to contribute to the removal of VWF from the circulation 
[7] and several receptors are now identified which are capable of binding VWF, for ex-
ample CLEC4M, Siglec-5, LRP1 and ASGPR [9]. These ligands could therefore mediate 
the removal of VWF from the circulation. 
Von Willebrand Disease
A decreased concentration or an abnormal function of the VWF protein is responsible 
for von Willebrand Disease (VWD), the most common inherited bleeding disorder 
with an estimated prevalence ranging from 3-4 per 100.000 to 1.3% of the population 
[10]. Prevalences based on the number of patients registered at specialized centers 
are much lower than estimates based on population screenings. Patients registered 
at hemostasis centers probably have a more symptomatic phenotype, while people 
identified during screening only have a mild form of the disease [11,12.] VWD is a het-
erogeneous disorder, which resulted in initial description of more than 20 subtypes. 
The current classification merged these to a total of 6 subgroups (Table 1) [13]. 
A reduced concentration of structurally normal VWF is classified as type 1 VWD. Qual-
itatively abnormal variants of VWF are classified as type 2 VWD (with subgroups 2A, 
2B, 2M and 2N). Complete deficiency of the VWF protein is classified as type 3 VWD.13 
For an update on type 3 VWD see Leebeek and De Wee [14]. 
Treatment of VWD is based on increasing functional plasma VWF levels. This may be 




Table 1. VWD Classification
VWD Subtype Description*
Type 1 Partial quantitative deficiency of VWF. Multimers may be abnormal, but the proportion of large multimers is not significantly 
decreased. Typically autosomal dominant in inheritance although diagnosis is complicated by reduced penetrance and 
variable expressivity.
Type 2A Qualitative VWF defect resulting in a reduction of VWF-dependent platelet adhesion. Associated with absence of the largest 
multimers. Generally autosomal dominant.
Type 2B Qualitative VWF defect resulting in increased VWF-dependent platelet adhesion. Associated with (usually) reduced high 
molecular weight multimers and often reduced platelet counts. Inheritance is autosomal dominant.
Type 2M Qualitative VWF defect associated with specific defects in platelet/VWF interaction but with a normal range of multimers. 
Inheritance is autosomal dominant.
Type 2N Qualitative VWF defect resulting from defective VWF binding to FVIII and consequently low levels of circulating FVIII. 
Inheritance is autosomal recessive.
Type 3 Clinically severe quantitative disorder resulting from a markedly reduced or absent platelet and plasma VWF (less than 5U/
dL). Consequently, FVIII activity is also reduced. Inheritance is autosomal recessive.
*From the ISTH-SSC VWF Online Database [10] and the latest classification update [9].
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stored in WPBs, via administration of DDAVP. Therefore treatment with DDAVP is 
only useful in type 1 VWD and in some cases of type 2 VWD. Responsiveness to DDAVP 
varies per person, but is rather stable intra-individually. Normally it will give a 2 to 
4-fold rise in VWF and FVIII levels. Clinical effectiveness to prevent or control bleed-
ing symptoms depends therefore (largely) on the plasma VWF levels achieved after 
administration, which in turn depends primarily on the basal levels in the patient. 
DDAVP is mainly effective in patients with baseline VWF ristocetin cofactor activity 
(VWF:Rco) and FVIII coagulant activity levels higher than 10U/dL [15].  
Type 1 Von Willebrand Disease
While type 3 is rare (1 in 1 million), type 1 VWD is the most common form of the dis-
ease (approximately 50-75% of all VWD cases). VWD type 1 is characterized by reduc-
tions in VWF antigen (VWF:Ag), VWF:Rco as well as FVIII, resulting in mild to mod-
erate bleeding tendency. The distribution pattern of the VWF multimers is normal. 
Diagnosis of type 1 VWD can be difficult, especially in cases with mild symptoms, as it 
is hard to distinguish them from healthy individuals who have VWF levels at the lower 
end of the normal distribution.
Low plasma levels in these VWD patients are the result from mutations, leading to 
decreased synthesis, impaired secretion, increased clearance or a combination of 
these conditions. Unlike type 3 patients, who are usually homozygous or compound 
heterozygous for VWF gene mutations in both alleles, type 1 patients usually have a 
single mutated allele. Since type 1 VWD is a quantitative defect, one would expect that 
these patients are carriers of type 3 mutations, and that the normal allele accounts 
for the reduced, but functionally normal VWF levels found in the plasma. However, 
mutations identified in type 1 VWD are predominantly missense mutations and only 
15% of the mutations lead to null alleles [16]. This is in sharp contrast to type 3 VWD, 
where approximately 85% of the mutations are predicted to result in null alleles. The 
majority of type 1 VWD patients thus do not appear to be just carriers of type 3 muta-
tions [17]. This difference in the genetic basis between the two quantitative defects is 
further supported by the fact that the average VWF level in obligatory type 3 carriers 
is significantly higher compared to obligatory type 1 carriers. This is also reflected by 
differences in bleeding symptoms; 40 % of the type 3 obligatory carriers have at least 
one bleeding symptom, compared to 89% of the type 1 obligatory carriers [18]. 
Three multicenter studies in Europe [19], Canada [20] and the UK [21] have recent-
ly investigated the molecular pathogenesis of type 1 VWD in over 300 patients. De-
spite the difference in recruitment criteria between the studies, the seven most com-
mon mutations found in Index Cases (IC) were both identified in Europe and Canada 
(Table 2). These studies further showed that genetic changes within the VWF gene 
are common and are highly penetrant in the more severe type 1 VWD cases. In the 
European “Molecular and Clinical Markers for the Diagnosis and Management of Type 
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IC. Similar results were found in studies performed in the UK (47%) and Canada (37%) 
[19-21]. The lack of finding a mutation in approximately 35-40% of the IC indicate that 
also other (environmental) factors outside the VWF gene can influence VWF levels in 
patients diagnosed with VWD type 1. In the next paragraphs several phenotypes and 
genotypes of patients diagnosed with type 1 VWD will be discussed to understand the 
large variability seen in phenotypes of patients with type 1 VWD.
Multimer patterns
Although one of the criteria for diagnosis of type 1 VWD is having a normal multim-
er pattern, several IC in the multicenter studies showed abnormal multimers in the 
plasma. In the UK and Canadian studies individuals with abnormal multimers were 
excluded. In the MCMDM-1VWD study 38% (57 out of 150) of the IC had abnormal 
multimer patterns and may formally not fit into the accepted criteria for type 1 VWD. 
However, when evaluated against the 2006 classification criteria [13] that state that 



















Y1584C 8 (25) 18 (14.6) 13 (8.7) 39 (12.8)
R1205H 4 (12.5) 3 (2.4) 10 (6.7) 17 (5.6)
R924Q 3 (9.4) 8 (6.5) 4 (2.7) 15 (4.9)
R854Q - 3 (2.4) 5 (3.3) 8 (2.6)
R2464C - 3 (2.4) 3 (2) 6 (2)
P1266L - 4 (3.3) 1 (0.7) 5 (1.6)
P2063S - 3 (2.4) 1 (0.7) 4 (1.3)
R1315C - - 4 (2.7) 4 (1.3)
R1374C - - 4 (2.7) 4 (1.3)
V1279I - 4 (3.3) - 4 (1.3)
C1130F - - 3 (2) 3 (1)
C1130R - - 3 (2) 3 (1)
M740I - - 3 (2) 3 (1)
N1231T - 3 (2.4) - 3 (1)
R1325C - 3 (2.4) - 3 (1)
V1229G - 3 (2.4) - 3 (1)
C2304Y - - 2 (1.3) 2 (0.7)
P1413L - 1 (0.8) 1 (0.7) 2 (0.7)
G1415D - - 2 (1.3) 2 (0.7)
R1374H - - 2 (1.3) 2 (0.7)
R1668S - 2 (1.6) - 2 (0.7)
Y1146C - 1 (0.8) 1 (0.7) 2 (0.7)
*Listed mutations were found in at least two or more IC, unless the mutation was also found in another study. In bold the mutations found in 
at least two out of the three studies. Note that the mutations that were only found in the European Study are all associated with an abnormal 
multimer pattern (figure 1). IC with these mutations could therefore have been excluded from the two other studies.
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significantly, 22 of 57 IC (39%) with abnormal multimers could be reclassified as type 
2, whereas 35 of 57 (61%) still fitted classification as type 1 VWD [22]. Furthermore, 
those abnormal multimers reflect only very subtle abnormalities and are different 
from the abnormal multimer pattern characteristic for type 2A or 2B VWD. Interest-
ingly, in all those IC with abnormal multimers mutations were found [19,23]. In con-
trast, in only 55 % of the IC with a normal multimer profile a mutation was identified. 
All mutations found in the group of abnormal multimers are located carboxyl to the 
D’ domain, except for a single occurrence of the R854Q mutation. None were found in 
the propeptide region (Figure 1). Three mutations were found in both the normal and 
abnormal multimer groups (R854Q, R1205H and C2304Y), indicating that a specific 
group of mutations is responsible for the abnormal multimer profile (Figure 1) [19]. In 
the Canadian study recent analysis of multimer patterns, using the same technique as 
in the European study, identified abnormal multimers in 39% of the IC, similar to the 
European study [24]. Several of those mutations leading to abnormal multimer pro-
files were expressed in COS-7 cells. Mutations located in the D4-CK domain (L2207P, 
C2257S, G2441C and C2477Y) all showed marked intracellular retention and impaired 
secretion of VWF. Also major loss of the HMW multimers and anodic shifts of mul-
timeric bands was observed in single transfections of the mutants. Cotransfections 
with wild-type VWF (wt-VWF), mimicking heterozygosity, largely corrected the 
decrease and anodic shifts [25]. The R2464C and Q2520P mutations, which showed 




Figure 1. Missense mutations found in index cases with normal and abnormal multimer patterns. The mu-
tations listed are placed at their specific position in the VWF protein. This figure is largely based on the results 
of the MCMDM-1VWD study, with some additions and deletions due to new insights [19]. Cysteines are shown 
as vertical lines and are connected for chemically defined disulfide bonds. N- and O-linked glycans are shown as 
closed and open lollipops, respectively. Boundaries of D assemblies are shown as vertical dashed lines. Image 
adapted from Zhou et al. [70].
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samples [22], showed abnormal anodic migration in single transfections. This was 
shifted towards (nearly) normal in cotransfections with wt-VWF [25]. Also other mu-
tations which showed a small loss or a relative decrease of the largest multimers in 
patients carrying those mutations [22] have been investigated in expression studies. 
For example C1130F/R showed impaired secretion, intracellular retention and abnor-
mal multimer pattern in cotransfections with wt-VWF [26,27]. In multimer patterns 
from other patients, the oligomers showed barely visible outer sub-bands with smears 
around the central band. This pattern is indicative of reduced proteolytic processing 
by ADAMTS13. Although the differences in multimers are minor, the group of abnor-
mal multimers is clearly distinguishable from the group with normal multimers: the 
average VWF:Ag level is much lower [19], linkage to VWF is much stronger [28] and 
the chance of finding a mutation is much higher in the group with abnormal multim-
ers (100%) than normal multimers (55%) [19,23]. 
Impaired synthesis and secretion
Decreased levels of VWF can be due to several mechanisms. Decreased synthesis of 
the VWF protein is the cause for reduced plasma levels in patients carrying a muta-
tion leading to a null allele. In the European cohort the average VWF levels in 8 IC who 
had a single mutation predicted to lead to a non-expressed allele, was 39 IU/dL [19]. 
Impaired secretion and increased intracellular retention of synthesized VWF protein 
seems to be the major mechanism involved in patients with missense mutations. We 
have expressed 14 mutations found in the MCMDM-1VWD study to evaluate their 
contribution to the phenotype observed in the patients. We have established that 7 
mutants, located throughout the VWF gene, contribute to the phenotype on the ba-
sis of increased intracellular retention and impaired secretion of VWF compared to 
wt-VWF, while 4 mutants are probably causative mutations based on the mild reduc-
tion of secreted VWF [25]. Patients with mutations G160W, N166I or M771I showed a 
normal VWF propeptide (pp)/VWF:Ag ratio and normal multimer structure. However 
the VWFpp levels were below the normal range. Reduced levels of VWFpp and VW-
F:Ag with normal multimer structure suggests that these mutations are responsible 
for reduced synthesis, rather than increased intracellular retention [29]. Several mu-
tations that were expressed are involved in the loss or gain of a cysteine residue. Four 
out of five (C2257S, C2304Y, G2441C, and C2477Y) caused marked intracellular reten-
tion and loss of HMW multimers in combination with faster migration of multimeric 
bands. Upon cotransfection with wt-VWF the defect was largely restored. Tjernberg 
et al. [30] have described similar results for another mutation (C2362F) involving 
cysteine residues, located in the same region. Although cysteines in these regions are 
not directly involved in the dimerization and multimerization process of VWF, the 
mutations do result in slightly abnormal multimer patterns. This is probably due to 
the fact that the unpaired cysteines lead to changes in the three-dimensional struc-
ture [26,31]. Impaired secretion of VWF may also be due to a defect in the WPB for-
mation. Indeed Michaux et al. showed that 3 type 1 VWD mutations had a delay in the 
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We have recently also identified impaired formation and reduced numbers of WPB in 
several VWF mutations (Chapter 3 and 4 of this thesis). Furthermore, we showed that 
impaired synthesis is frequently observed in type 1 VWD patients (Chapter 6 of this 
thesis). 
Accelerated clearance
Another mechanism that could explain the low VWF plasma levels in type 1 VWD 
is increased clearance of VWF. Some clearly causative mutations show significant-
ly reduced VWF levels upon expression, however in co-transfections with wt-VWF 
the expression seems normal. This led to the hypothesis that mutations may be in-
volved in faster clearance of the protein. The first report on increased clearance de-
scribed the rapid disappearance of VWF upon DDAVP infusion in 7 patients carry-
ing the combined M740I/R1205H mutations (Type Vicenza) [33]. Haberichter et al. 
[29] identified seven patients with reduced VWF survival predicted by a markedly 
increased VWFpp/VWF:Ag ratio. In all these seven patients mutations were identified 
that have been previously reported with reduced VWF survival, including R1205H, 
C1130G/F/R and W1144G. The majority of the cases with decreased VWF survival is 
characterized by significantly reduced steady-state VWF:Ag levels, usually below 30 
IU/dl [34,35]. The half-life of VWF:Ag is also markedly reduced after DDAVP infusion. 
In the MCMDM-1VWD cohort it became evident that the extent of increased clear-
ance was not the same for all missense mutations, and the highest VWFpp/VWF:Ag 
ratios clustered in the VWF D3 and A1 domains (Figure 2)[36]. The increased VWFpp/





Figure 2. Location of VWF mutations associated with increased VWF clearance in type 1 VWD. The muta-
tions listed are placed at their specific position in the VWF protein. This figure is based on the results of the 
MCMDM-1VWD study [36]. Patients with listed mutations had a median VWFpp/VWF:Ag ratio above the upper 
limit of normal reference range (>2.2). Cysteines are shown as vertical lines and are connected for chemically 
defined disulfide bonds. N- and O-linked glycans are shown as closed and open lollipops, respectively. Bounda-
ries of D assemblies are shown as vertical dashed lines. Image adapted from Zhou et al. [70].
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The possible contribution of ADAMTS13 proteolysis to the rapid clearance has been 
postulated. Indeed one mutation, the Y1584C, seems to be linked with increased sus-
ceptibility of VWF to ADAMTS13 proteolysis [37]. But detailed analysis of mutations 
C1130F and C1149R revealed that increased clearance in these cases was not due to 
increased proteolysis by ADAMTS13 [34]. Sialic acid residues on the VWF glycans are 
known to promote ADAMTS13-mediated proteolysis and also seem to play a role in the 
clearance of the protein. Asialo-VWF is cleared more rapidly than sialylated VWF in 
animal models [38]. The Ashwell receptor, an asialoglycoprotein receptor on hepato-
cytes, is able to bind asialo-VWF [7], thereby removing it from the circulation. 
Recent data suggest that the receptor might also be able to bind sialylated glyco-
proteins [39], but whether this is the case for VWF remains unknown. The VWFpp/
VWF:Ag ratio measured in healthy blood group O subjects indicate that they have a 
faster VWF clearance than non-O subjects [40]. This suggests that changes in carbo-
hydrate structure of VWF may affect clearance and therefore VWF levels. For the clin-
ical practice increased clearance might be an important phenotype to be considered. 
Insight into the survival of VWF after DDAVP infusion is relevant for the treatment 
of type 1 VWD patients. If the half-life of endogenous circulating VWF after DDAVP 
treatment is too short, it might be preferable to treat the patient with a VWF concen-
trate instead of DDAVP infusion. 
Factors outside the VWF gene
The lack of finding a mutation in approximately 35-40% of the IC in the multicenter 
studies, indicate that also other (environmental) factors outside the VWF gene can 
influence VWF levels in patients diagnosed with VWD type 1. Also the variability of 
responses to DDAVP treatment between patients with the same mutation suggests 
that other factors contribute to the VWF levels [41]. This notion is also reflected in the 
2006 VWD classification that no longer restricts the diagnosis VWD to mutations in 
the VWF gene [13].
Blood groups. It has been shown that 66% of the variation in VWF levels is geneti-
cally determined and that the ABO blood group locus accounts for 30% of that vari-
ation [42]. VWF is one of the few plasma proteins that contain the ABO blood group 
sugars. The ABH antigens are only attached to the N-linked oligosaccharide chains of 
VWF. Almost 30 years ago it was recognized that the ABO blood groups are associated 
with VWF plasma levels [43], and this has been confirmed in several other studies 
[44]. Individuals with blood group O have approximately 25% lower VWF plasma lev-
els compared to non-O individuals. Furthermore, blood group O is overrepresented 
among VWD type 1 patients. The mechanisms how ABO blood groups are responsible 
for VWF levels remain unknown. A direct mechanism seems likely as individuals with 
the Bombay blood group phenotype, who lack expression of the ABH antigens, even 
have lower plasma levels than individuals with blood group O [45]. Furthermore, the 
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ecule [46,47]. The ABH antigens may have an effect on biosynthesis, secretion, clear-
ance of VWF or a combination thereof. The ABH antigens on VWF do not seem play 
a role in synthesis and secretion as the plasma propeptide levels are independent of 
the ABO blood group [48]. Platelet VWF levels are independent of ABO blood group, 
which is probably explained by the fact that platelet VWF does not express the ABH 
antigens [49]. Another study showed that the rise in VWF level after DDAVP treatment 
appears to be similar between patients with type 1 VWD with different blood groups, 
suggesting that secretion efficiency is not affected by the blood group antigens [50]. 
Nossent et al. [48] estimated that the half-life of VWF in controls with blood group O 
is almost 2 hours shorter compared to non-O blood group controls and it was shown 
that in healthy individuals the VWF half-life after DDAVP administration was shorter 
in blood group O individuals [40]. Furthermore, the ratio between propeptide and 
mature VWF, which are released in an equimolar ratio, is increased in individuals that 
have blood group O compared to non-O individuals [35,48]. These observations sug-
gest that the ABH antigens on VWF determine its clearance rate, where blood group 
O-VWF might be cleared faster compared to non-O VWF. However, this supposition 
is not yet challenged in a direct comparison, nor have the molecular mechanisms 
been elucidated. New insights into the mechanism how ABO blood group influences 
VWF plasma levels have been described in Chapter 5 of this thesis. One VWF mutation 
seems to be linked with the ABO blood group. In the UK study the Y1584C mutation 
was found together with blood group O in 95% of the VWD cases [21], and in another 
study 11 out of the 12 IC had blood group O [51], a higher proportion than the overall 
77% prevalence of group O reported among type 1 VWD [52]. 
Age. In preterm neonates the VWF levels are moderately low, but at birth the levels 
rise above adult norms. Stress in the neonate during the delivery might be the cause 
of this rise, since it’s known that stress or exercise can induce significant release of 
VWF [53]. Several other reports have shown that with age the VWF levels slowly in-
crease, with a rate of approximately 10 IU/dl per decade [52,54]. This increase during 
life has an influence on the diagnosis in relation to age. Diagnosis of VWD at a young 
age might be questioned later in life.
Genetic modifiers. Besides the ABO locus, a number of other loci have been identi-
fied as determinants for VWF plasma levels. Genome-wide association studies iden-
tified more than 20 SNPs in over 10 genes such as STXBP5, SCARA5, STAB2, STX2, 
CLEC4M [55] that are associated with VWF levels. Among type 1 VWD patients the 
frequency of the integrin α2β1 807C allele, which is associated with low receptor den-
sity, was found significantly higher than in the normal population [56]. Low density 
of the integrin α2β1 might result in less efficient binding of platelets to collagen and 
may explain the variability between bleeding symptoms in patients with the same 
VWF levels. Indeed Kunicki et al. [57] found that this haplotype was associated with an 
increased bleeding score. The integrin αIIb haplotype 1 was also associated with an in-
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Daly et al. [58] who identified a heterozygous mutation in the P2Y12 ADP receptor gene 
in a patient with mild type 1 VWD and a VWF defect. Platelets from this patient showed 
reduced and reversible aggregation in response to ADP. So the defect in the P2Y12 gene 
could contribute to the bleeding tendency in type 1 VWD patients [58]. We have found 
a polymorphism in the arginine vasopressin 2 receptor (V2R) gene, which was asso-
ciated higher VWF propeptide, VWF and FVIII levels [59]. Recently, Rydz et al. [60], 
have shown that polymorphisms in the CLEC4M gene, a mannose specific receptor on 
endothelial cells, contribute to variable plasma levels of VWF probably by differences 
in VWF binding and internalization. Some modifier genes for plasma VWF levels have 
been identified in mice, but human homologues remain to be identified [61,62]. 
Hormonal influences. Data obtained from several studies on the relationship be-
tween menstrual cycle and VWF level are contradictory. One study showed no change 
in VWF:Ag and VWF:RCo levels during the normal menstrual cycle [63]. A similar 
study however found lower levels for both parameters in the follicular phase [54], 
while another study showed significantly lower levels of VWF:Ag during menses 
compared with the follicular phase [64]. Women investigated in these studies were 
healthy women; no data are available about the possible change in VWF levels during 
the menstrual cycle in VWD type 1 patients. The use of oral contraceptives causes a 
small rise in levels of both VWF:Ag en VWF:RCo, but again no data are available for 
women who have VWD [65]. During pregnancy the level of VWF increases 3 to 5-fold 
in women without VWD, and in most women with VWD type 1 the levels will reach 
normal range at the end of pregnancy. Castaman et al. [66] studied 23 women with 
VWD during pregnancy. Women with R854Q, R1374H, V1665E, V1822G and C2362F 
mutations showed complete normalization of VWF levels during their pregnancy. 
Women with R1205H and C1130F mutations had only a slight increase of VWF during 
pregnancy [66]. This correction during pregnancy might have clinical consequences 
for the therapy, although postpartum hemorrhage may occur due to a rapid fall of 
VWF after delivery [67]. 
Conclusions
In the large multicenter studies on type 1 VWD many mutations were found, located 
throughout the entire VWF gene. The majority of these mutations are missense mu-
tations and only a few IC had mutations that were predicted to lead to null alleles. An 
interesting finding in the two large European and Canadian cohorts was the fact that 
although VWD type 1 is a quantitative defect, some patients showed slightly abnor-
mal multimer patterns. This observation asks for reconsideration of the criteria for 
VWD type 1. The mechanisms by which these mutations cause the observed clinical 
manifestations are slowly revealed. For some mutations it has been shown in expres-
sion studies that they cause impaired secretion by intracellular retention or degrada-
tion. This seems to be the more general mechanism for the reduced levels found in the 
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were found to (also) have an association with increased clearance, which may have 
therapeutic implications.
Besides mutations in VWF other factors have an influence on VWF levels or bleeding 
phenotype. The ABO blood group is one of the major determinants of plasma levels. 
Blood group O individuals have approximately 25% lower levels and are overrepre-
sented among patients with type 1 VWD. Other environmental factors such as age, 
stress and hormonal influences also alter plasma levels, making the diagnosis of type 
1 VWD even more complicated. Recently some polymorphisms in platelet integrins 
were found to be associated with increased severity bleeding scores and polymor-
phisms in the V2R and CLEC4M are associated with VWF levels. All these genetic var-
iants, along with genetic modifiers that have yet to be identified, show that VWD type 
1 is a multifactorial disorder, where all these factors contribute to the highly variable 
genotype and phenotype of this bleeding disorder. With all the knowledge now avail-
able on the variety of mutations found in type 1 VWD, the question arises whether 
we should screen patients with possible VWD for VWF gene mutations (for a recent 
debate see Peake [68] and Favaloro [69]). When laboratory testing shows abnormal 
multimer patterns screening for mutations seems rather pointless, because a muta-
tion will be found in 100% of the cases as evidenced in the MCMDM-1VWD study. 
Finding a mutation in these cases will not add any information that will change the 
diagnosis or treatment of the patient. One could argue that screening may be useful in 
cases where the mutation leads to accelerated clearance, for example the R1205H and 
C1130F mutations, since this might change the therapy in case of bleedings. But ge-
netic testing is time-consuming and costly, while more accurate information on clear-
ance will be available from a DDAVP test infusion when blood samples are taken at 
later time points. And, as shown in the multicenter studies, genetic testing will fail to 
find a causative mutation in approximately one third of the patients. As discussed ear-
lier, several other factors beside a VWF gene mutation can influence plasma levels and 
ultimately the clinical manifestation. So this only leaves a very small group of patients 
with type 1 VWD where screening for a mutation might be more informative. For clin-
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Background: Mutations of cysteine residues in von Willebrand factor are known to 
reduce the storage and secretion of this factor, thus leading to reduced antigen levels. 
However, one cysteine mutation, p.Cys2773Ser, has been found in patients with type 2A 
von Willebrand disease who have normal plasma levels of von Willebrand factor. We 
hypothesize that disruption of either intra- or interchain disulfide bonds by cysteine 
mutations in von Willebrand factor has different effects on the biogenesis of Weibel-
Palade bodies. Design and Methods: The effect of specific cysteine mutations that either 
disrupt intrachain (p.Cys1130Phe and p.Cys2671Tyr) or interchain (p.Cys2773Ser) 
disulfide bonds on storage and secretion of von Willebrand factor was studied by 
transient transfection of human embryonic kidney cell line 293. Upon expression 
of von Willebrand factor these cells formed endothelial Weibel-Palade body-like 
organelles called pseudo-Weibel-Palade bodies. Storage of von Willebrand factor was 
analyzed with both confocal immunofluorescence and electron microscopy. Regulated 
secretion of von Willebrand factor was induced by phorbol 12-myristate 13-acetate. 
Results: p.Cys1130Phe and p.Cys2671Tyr reduced the storage of von Willebrand factor 
into pseudo-Weibel-Palade bodies with notable retention of von Willebrand factor in 
the endoplasmic reticulum, whereas p.Cys2773Ser-von Willebrand factor was stored 
normally. As expected, wild-type von Willebrand factor formed proteinaceous tubules 
that were seen under electron microscopy as longitudinal striations in pseudo-
Weibel-Palade bodies. p.Cys2773Ser caused severe defects in von Willebrand factor 
multimerization but the factor formed normal tubules. Furthermore, the basal and 
regulated secretion of von Willebrand factor was drastically impaired by p.Cys1130Phe 
and p.Cys2671Tyr, but not by p.Cys2773Ser. Conclusions: We postulate that natural 
mutations of cysteines involved in the formation of interchain disulfide bonds do not 
affect either the storage in Weibel-Palade bodies or secretion of von Willebrand factor, 
whereas mutations of cysteines forming intrachain disulfide bonds lead to reduced 
von Willebrand factor storage and secretion because the von Willebrand factor is 
retained in the endoplasmic reticulum.
Introduction
Von Willebrand factor (VWF) is a multimeric plasma glycoprotein that facilitates 
platelet adhesion to an injured vessel wall and carries coagulation factor VIII in the 
circulation [1]. Aberrations in the function or concentration of VWF may lead to the 
most common human inherited bleeding disorder von Willebrand disease (VWD). 
The main source of plasma VWF is the endothelial cell which stores VWF in a unique 
organelle called the Weibel-Palade body (WPB). VWF is released from WPB by basal 
and regulated mechanisms [2,3]. During its biosynthesis, VWF undergoes extensive 
post-translational modifications that include formation of intrachain and interchain 
disulfide bonds. The interchain disulfide bonds bridge the cysteine knot domains 





(“tail-to-tail”) and D3 domains (“head-to-head”) of VWF to form dimers and multim-
ers of up to 80 monomeric subunits [1,4,5]. Such interchain disulfide bond formation 
has recently been shown to be facilitated by the low pH seen in the trans Golgi and 
WPB [6,7]. Through a process called tubulation, VWF is organized at the trans Golgi 
into proteinaceous tubules that are stored in the WPB. Under an electron microscope 
VWF tubules appear as striations (if viewed longitudinally) or as hollow rings (if 
viewed in cross-section) [4,5].
VWF contains numerous cysteines [8] and a large number of mutations of cysteines 
have been identified in VWD patients with either quantitative (VWD types 1 and 
3) or qualitative (VWD type 2) defects of VWF (ISTH-SSC VWF mutation database 
(www.vwf.group.shef.ac.uk/). The mechanisms by which specific cysteine mutations 
lead to the different clinical phenotypes of VWD are largely unknown. Based on the 
expression data of cysteine mutations in VWF, we and others have shown that intra-
cellular retention of VWF is a common mechanism underlying VWD with quantita-
tive deficiencies of VWF [9-12]. Recently we showed that impaired WPB formation 
and reduced regulated secretion of VWF contribute to this intracellular retention 
[13]. However, cysteines p.Cys2771 and p.Cys2773, which are involved in interchain di-
sulfide bond formation at the cysteine knot domain, [14] have been implicated in type 
2A(IID) VWD in patients with normal plasma VWF antigen level [15-17] suggesting 
normal storage and secretion. We, therefore, hypothesized that disruption of inter-
chain disulfide bonds may not hamper VWF induced biogenesis of WPB and secretion 
into the circulation whereas disruption of intrachain disulfide bonds does.
To address this hypothesis, the intracellular storage and secretion of p.Cys2773Ser-VWF 
mutant was compared with that of two other VWF mutants, p.Cys1130Phe-VWF and 
p.Cys2671Tyr-VWF, in which intrachain disulfide bonds are disrupted. We found that 
disruption of intrachain disulfide bonds in VWF by mutations p.Cys1130Phe and p.Cy-
s2671Tyr impairs WPB biogenesis whereas disruption of an interchain disulfide bond 
by p.Cys2773Ser does not affect WPB formation. Our findings also confirmed that VWF 
tubulation and storage in WPB are not dependent on C-terminal dimerization.
Design and Methods
Patients and mutations
The mutations investigated in this study had all been identified earlier in VWD pa-
tients. p.Cys1130Phe (c.3389G>T) was identified in a heterozygous state in patients 
originally diagnosed with type 1 VWD with moderately severe bleeding tendencies 
[18,19]. The phenotype of patients carrying p.Cys1130Phe has more recently also been 
classified as 2A(IIE) [20,21]. p.Cys2671Tyr (c.8012G>A) was described in a compound 
heterozygous type 3 VWD patient with a deletion of the second allele [22]. p.Cys2773S-
er (c.8318G>C) was identified in heterozygous type 2A(IID) patients [17].






Recombinant pSVH expression plasmids containing full length cDNA encoding either 
the wild-type human VWF (WT-VWF) or the p.Cys2671Tyr and p.Cys2773Ser VWF var-
iants have been described before [9]. The full-length VWF cDNA fragments, obtained 
by EcoRI restriction of these pSVH-VWF plasmids, were cloned into the pCI-neo mam-
malian expression vector (Promega, Madison, WI, USA). Mutation p.Cys1130Phe was 
introduced into pCI-neo WT-VWF plasmid with the QuikChange XL SiteDirected Mu-
tagenesis Kit (Stratagene, La Jolla, CA, USA) and verified by sequencing.
Cell culture and transfection
Cells of the human embryonic kidney cell line 293 (HEK293) were purchased from the 
American Type Culture Collection (ATCC, Rockville, USA) and cultured in minimum es-
sential medium Eagle alpha modification (MEM- α, Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with 10% fetal calf serum, 2 mM L-glutamine and 50 μg/mL gen-
tamicin (Invitrogen, Carlsbad, CA, USA). Using the FuGENE HD transfection reagent 
(Roche Diagnostics, Mannheim, Germany), 0.66 μg/mL plasmid constructs (final 
concentration in the medium; 0.33 μg/mL WT-VWF and mutant VWF plasmids for 
co-transfections) were transiently transfected into HEK293 cells according to the 
manufacturer’s instruction. 
Immunofluorescent staining and antibodies
Transfected cells were stained with immunofluorescent antibodies and analyzed 
with a Leica SL confocal laser scanning microscope with a 63X/1.40 NA oil objective, 
as previously described [13]. Monoclonal antibody CLB-RAg35 and polyclonal rab-
bit anti-human protein disulfide isomerase (PDI) antibody A66 (obtained from Prof. 
I. Braakman, Department of Chemistry, Utrecht University, Utrecht, The Netherlands) 
were used as primary antibodies against VWF and the endoplasmic reticulum (ER) 
marker PDI, respectively [23,24]. Alexa 488- and Alexa 594-conjugated secondary an-
tibodies were purchased from Invitrogen. To quantify the extent of retention of VWF 
in the ER, we determined the percentage of cells expressing VWF which also showed 
retention of VWF in the ER by co-staining the VWF with PDI.
Transmission electron microscopy
Transfected cells grown on 35-mm Petri dishes were fixed and prepared for transmis-
sion electron microscopy as previously described [13,25]. Briefly, cells treated with 
osmium tetroxide and tannic acid were serially dehydrated with ethanol and embed-
ded in Epon. The samples cut into thin sections of 70-100 nm were stained with uranyl 
acetate and lead citrate, and then analyzed with a Tecnai 12 at 120 kV equipped with a 
4kx4k CCD camera (Model Eagle, Fei Company, The Netherlands).
Structural analysis of von Willebrand factor 
Seventy-two hours after transfection cells were incubated with release medium [OP-
TIMEM1 medium, 10 mM HEPES (N-2hydroxyethylpiperazine-N’-2-ethanesulfon-





ic acid), 0.2% bovine serum albumin, pH 7.4] for 24 h. The conditioned media were 
electrophoresed through 1.6% agarose gel containing 1% sodium dodecyl sulfate for 
multimer analysis. VWF multimers were visualized by western blotting as described 
elsewhere [9]. Electrophoresis and blotting were performed under non-reduc-
ing conditions. To analyze the processing of VWF, reducing sodium dodecyl sulfate 
polyacrylamide gel electrophoresis and western blotting were performed for the con-
ditioned media and cell lysates. Cell lysates were prepared with Passive Lysis Buffer 
(Promega) supplemented with 100 μM phenylmethylsulfonyl fluoride (Roche) and 
the protease inhibitor cocktail CompleteTM with EDTA (Roche). Samples were reduced 
using 20 mM dithiothreitol, separated by Novex 6% Tris-Glycine gel electrophoresis 
(Invitrogen), immunostained with polyclonal rabbit anti-human VWF conjugated to 
horseradish peroxidase (DAKO) and visualized with Supersignal WestFemto (Thermo 
Scientific, Rockford, IL, USA).
Basal and regulated secretion of von Willebrand factor
In the absence of stimulation, VWF is mainly secreted via the basal secretory pathway 
from WPB [3]. HEK293 cells are known to form pseudo-WPB that are similar to the 
WBP in endothelial cells [13]. Basal and regulated secretion of VWF was determined 
as previously described [13]. Briefly, 24 h after transfection, cells were incubated with 
fresh culture medium for 48 h and then the conditioned media and cell lysates were 
collected to determine basal secretion of VWF. To analyze the regulated secretion of 
VWF, 72 h after transfection cells were incubated for 60 min with release medium 
containing 160 nM phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) or vehicle 
(dimethylsulfoxide). VWF:Ag in the media and cell lysates was determined by an en-
zyme-linked immunosorbent assay. For the calculation of regulated secretion, secret-
ed VWF was expressed as a fraction of total VWF (amount in the medium plus lysate). 
Statistical analyses were performed with Student’s t-test using GraphPad Prism soft-
ware (version 4.02).
Results
Retention of von Willebrand factor in the endoplasmic reticulum
As shown in Figure 1, WT-VWF formed numerous elongated pseudo-WPB organelles. 
Each of the VWF mutants was able to form pseudo-WPB although these organelles 
were relatively short or more granular compared with those formed by WT-VWF. As 
indicated by the co-localization of VWF and the ER marker PDI, both p.Cys1130Phe 
and p.Cys2671Tyr led to considerable retention of synthesized VWF in the ER. In con-
trast, most of the p.Cys2773Ser-VWF was stored in pseudo-WPB similar to those ob-
served for WT-VWF. Quantification of VWF storage showed that 60-80% of cells ex-
pressing p.Cys1130Phe or p.Cys2671Tyr displayed retention of VWF in the ER, whereas 
this was less than 10% for WT-VWF or p.Cys2773Ser-VWF (Figure 1). The retention of 
p.Cys1130Phe-VWF in the ER was reduced by co-transfection with WT-VWF. In this 
case the proportion of cells showing ER retention of VWF decreased from 83% to 26%. 





Figure 1. Intracellular localization of VWF variants in transfected HEK293 cells. HEK293 cells were transiently 
transfected with WT-VWF or VWF mutants as indicated. Fixed cells were stained for VWF (left panel, green) and 
for PDI (the ER marker, middle panel, red). In the right panel (merge of green and red channels), the pseudo-
WPB show up in green (VWF staining only), and the ER containing VWF shows up in yellow as a result of 
double staining for VWF and PDI. Scale bar = 5 μm. 175~370 cells expressing each of VWF variants from two 
independent experiments were analyzed and the percentage of cells that showed retention of VWF in the ER 
(cells displaying yellow) is indicated on the right.
There was no reduction in ER retention of p.Cys2671Tyr-VWF upon co-transfection 
with WT-VWF. The different efficiencies in storage of VWF variants were also reflect-
ed by PMA-induced pseudo-WPB exocytosis (see section on Secretion of VWF). 
Analysis of the cell ultrastructure with transmission electron microscopy revealed 
pseudo-WPB containing VWF tubules in cells expressing WT-VWF as well as each of 
the mutants (Figure 2A-E). The tubules formed by the three VWF mutants appeared 
normal compared to those formed by WT-VWF (Figure 2A) [25]. This indicates that 
all three mutants were able to form pseudo-WPB although p.Cys1130Phe-VWF did so 
rarely. Furthermore, grossly dilated ER was frequently observed in cells expressing 
p.Cys1130Phe (Figure 2F) or p.Cys2671Tyr (Figure 2G). The ER morphology in cells ex-
pressing p.Cys2773Ser was normal (Figure 2H). 
The retention of VWF mutants in the ER was further confirmed, using western blot-
ting under reducing conditions, by evaluating the extent to which VWF was processed 
into its mature form. Secreted VWF consisted mainly of fully processed mature VWF 
subunits (Figure 3A). In the cell lysates, both mature subunits and uncleaved pro-VWF 





Figure 2. Ultrastructure of transfected HEK293 cells visualized by TEM. HEK293 cells were transiently 
transfected as indicated. Pseudo-WPB displaying VWF tubules were formed by WT-VWF (A) and the three 
mutants (B-E). Dilated ER was observed in cells expressing p.Cys1130Phe (F) or p.Cys2671Tyr (G) but not in cells 
expressing p.Cys2773Ser (H) or WT-VWF (not shown). Note that the VWF tubules were clearly visualized in the 
cross sections of pseudo-WPB (indicated by the arrows in panels B and E). The ER (indicated by the arrowheads) 
shown in panels F, G and H were imaged respectively in the same cells shown in panels B, C and D. The stars in 
panels C, G and H indicate mitochondria. In panel A-E, scale bar = 200 nm; in panels F-H, scale bar = 500 nm.
Figure 3. Subunit composition of 
VWF under reducing conditions. 
HEK293 cells were transiently 
transfected with WT-VWF or VWF 
mutants as indicated. VWF secreted 
into the medium (panel A: Medium) 
or VWF retained in lysate (panel B: 
Lysate) was reduced with DTT and 
analyzed with SDSPAGE and Western 
blot. In panel C, the ratio of proVWF 
(p) and mature VWF subunit (m) in 
the cell lysate was analyzed with 
Image J (NIH software, version 1.44P). 
Note that in panels A and B the parts 
separated by the space between 
p.Cys2671Tyr and p.Cys2773Ser are 
from the same Western blot.





were detectable for all VWF variants (Figure 3B). However, p.Cys1130Phe-VWF and 
p.Cys2671Tyr-VWF showed relatively much more uncleaved pro-VWF compared to 
WT-VWF and p.Cys2773Ser-VWF (Figure 3C), indicating that p.Cys1130Phe-VWF and 
p.Cys2671Tyr-VWF were retained in the ER, and did not reach the Golgi apparatus 
where furin cleaves pro-VWF [26-28].
Secretion of von Willebrand factor 
WPB contributes to both the basal and regulated secretion of VWF [3]. To determine 
the effect of pseudo-WPB formation on the secretion of VWF mutants, both secre-
tory pathways were examined. Basal secretion of VWF was defined as the secreted 
VWF:Ag level in the conditioned medium over 48 h (Table 1). Compared to WT-VWF, 
both p.Cys1130Phe-VWF and p.Cys2671Tyr-VWF showed significantly reduced basal 
secretion, which was apparent from a decrease in VWF level in the medium as well 
as from the decreased ratio of VWF:Ag in medium over lysate. In contrast, the basal 
secretion of the p.Cys2773Ser variant of VWF was normal, with a similar medium/
lysate ratio as that of WT-VWF. To mimic the heterozygous state of the mutations in 
carriers, cells were co-transfected with VWF mutants and WT-VWF at a 1:1 ratio. After 
this co-transfection with WT-VWF and mutant VWF, the basal secretion of VWF:Ag 
into medium was similar for all three mutants. However, the decreased ratio of VW-
F:Ag in medium over lysate observed for p.Cys1130Phe-VWF and p.Cys2671Tyr-VWF 
indicates that the secretion of these VWF variants remained compromised in the 
heterozygous state (Table 1). Furthermore, the absolute amount of VWF protein pro-
duced by WTVWF or the three variants was similar (total VWF:Ag in the medium and 
lysates; about 100 mU VWF per 7×105 cells) for both single transfections and co-trans-
fections, confirming that the effects on WPB formation and ER retention of VWF (Fig-
ure 1) could not be explained by the expression level of the mutants. The secretion 
and total amount (medium plus lysate) of p.Cys2773Ser-VWF was higher than that of 
WT-VWF, although the difference was not statistically significant (Table 1; 126.5 mU 
in single transfections and 117.7 mU in cotransfections versus 97.9 mU for WT-VWF per 
Table 1. Expression of VWF variants in transfected HEK293 cells.
Variant Transfection VWF:Ag* Medium VWF:Ag* Lysate Ratio†
mU % mU %
WT-VWF 74.1 ± 4.7 100 23.8 ± 3.2 100 3.2 ± 0.2
p.Cys1130Phe Single transfection 41.3 ± 2.7 56.4 ± 6.4 59.2 ± 11.1 255.9 ± 56.7 0.7 ± 0.1‡
Co-transfection 63.7 ± 4.8 86.3 ± 4.1 44.0 ± 5.8 186.3 ± 9.9 1.5 ± 0.1‡
p.Cys2671Tyr Single transfection 55.2 ± 5.8 76.0 ± 12.7 45.5 ± 4.8 194.3 ± 18.2 1.2 ± 0.2‡
Co-transfection 65.8 ± 4.4 89.0 ± 4.1 32.2 ± 3.2 136.5 ± 5.9 2.1 ± 0.1‡
p.Cys2773Ser Single transfection 90.8 ± 10.7 124.0 ± 18.2 35.7 ± 2.1 154.1 ± 16.1 2.5 ± 0.2§
Co-transfection 84.1 ± 11.6 114.7 ± 17.7 33.6 ± 4.1 142.1 ± 5.9 2.5 ± 0.4§
* VWF:Ag (mU) was produced by about 7x105 cells in the medium or lysate. In parallel, VWF:Ag is expressed as percentage relative to the amount 
of VWF:Ag in the medium and lysate of cells expressing WT-VWF. Each value represents the mean ± SEM of three independent experiments in 
duplicate. † Ratio of the absolute amount of VWF:Ag in medium to VWF:Ag in lysate. ‡ Compared with WT-VWF p < 0.01. § Compared with WT-
VWF p > 0.05.





Figure 4. Regulated secretion of WT-VWF or 
VWF variants. HEK293 cells were transient-
ly transfected with WT-VWF, p.Cys1130Phe, 
p.Cys2671Tyr and p.Cys2773Ser, respectively 
(Panel A). In panel B, p.Cys1130Phe, p.Cys-
2671Tyr or p.Cys2773Ser were co-transfected 
with WT-VWF at 1:1 ratio. Seventy-two hours 
post transfection HEK293 cells were rinsed 
twice with the release medium and incubated 
at 37°C for 60 minutes in the release medi-
um without (Ctr) or with 160 nM PMA (PMA). 
Each bar represents VWF secreted into the re-
lease medium as a fraction of total VWF (me-
dium plus lysate) times 100%. Mean and SEM 
are based on three independent experiments 
in duplicate. The numbers above the bars in-
dicate the fold increase of secreted VWF com-
paring the stimulated (PMA) and control (Ctr) 
samples.
7×105 cells), consistent with the normal to high plasma levels of VWF in the patients 
[17].  Rapid clearance in vivo was shown to account for the more severe phenotypes of 
patients with p.Cys1130Phe-VWF and p.Cys2671Tyr-VWF [29].
The regulated secretion of VWF was analyzed by using PMA, which efficiently induc-
es exocytosis of pseudoWPB in HEK293 cells [13]. Incubation of HEK293 cells for 60 
min with PMA increased the secretion of WT-VWF by 2.7-fold (12.2% of total VWF 
was secreted by PMA-stimulated cells versus 4.5% by control cells, Figure 4). Both p.
Cys1130Phe- and p.Cys2773Ser-transfected cells showed good response to PMA stimu-
lation although the total secretion of p.Cys1130Phe-VWF was much lower. Only a min-
imal increase in the secretion of p.Cys2671Tyr-VWF was observed after stimulation. 
Cotransfections with p.Cys2773Ser or p.Cys1130Phe produced a regulated secretion of 
VWF comparable to that of WT-VWF if judged by the fold increases, but to a much 
lower absolute level in the case of p.Cys1130Phe. Cotransfection of p.Cys2671Tyr only 
slightly increased the secretion of VWF during stimulation. These in vitro data for 
p.Cys1130Phe (co-transfection mimicking the heterozygous state) and p.Cys2671Tyr 
(single transfection mimicking the compound heterozygous state) are consistent with 
the response to DDAVP infusion in the patients with these mutations [29,30]. One 
may speculate that patients with p.Cys2773Ser will show a normal response to DDAVP; 
however, no patient was available for direct testing.
Multimeric analysis of secreted von Willebrand factor
We performed multimer analysis of the conditioned media (Figure 5). A full range 
of VWF multimers was present in the conditioned medium for WT-VWF and p.Cy-
s2671Tyr-VWF, while p.Cys1130Phe-VWF showed relative loss of large multimers 





Figure 5. Multimer analysis of secreted 
VWF. Multimers are shown for single 
transfections (A) and cotransfections 
with WT-VWF at 1:1 ratio (B). The 
N-terminal dimers and odd-numbered 
multimers formed by VWF p.Cys2773Ser 
are indicated by the arrow and 
arrowheads, respectively. In panel A, 
the multimers of VWF p.Cys2671Tyr are 
from a different gel, the other separated 
parts are from one same gel. In panel B, 
the separated parts are from the same 
gel. The multimer patterns of secreted 
VWF were analyzed by SDS-agarose gel 
electrophoresis and Western blot under 
non-reducing conditions.
indicating that mutations close to the interchain disulfide bonds may have a minor 
but significant effect on VWF multimerization. p.Cys2773Ser-VWF mainly formed 
monomers and dimers. The appearance of double bands for the dimers was caused by 
the different mobility between C-terminal dimers and N-terminal dimers formed by 
p.Cys2773Ser [17]. The multimeric defects caused by p.Cys1130Phe and p.Cys2773Ser 
were only partly restored by co-transfection with WT-VWF. This is consistent with the 
multimer patterns in the patients [17,19,20].  Furthermore, the odd-numbered VWF 
multimers produced by co-transfection of p.Cys2773Ser with WT-VWF confirmed 
co-expression of both constructs in individual cells.
Discussion
Chemical modification and mutagenesis studies have demonstrated that cysteines p.
Cys2771 and p.Cys2773 are involved in interchain disulfide bond formation and are 
equally essential for VWF dimerization [14]. Natural mutations in the two cysteines 
lead to essentially the same clinical phenotype [15-17]. In addition, extensive studies 
have indicated that p.Cys1130 at the N-terminal and p.Cys2671 at the C-terminal are 
not involved in the interchain disulfide bonds but rather are involved in the intrachain 
disulfide bonds [14,31,32]. We, therefore, selected the three mutations p.Cys2773Ser, p.
Cys1130Phe and p.Cys2671Tyr that were identified in our center [17,18,22] as exempla-
ry mutants to examine the differential effects of interchain versus intrachain disulfide 
bonds on WPB biogenesis. p.Cys2773SerVWF was normally stored in and secreted 
from transfected HEK293 cells despite strongly reduced dimerization and multimer-
ization. In contrast, p.Cys1130Phe and p.Cys2671Tyr resulted in strong retention of 
VWF in the ER and less VWF stored in pseudo-WPB, which is consistent with previ-
ous reports for other cysteine mutations that disrupt intrachain disulfide bonds in 





Figure 6. Schematic illustration of VWF intracellular trafficking. WT-VWF (left) is synthesized and dimerized 
in the ER, and passes the quality control to Golgi apparatus to multimerize and tubulize therein, and is 
eventually packed into WPB. Part of VWF mutants with impaired intrachain disulfide bond formation (middle) 
escape the quality control and are stored in WPB, the other part are retained in the ER undergoing aggregation 
or intracellular degradation. VWF mutants with impaired C-terminal interchain disulfide bond formation (right) 
fail to form C-terminal dimers in the ER. The monomers can get through the ER to the Golgi and partly form 
N-terminal dimers which are tubulized and stored into WPB. The remaining monomers are presumably stored 
into WPB, however, whether they are incorporated into VWF tubules is unknown. This hypothesis may also 
apply to the mutants lacking N-terminal interchain disulfide bonds.
VWF [13,33].  Our data, therefore, suggest that VWF mutations that disrupt interchain 
disulfide bonds differ from mutations that disrupt intrachain disulfide bonds in the 
effect on WPB biogenesis.
The mutations that were analyzed in this study are located in different domains in 
VWF: p.Cys1130Phe in the D3 domain, p.Cys2671Tyr in the region immediately ami-
no-terminal to the cysteine knot domain and p.Cys2773Ser in the cysteine knot do-
main itself. The different phenotypes of these mutations may be ascribed to the 
fact that they disrupt different domains of VWF but the differences in phenotypes 
may also be related to interchain versus intrachain defects. Several cysteine muta-
tions, all involved in intrachain disulfide bonds, located in the D’ (p.Cys788Arg), D3 
(p.Cys1060Tyr, p.Cys1149Arg and p.Cys1225Gly) and cysteine knot (p.Cys2739Tyr and 
p.Cys2754Trp) domains showed very similar disruptive effects on the storage and se-
cretion of VWF as p.Cys1130Phe and p.Cys2671Tyr [13,33]. This suggests that the effects 
are not domain-specific. Furthermore, p.Cys2739Tyr and p.Cys2754Trp in the cysteine 
knot domain are not stored properly, whereas p.Cys2773Ser in the same domain but 
involved in interchain disulfide bonds showed normal storage [13]. In addition, an-
other mutation p.Cys1099Tyr in the D3 domain that disrupts interchain disulfide 
bonds between N-termini of VWF was identified in VWD type II C Miami patients 





characterized by normal plasma level of VWF [31,34,35]. Even stronger support for 
our hypothesis comes from the 2010 version of the ISTH-SSC VWF mutation database 
(www.vwf.group. shef.ac.uk/). It lists with 72 different mutations involving cysteine 
residues, 50 with loss of cysteines, 18 with gain of cysteines and 4 with premature 
stop codons (Table 2). Among these mutations, 42 that predict the loss of intrachain 
disulfide cysteines are associated with low plasma levels of VWF, whereas five (p.Cy-
s1099Tyr, p.Cys2771Ser/Tyr and p.Cys2773Arg/Ser) that predict the loss of interchain 
disulfide cysteines are associated with normal to relatively high plasma levels of VWF 
[14-17,31,35]. We, therefore, believe that the differences are related to differential ef-
fects of mutations involved in intrachain versus interchain disulfide bonds. 
We propose a model to explain the differential effects of intrachain versus interchain 
disulfide bonds on WPB formation (Figure 6). Disruption of intrachain disulfide 
bonds in VWF may mainly disturb the conformation of VWF such that the ER quality 
control system prevents trafficking to the Golgi apparatus [36]. Retained VWF mole-
cules either aggregate in the ER to lead to ER dilation (Figure 2F-G)[13,33] or undergo 
intracellular degradation [13,37]. Some mutant VWF molecules appear to escape the 
quality control system and are able to reach the Golgi apparatus. The extent to which 
this escape takes place appears to depend on the nature of the defects. Once the mu-
tants get to the trans Golgi, where further processes of VWF are highly regulated by 
pH, [6,7,38] their effects are minimal unless the defects cause severe changes in VWF 
conformation. In contrast, disruption of interchain disulfide bonds such as that in the 
VWF C-termini does not hamper trafficking to the Golgi apparatus and WPB thereaf-
ter. C-terminal dimerization of VWF is not, therefore, required for WPB formation. 
According to the notion that N-terminal dimerization (i.e. multimerization) of VWF is 
not required for WPB formation, [39] the mutations that disrupt interchain disulfides 
in VWF N-terminal may not disrupt the biogenesis of WPB as well. It is thus tempting 
to speculate that unpairing all the five interchain disulfide bonds (two at the N-termi-
nal and three at the C-terminal) should have minimal, if any, effect on the storage and 
secretion of VWF. 
Tubulation is a key step in the storage of VWF into WPB. Recent studies provide emerg-
ing evidence in support of a hypothesis that VWF tubulation is regulated by the low 
pH in trans Golgi and WPB [7,38,40,41]. In a cell-free system with low pH as in trans 
Golgi, Huang and colleagues showed that truncated N-terminal dimers of VWF D’D3 
domains together with VWF propeptide formed tubular structures by self-assembly 
[38]. The present data confirmed this finding for full-length VWF in a cell system. The 
VWF p.Cys2773Ser that forms N-terminal dimers [17] and partly remains as monomers 
showed normal tubulation (Figure 2E). The persistence of monomers raises two ques-
tions: (i) whether (and how) the monomers are stored into pseudoWPB; and (ii) are 
these monomers able to form VWF tubules? As VWF is mainly secreted from WPB via 
basal and regulated pathways, the large amount of monomers that was detected in the 
medium of cells expressing p.Cys2773Ser (Figure 5A) suggests that VWF monomers 





Table 2. VWF cysteine mutations identified in VWD*.
Loss of Cysteine Gain of Cysteine
Domain Mutation VWD type VWF level Domain Mutation VWD type VWF level
D1 p.Cys57* 3 ↓ D1 p.Trp377Cys 3 ↓
D1 p.Cys263_E270del 3 ↓ D2 p.Arg760Cys 2N ↓
D1 p.Cys275(Ser/Arg)† 1 or 3 ↓ D’ p.Tyr795Cys 2N ↓
D2 p.Cys570Ser 2A ↓ D3 p.Tyr1107Cys Unclassified ↓
D2 p.Cys623Trp 2A ↓ D3 p.Tyr1146Cys 1 ↓
D’ p.Cys709Leufs*3 2A ↓ A1 p.Arg1308Cys 2B n.a
D’ p.Cys788 (Arg/Tyr) 2N ↓ A1 p.Trp1313Cys 2B n.a
D’ p.Cys804Phe 2N ↓ A1 p.Arg1315Cys 1 or 3 ↓
D’ p.Cys858Phe 2N ↓ A1 p.Arg1342Cys 1 ↓
D3 p.Cys996Gly 1 ↓ A1 p.arg1374Cys 1 or 2A or 2M ↓
D3 p.Cys1060(Arg/Tyr) 1 or 2N ↓ A1 p.Arg1379Cys 1 or Unclassified ↓
D3 p.Cys1071Phe 3 ↓ A1 p.Arg1399Cys Unclassified n.a
D3 p.Cys1099Tyr‡§ IIC Miami =/↑ A2 p.Phe1514Cys 2A n.a
D3 p.Cys1101(Arg/Trp) Unclassified n.a A2 p.Tyr1584Cys 1 ↓
D3 p.Cys1111Tyr 1 ↓ A3 p.Trp1745Cys 2M ↓
D3 p.Cys1130(Phe/Gly/Arg) 1 ↓ B1-B3 p.Arg2379Cys 1 ↓
D3 p.Cys1149Arg 1 ↓ C2 p.Gly2441Cys 1 ↓
D3 p.Cys1157Phe Unclassified ↓ C2 p.Arg2464Cys 1 or Unclassified ↓
D3 p.Cys1190Arg 1 ↓
D3 p.Cys1196Arg 2M or 3 ↓
D3 p.Cys1225Gly 2N ↓
D3 p.Cys1227Arg 1 ↓




A1 p.Cys1458Tyr 2A n.a
D4 p.Cys2174Gly 3 ↓
D4 p.Cys2257Ser 1 ↓
B1-B3 p.Cys2304Tyr 1 ↓
B1-B3 p.Cys2340Arg 1 ↓
B1-B3 p.Cys2362Phe 1 or 3 ↓
C2 p.Cys2477(Ser/Tyr) 1 ↓
C2 p.Cys2533* Unclassified ↓
C2 p.Cys2557Serfs*8 3 ↓
C2-CK¶ p.Cys2671Tyr 3 ↓
C2-CK¶ p.Cys2693Tyr 1 ↓
CK p.Cys2739Tyr 3 ↓
CK p.Cys2754Trp 3 ↓
CK p.Cys2771(Ser/Tyr)‡ 2A(IID) =/↑
CK p.Cys2773(Arg/Ser)‡ 2A(IID) =/↑
CK p.Cys2804(Tyr/fs) 1 or 3 ↓
CK p.Cys2806Arg Unclassified ↓
* Summarized from the ISTH-SSC VWF mutation database up to 2010 (www.vwf.group.shef.ac.uk/). †When there are multiple mutations reported 
at a position the various amino acid substitutions are indicated in brackets. ‡ Cysteines involved in the interchain disulfide bonds in VWF; n.a., data 
not available. § Not yet in the ISTH-SSC VWF mutation database [35]. ¶ The connecting area between C2 and CK domain.





are probably stored in the pseudo-WPB. Furthermore, immunofluorescent staining 
showed that very little VWF p.Cys2773Ser was localized in the ER (Figure 1D), indicat-
ing that the excessive monomers found in the lysate (data not shown) are indeed stored 
in the pseudo-WPB. It is unknown whether those monomers are able to form tubules 
in the trans Golgi network as it has been suggested that N-terminal dimerization is 
required for the tubulation of VWF in a cell-free system [38]. Strikingly, Zhou and 
colleagues observed a dimeric bouquet-like VWF complex formed at the acidic pH of 
the trans Golgi and WPB [7]. The C-terminal dimer of VWF was zipped up by the acidic 
pH from the cysteine knot to B1 domain (six domains) into a dimeric stem. This pro-
cess was proposed to facilitate VWF tubulation [7]. As such, unpairing the interchain 
disulfide bonds at the cysteine knot domain, for example, by mutation p.Cys2773Ser, 
would unlock the start point of the zip. It is unknown whether the stability and/or 
conformation of the dimeric complex would be affected. As formation of the dimeric 
complex is highly pH-dependent, the p.Cys2773Ser monomers are likely to form the 
bouquet-like complex and, therefore, to incorporate into VWF tubules. In contrast, 
VWF mutations p.Cys2739Tyr and p.Cys2754Trp which cause severe conformational 
changes by defects in intrachain disulfide bonds led to disorganized tubular storage 
of VWF [13]. This suggests that the conformational changes in VWF may be more dis-
ruptive to VWF tubulation than no interchain pairing.
In conclusion, we postulate that natural mutations of cysteines involved in the forma-
tion of interchain disulfide bonds, p.Cys2771, p.Cys2773 and p.Cys2811 in the cysteine 
knot domain and p.Cys1099 and p.Cys1142 in the D3 domain, do not affect the storage 
and secretion of VWF, whereas mutations of cysteines forming intrachain disulfide 
bonds lead to reduced VWF storage and secretion due to ER retention.
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Abstract
Von Willebrand disease (VWD) is a bleeding disorder characterized by reduced plas-
ma von Willebrand factor (VWF) levels or functionally abnormal VWF. Low plasma 
levels in VWD patients are the result of mutations in the VWF gene that lead to de-
creased synthesis, impaired secretion, increased clearance or a combination thereof. 
However, expression studies of variants located in the A domains of VWF are limited. 
We therefore characterized the biosynthesis of VWF mutations, located in the VWF 
A1-A3 domains, which were found in families diagnosed with VWD. Human Embry-
onic Kidney 293 (HEK293) cells were transiently transfected with plasmids encoding 
full-length wild-type VWF or mutant VWF. Six mutations in the A1-A3 domains were 
expressed. We found that all mutants, except one, showed impaired formation of elon-
gated pseudo-Weibel-Palade bodies (WPB). In addition, two mutations also showed 
reduced numbers of pseudo-WPB, even in the heterozygous state, and increased en-
doplasmic reticulum retention, which is in accordance with the impaired regulated 
secretion seen in patients and. Regulated secretion upon stimulation of transfected 
cells reproduced the in vivo situation, indicating that HEK293 cells expressing VWF 
variants found in patients with VWD can be used to properly assess defects in regu-
lated secretion. 
Introduction
Von Willebrand factor (VWF) is a multimeric glycoprotein. Upon vascular damage 
VWF serves as an adhesion molecule for platelets thereby initiating platelet plug for-
mation. VWF is also the carrier protein of coagulation factor VIII (FVIII). VWF is syn-
thesized in endothelial cells and megakaryocytes and is either secreted constitutively 
into plasma or stored in specific organelles; Weibel-Palade bodies (WPB) in endothe-
lial cells or α-granules in megakaryocytes and platelets. The highest molecular weight 
VWF multimers are stored and are released from endothelial cells in response to ag-
onists like thrombin, epinephrine, and vasopressin or its synthetic analogue desmo-
pressin (DDAVP) [1,2]
A decreased plasma level or abnormal function of VWF is responsible for von Wil-
lebrand disease (VWD), the most common inherited bleeding disorder with an esti-
mated prevalence ranging from 0.035% to 1.3% of the population [1,3]. Mutations in 
the VWF gene may lead to decreased VWF plasma levels via decreased synthesis, im-
paired secretion, increased clearance or a combination of these conditions. A subset 
of VWD patients shows a reduced response to DDAVP, a specific agonist for release of 
WPB, which is clinically applied to raise VWF plasma levels [4]. The lack of response 
to DDAVP suggests the absence of recruitable WPB. The VWF propeptide (D1-D2 do-
mains) and D’D3 domains are involved in the tubular assembly of VWF, which drives 
WPB formation [5,6]. Michaux et al. [6] showed that for elongation of the WPB at least 
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absent response to DDAVP was mainly found among patients with mutations in the 
D3-A3 domain of VWF [4]. This suggests that determinants for biogenesis of recruita-
ble WPB are also located outside of the D1-A1 domains. However, most expression 
studies on the storage and secretion of VWF are focussed on VWF variants located 
in the D1-D3 or D4-CK domains of VWF [7-10]. Currently 364 different mutations are 
registered in the VWF database [11]; 161 (44%) of these mutations are located in the 
A1-A3 domains of VWF. However, expression studies on variants located in the A do-
mains of VWF are limited, especially for variants which are not identified as apparent 
type 2A or 2B VWD. We therefore aimed to investigate and characterize the synthesis 
and secretion of VWF variants in the VWF A1-A3 domain.
Materials and Methods
Patients and Mutations
The mutations (Tables 1 and 2) that we have selected were originally identified in pa-
tients historically diagnosed with VWD type 1 [12-15]. However, subsequent detailed 
analysis of the multimeric patterns has revealed that some of those mutations were 
associated with minor multimer abnormalities [16]. Those multimer abnormalities 
were less outspoken than in classical type 2A patients; some may still be classified as 
type 1, whereas others should be better reclassified as type 2A (Table 1) [16,17]. 
Plasmid Constructs
Recombinant pCI-neo expression plasmid containing full-length wild-type human 
VWF (WT-VWF) cDNA has been described [7]. Mutations were introduced into pCI-
neo WT-VWF plasmid with the QuikChange XL Site-Directed Mutagenesis Kit (Strat-
agene, La Jolla, CA, USA). DNA was purified using the PureYield™ Plasmid Maxiprep 
System (Promega) and preparations were verified by sequencing.
Cell culture and transfections
HEK293 cells from ATCC (Rockville, USA) were cultured and transfected as described 
[7]. Briefly, using FuGENE HD transfection reagent (Roche Diagnostics, Mannheim, 
Germany) plasmid constructs were transiently transfected into HEK293 cells at a fi-
nal concentration of 0.66 µg/mL (0.33 µg/mL WT-VWF and mutant VWF plasmids, 
respectively, for co-transfections). All data were collected 72 hours post-transfection.
Immunostaining
Cells were stained with immunofluorescent antibodies and analyzed by Leica SL 
confocal laser scanning microscopy with a 63X/1.40 NA oil objective [7]. Polyclonal 
FITC-conjugated sheep anti-human VWF antibody (Abcam, Cambridge, UK) and pol-
yclonal rabbit anti-human protein disulfide isomerase (PDI) antibody A66 (obtained 
from Prof. I. Braakman, Department of Chemistry, Utrecht University, Utrecht, The 
Netherlands) were used as primary antibodies against VWF and the endoplasmic re-
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purchased from Invitrogen. Monoclonal mouse anti-LAMP1 (mAb BB6; kindly provid-
ed by Dr. S. Carlsson, Umeå, Sweden) was used to visualize lysosomes. The percentage 
of cells that showed ER retention of VWF was determined in two independent exper-
iments for all VWF variants; in total 200 cells were analyzed per variant.  To quantify 
pseudo-WPBs, 100 VWF-positive cells from two independent experiments were ran-
domly selected and analyzed. We used similar morphological criteria as reported by 
Michaux et al [18]. Briefly, we categorized the pseudo-WPBs with a ratio of length over 
diameter <2 as “round pseudo-WPBs” and those with a ratio ≥2 as “elongated pseu-
do-WPBs.”
Structural analysis of VWF
VWF multimer analysis was performed as previously described [7]. Processing of 
VWF was analysed by reducing SDS-PAGE and Western blot analysis for the condi-
tioned media and cell lysates. Samples were reduced using 20 mM dithiothreitol, 
separated by Novex 6% Tris-Glycine gel electrophoresis (Invitrogen), immunostained 
with polyclonal rabbit anti-human VWF conjugated to horseradish peroxidase (DAKO, 
Glostrup, Denmark) and visualized with Supersignal WestFemto (Thermo Scientific, 
Rockford, IL, USA).
Basal and regulated secretion of VWF
Basal secretion of VWF was determined in media and cell lysates collected 72 hours 
post-transfection as described previously [7]. Briefly, cells grown until 80% conflu-
ency, were transfected with plasmids and 24 hours after transfection medium was 
refreshed. 48 hours after refreshment medium was collected and cells were lysed. To 
analyze the regulated secretion of VWF, 72 hours post-transfection cells were incu-
bated for 60 minutes with release medium containing 160 nM phorbol 12-myristate 
13-acetate (PMA) (Sigma-Aldrich, St Louis, MO, USA) or vehicle (DMSO). VWF:Ag in 
media and cell lysates was determined by ELISA [19]. Regulated secretion is expressed 
as secreted VWF as a fraction of total VWF (medium plus lysate). Statistical analyses 
were performed by the Student’s t-test using GraphPad Prism (version 4.02).
Transmission electron microscopy
Transfected cells grown on 35-mm petri dishes were fixed and prepared for trans-
mission electron microscopy (TEM) as described [20]. Briefly, osmium tetroxide and 
tannic acid treated cells were serially dehydrated with ethanol and embedded in Epon. 
Samples were cut into thin sections of 70-100 nm, stained with 7% uranyl acetate and 
Reynolds lead citrate, and analyzed with a FEI company Tecnai 12 at 120 kV equipped 
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Results
The mutations that we have selected were originally identified in patients historically 
diagnosed with VWD type 1 [12-15]. Characteristics of VWD patients carrying the se-
lected mutations are given in Tables 1 and 2. 
Pseudo Weibel-Palade body formation in VWF transfected cells
We analysed the formation and intracellular distribution of pseudo-WPB in HEK293 
cells by transiently transfecting cells with VWF variants. Cells transfected with WT-
VWF or VWF p.Arg1583Trp formed numerous elongated pseudo-WPB (Figure 1). 
p.Ser1285Pro, p.Leu1307Pro, p.Arg1374His, p.Tyr1584Cys and p.Val.1822Gly induced 
pseudo-WPB that appeared to be shorter and rounder when compared to those 




Table 1. Summary of patient characteristics obtained from the MCMDM-1VWD study.*















p.Ser1285Pro A1 1 27 3 16 8 1.69 relative decrease of the 
large multimers, but 
normal triplet structure
1
p.Leu1307Pro A1 1 33 7 16 6 2.06 relative decrease of the 
large multimers, but 
normal triplet structure
2A
p.Arg1374His A1 2 48-79 10-16 29-74 22-23 1.07-1.66 classical 2A(IIE) pattern 2A
p.Arg1583Trp A2 1 56 54 52 57 1.07 normal 1
p.Tyr1584Cys A2 10 21-182 36-93 21-80 20-115 0.70-2.32 normal 1
p.Val1822Gly A3 1 35 26 19 45 1.84 2A(IIE); relative decrease 
of the large multimers, 
barely visible outer sub-
bands. Typical pattern but 
less pronounced
1
* Data previously obtained in the MCMDM-1VWD.
† (Sub) type designated by Budde et al. according to the 2006 classification.
Table 2. Summary of DDAVP characteristics.* 
Variant FVIII:C IU/dL VWF:Rco IU/dL VWF:Rco/Ag Response‡
Before Peak Fold 
increase
Before Peak Fold 
increase
Before Peak
p.Leu1307Pro 36 118 3.3 6 22 3.7 0.43 0.46 Partial
p.Arg1374His 73 213 2.9 18 34 1.9 0.22 0.18 Non-responder
p.Arg1583Trp 31 97 3.1 48 130 2.7 0.92 0.91 Complete
p.Tyr1584Cys 91 113 1.2 75 136 1.8 0.94 1.36 Complete
p.Val1822Gly 38 79 2.1 16 48 3.0 0.55 0.83 Partial
* Data reported by the MCMDM-1VWD study and own clinical data.
‡Patients were defined as follows: complete responders: both VWF:RCo and FVIII:C were 50 IU/dL or higher after desmopressin; partial responders: 
VWF:RCo or FVIII:C were lower than 50 IU/dL but increased at least 3-fold; and nonresponders: neither criterion. Patients with VWF:RCo and/or FVIII:C 50 
IU/dL or higher at baseline at time of testing were considered as complete responders if a level of 100 IU/dL or higher was reached for both measurements.





Figure 1. Intracellular localization of VWF in transfected HEK293 cells. HEK293 cells were transiently transfected 
with WT-VWF or mutant VWF (single transfections, left panel) or with WT- and mutant VWF (co-transfections, right 
panel). Cells were fixed for immunofluorescence imaging 72 hours post-transfection and stained for VWF (green channel) 
and PDI (an ER marker, red channel). In merged images, pseudo-WPB show up in green (VWF staining only), and VWF in 
the ER shows up as yellow (double staining of VWF and PDI). Scale bar = 5µm. The percentage of cells (indicated in the 
middle) that showed ER retention of VWF was determined in two independent experiments in 200-260 cells expressing 
each VWF variants in single and co-transfections with WT.
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No VWF was detectable by immunofluorescent staining in lysosomes (data not shown), 
indicating that the round organelles are not VWF containing lysosomes. Increased 
retention of VWF in the ER, identified by the co-localization of VWF and PDI (yel-
low colour), was observed for p.Ser1285Pro, p.Leu1307Pro and p.Val1822Gly (Figure 
1).  Percentage of ER retention of p.Arg1374His, p.Arg1583Trp and p.Tyr1584Cys was 
similar to that of WT-VWF (Figure 1). To mimic the heterozygous state of patients, 
co-transfections of the variants with WT-VWF were performed. Upon co-transfection 
of mutant and WT-VWF (Figure 1, right panels) the percentage of transfected cells 
with ER retention was similar to that observed for the single transfections (Figure 1). 
For quantification of the number and shape of pseudo-WPB we randomly selected con-
focal microscopy fields and analysed 100 cells from each sample. Pseudo-WPB were 
defined by a positive VWF staining, and the absence of co-staining with the ER marker 
PDI. For WT-VWF, 70% of the transfected cells contained more than 30 pseudo-WPB 
per cell. Similar numbers of pseudo-WPB were found for the VWF variants, except 




Figure 2. Defects in pseudo-WPB number and formation. HEK293 cells were transfected, fixed and stained 
as described in Figure 1. Images were taken by confocal microscopy and cells were analysed for quantitative 
analysis. Cells were divided into three categories according to the number of pseudo-WPB per cell (Panel A): 
more than 30; from 11-30; 10 or less per cell; or according to the number of elongated pseudo-WPB per cell 
(Panel B): more than 4; from 1 to 4; non elongated pseudo-WPB per cell. Per VWF variant, 100 cells expressing 
VWF were analysed for each bar. Each bar represents the mean of two independent experiments.
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contained more than 30 pseudo-WPB respectively (Figure 2A). Co-transfection with 
WT-VWF only marginally increased the number of WPB formed by these variants 
(Figure 2A). When considering the shape of the pseudo-WPB, 89% of the WT-VWF 
transfected cells had 4 or more elongated (length over diameter >2) pseudo-WPB. 
For all variants, except the p.Arg1583Trp, a decrease in the number of elongated 
pseudo-WPBs per cell was observed. No elongated organelles could be found for the 
p.Leu1307Pro variant. Upon co-transfection with WT-VWF the percentage of cells 
displaying elongated pseudo-WPBs was not significantly improved for the VWF var-
iants (Figure 2B).
Pseudo-WPB formation was further studied using TEM. In WT-VWF or p.Arg1583Trp 
transfected cells, elongated and electron dense pseudo-WPB were observed with the 




Figure 3. Ultrastructure of transfected HEK293 cells visualized by TEM. HEK293 cells were transiently 
transfected as indicated. Pseudo-WPB displaying VWF tubules were formed by WT-VWF (A) and the mutants 
(B, D-G’). White arrows indicate visible cross-sections of tubules (D,G). For the p.Leu1307Pro we were not 
able to visualize with certainty organelles with internal tubules (C’, black square), however, dilated ER was 
predominantly observed (C, C’). The arrowheads, stars and black arrow indicate ER, mitochondria and Golgi, 
respectively. Scale bar panels A,C,E,G = 500nm; scale bar panels B,C’,D,F,G’ = 200nm.
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round pseudo-WPB were found in cells expressing VWF p.Ser1285Pro, p.Arg1374His 
or p.Tyr1584Cys (Figure 3B, D, F). The p.Val1822Gly variant showed a few elongated 
pseudo-WPB, while round structures were found frequently (Figure 3G-G´), in 
concordance with the confocal images where most VWF-containing structures were 
short or round (Figure 2B). The round structures that we observed for the variants 
are recognizable as pseudo-WPB as they contain tubular structures resembling 
stored VWF (Figure 3B, D, F-G’). Grossly dilated ER surrounded by mitochondria 
was frequently observed in cells expressing the p.Leu1307Pro variant (Figure 3C), 
in accordance with the observed ~50% ER retention (Figure 1). We could not with 
certainty visualize organelles with internal tubules for p.Leu1307Pro, but round 




Figure 4. Subunit composition of VWF under reducing conditions. VWF secreted into medium or VWF 
retained in lysates was reduced with DTT and analyzed with SDS-PAGE and Western blot (A). In panel B, the 
ratio of proVWF (p) and mature VWF subunit (m) in the cell lysate was analyzed with Image J (NIH software, 
version 1.44P).
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Retention of VWF was further investigated by evaluating the amount of processed 
VWF with Western blotting under reducing conditions. VWF secreted into the 
medium consisted of fully processed mature VWF subunits (Figure 4A). Cell lysates 
showed both mature VWF subunits and unprocessed proVWF. The p.Ser1285Pro, 
p.Leu1307Pro and p.Val1822Gly variants showed relatively more uncleaved proVWF 
compared to WT-VWF as indicated by the ratio between mature VWF and proVWF 
(Figure 4B, upper panel). This is in accordance with the increased ER retention 
measured in the transfected cells of these variants (Figure 1). Upon co-transfection 
with WT-VWF some increase in the relative amount of cleaved VWF was observed for 
p.Ser1285Pro and p.Leu1307Pro (Figure 4B, lower panel). 
Multimeric structure of VWF
Compared to WT-VWF all variants, except p.Leu1307Pro, showed a similar and nor-
mal VWF multimer distribution in medium (Figure 5A) and lysate (Figure 5B). The 
p.Leu1307Pro mutation, however, led to a relative loss of the larger multimers in both 
medium and lysate. Upon co-transfection of p.Leu1307Pro with WT-VWF also larger 
multimers were observed (Figure 5). However, relatively more dimers and tetramers 
were observed in the multimer pattern of the p.Leu1307Pro/WT-VWF co-transfection 
when compared to the multimer pattern of WT-VWF alone. In the MCMDM-1VWD 
study subtle differences in multimer distribution were also observed in plasma sam-
ples of patients with mutations p.Ser1285Pro, p.Arg1374His and p.Val1822Gly (Table 
1). The apparent discrepancy with the multimer analysis presented in this study may 
be explained by the fact that different techniques were used to visualize VWF multim-
ers. Furthermore, in our study we analyzed multimer patterns of VWF released into 
medium whereas in the MCMDM-1VWD study plasma samples were used. Proteolysis 





Figure 5. Multimeric analysis 
of recombinant VWF. Multimer 
patterns were analysed in condi-
tioned media (A) and cell lysates 
(B). Multimers are shown for sin-
gle- and co-transfections. The 
multimer patterns were analyzed 
by SDS-agarose gel electropho-
resis and Western blot under 
non-reducing conditions. The sep-
arate lanes in panel B are from the 
same blot, but normal pool plas-
ma (NPP) and wt-VWF (WT) were 
switched for consistency in the 
order of lanes.
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Basal and regulated secretion of VWF
To investigate the effect of VWF mutants on the secretion of VWF, both basal and 
regulated secretion were studied. Basal secretion was defined as the amount of 
VWF:Ag in conditioned medium 72 hours post-transfection (Table 3 and Figure 6A). 
p.Ser1285Pro, p.Arg1583Trp and p.Tyr1584Cys variants show normal basal secre-
tion of VWF compared to WT-VWF (Figure 6A) in the single transfections. Further-
more, total VWF production (VWF in both medium and lysate) was similar for WT-
VWF and these mutants (Table 3). In contrast, basal secretion of single transfected 
p.Leu1307Pro, p.Arg1374His and p.Val1822Gly mutations was markedly reduced when 
compared to WT-VWF. This was apparent from both the amount of VWF secreted into 
the medium as well as the reduced ratio between the absolute amount of VWF present 
in medium and lysate (Table 3). Also, the total amount of VWF (medium plus lysate) 
was significantly reduced (60-70mU VWF for the variants versus ± 100mU VWF for 
WT-VWF) (Table 3). 
Previously we showed that in co-transfection experiments both constructs are ex-
pressed in individual cells [8]. After co-transfection with WT-VWF basal secretion 
was restored for the p.Arg1374His mutation to almost normal (85%±2.4 relative to 
WT-VWF). The absolute amount of VWF produced by this mutant was also restored to 
normal levels upon co-expression of WT-VWF (95mU±4.8 versus 102mU±3.7 for WT-
VWF). The secretion defect observed for the variants p.Leu1307Pro and p.Val1822Gly 




Table 3. Expression of VWF variants in transfected HEK293 cells.





mU % mU % mU medium/
lysate
medium/lysate
WT-VWF 71±2.3 100 32±2.0 100 102±3.7 2.2±0.12 1
p.Ser1285Pro Single transfection 73±3.1 103±4.5 39±2.7 123±1.2 112±5.8 1.9±0.05 0.9
Co-transfection 71±2.4 100±1.2 35±2.2 112±2.1 105±5.7 2.0±0.12 0.9
p.Leu1307Pro Single transfection 28±1.2 40±2.3 42±3.3 132±2.9 70±4.4‡ 0.7±0.03‡ 0.3
Co-transfection 36±1.0 51±0.9 35±2.0 112±2.9 72±2.6‡ 1.0±0.06‡ 0.5
p.Arg1374His Single transfection 43±2.5 61±2.8 25±1.4 80±2.3 68±3.0‡ 1.7±0.14‡ 0.8
Co-transfection 60±1.2 85±2.4 35±3.8 111±6.4 95±4.8 1.7±0.14‡ 0.8
p.Arg1583Trp Single transfection 69±1.9 97±3.5 27±1.4 84±2.1 95±3.1 2.6±0.09 1.2
Co-transfection 72±3.7 102±4.3 31±2.9 97±3.8 103±2.5 2.4±0.3 1.1
p.Tyr1584Cys Single transfection 72±5.2 101±4.0 27±2.8 87±9.0 99±8.1 2.6±0.08 1.2
Co-transfection 71±3.9 101±4.2 32±2.1 102±2.2 104±6.0 2.2±0.03 1
p.Val1822Gly Single transfection 36±2.0 51±3.2 21±2.2 50±8.7 57±4.1‡ 1.8±0.12‡ 0.8
Co-transfection 52±1.5 73±0.6 33±2.7 105±5.7 85±4.2‡ 1.6±0.09‡ 0.7
*VWF:Ag (mU) was produced by about 7×105 cells in medium or lysate. VWF:Ag is also expressed as percentage relative to the amount of VWF:Ag 
in WT-VWF transfected cells. Each value represents the mean ± SEM of three independent experiments performed in duplicate.
‡ Compared with WT-VWF p<0.05 (student’s-t test)
§ Ratio for WT-VWF is set at 1, ratios of variants are then normalized against WT-VWF.





Figure 6. Basal and regulated secretion of VWF. HEK293 cells were transiently transfected with WT-VWF or 
mutants, or the mutants were co-transfected with WT-VWF at 1:1 ratio. (A) 72 hours post-transfection condi-
tioned media and cell lysates were collected to determine basal secretion of VWF. WT-VWF is set at 100%. (B, 
C) Regulated secretion of VWF was analyzed as follows: 72 hours post-transfection HEK293 cells were rinsed 
and incubated at 37°C for 60 minutes in release medium with DMSO (Control) or with 160 nM PMA (PMA). Panel 
B shows regulated secretion of single transfections, panel C shows secretion of co-transfections. Each bar rep-
resents VWF secreted into the medium as a fraction of total VWF (secreted plus intracellular). Mean and SEM 
are based on three independent experiments in duplicate. Numbers above the bars indicate the fold increase of 
secreted VWF upon stimulation.
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tively); the total VWF amount (medium plus lysate) remained reduced (72mU±2.6, and 
85mU±4.2, respectively, compared to 102mU±3.7 for WT-VWF). When compared with 
patients (Table 1), secreted levels of VWF in transfected cells were in concordance 
with plasma levels measured in patients with the corresponding mutations. Only the 
p.Ser1285Pro variant shows normal secretion in our system whereas the plasma level 
was significantly reduced in the patient (16 IU/dl). This difference is probably due to 
increased clearance of this VWF variant, as patients had increased VWFpp/VWF:Ag 
ratios [22].
The regulated secretion pathway of VWF was analyzed using PMA, which has been 
shown to efficiently induce exocytosis of pseudo-WPBs from transfected HEK293 cells 
and HUVECs [7,18,23]. After stimulation with PMA for 60 minutes, secretion of WT-
VWF was increased almost 3-fold (9% of total VWF was secreted by cells stimulat-
ed with PMA versus 3% by non-stimulated cells, Figure 6B). Compared to WT-VWF 
transfected cells, p.Arg1583Trp and p.Tyr1584Cys transfected cells showed similar re-
sponses to PMA stimulation in both single and co-transfections (Figure 6B-C). This is 
also in line with the adequate response found in patients carrying these mutations af-
ter DDAVP infusion (2.7-fold and 1.8-fold increase of VWF:RCo) (Table 2) [4]. Cells ex-
pressing p.Ser1285Pro, p.Leu1307Pro, p.Arg1374His and p.Val1822Gly responded less 
well to PMA stimulation (0.8 to 1.6 fold increase following PMA stimulation) (Figure 
6B-C). Co-transfection with WT-VWF corrected the response for p.Arg1374His and 
partially increased the response for p.Val1822Gly, but did not increase the response 
for p.Ser1285Pro and p.Leu1307Pro (Figure 6C).
Discussion
In this study we have expressed six VWF variants located within the A domains of 
VWF that were previously identified in patients diagnosed with VWD [12-15]. The 
p.Ser1285Pro (Figure 7A), p.Leu1307Pro (Figure 7B) and p.Arg1374His (Figure 7C) 
mutations are located within the A1 domain, the p.Arg1583Trp (Figure 7D) and p.Tyr-
1584Cys (Figure 7E) are located in the A2 domain and the p.Val1822Gly (Figure 7F) 
mutation is located in the A3 domain of VWF. We studied the ability of these VWD 
variants to induce the formation of pseudo-WPBs in HEK293 cells and we assessed 
whether PMA-induced WPBs release was impaired for these variants (Table 3).
Of the six mutations studied, the p.Arg1583Trp and p.Tyr1584Cys variants had normal 
basal VWF levels and responded adequately to PMA stimulation in the heterozygous 
state (Figure 6). However, the other four variants led to decreased basal secre-
tion (p.Arg1374His), impaired regulated secretion (p.Ser1285Pro) or a combination 
thereof (p.Leu1307Pro and p.Val1822Gly) in the heterozygous state. A summary of the 
observed defects is given in Table 4.
Substitutions in the VWF gene may lead to misfolding of the VWF protein. ER localized 
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degradation [24-26]. Inspection of the A1-A3 substitutions analyzed in this study sup-
port a role for misfolding in ER retention. The serine at position 1285 is part of the gly-
cosylation motif Asp-X-Ser [27] (Figure 7A). Disruption of this motif by substituting 
aspartic acid at position 1283 by alanine attenuated binding of the protein to glycopro-
tein Ib, probably by relaxation of the A1 domain fold [27]. Whether relaxation caus-
es the defects seen in this variant remains to be determined. The leucine at position 
1307 is located in the hydrophobic pocket at the end of the α1 helix of the A1 domain 
(Figure 7B). Proline has a poor helix forming propensity because it cannot donate an 
amide hydrogen bond and because its side chain interferes sterically with the back-
bone of the preceding turn [28]. Prediction software suggested that the substitution 
to a proline will lead to loss of stability of the protein (SIFT [29] and PolyPhen2 [30], 
data not shown), and this could therefore be the cause of increased ER retention of this 
VWF variant. The arginine at position 1374 makes important interactions in the α3β4 
loop of the A1 domain [31]. Within the crystal structure of the A1 domain the arginine 
is buried (Figure 7C) and its replacement by a histidine will probably destabilize the 




Figure 7.  Secondary structure of the VWF A domains. Secondary structures of the A1, A2 and A3 domain of 
VWF were prepared using Pymol version 1.3. The positions of the mutations are indicated in red and visualised 
as “sticks”. Panel A shows the mutations that are located within the A1 domain, panel B the mutations that are 
located in the A2 domain and panel C shows the mutation located in the A3 domain of VWF
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strand of the A3 domain and is buried in a hydrophobic pocket (Figure 7F). Substitu-
tion of a valine for a glycine will affect interactions with neighbouring hydrophobic 
residues, possibly resulting in destabilization of the A1 domain.
Except for the p.Arg1583Trp variant, all mutations formed round pseudo-WPB as ev-
idenced by both confocal imaging and electron microscopy (Figures 1,3). The p.Ser-
1285Pro variant led to the formation of round pseudo-WPB and showed ER retention 
(Figures 1,2), which was supported by the relative increase of unprocessed proVWF 
(Figure 4). The impaired synthesis we observed is supported by the increased FVIII/
VWF ratio found in patients (1.69, Table 1), which also suggests impaired synthesis 
of the VWF protein. Blood outgrowth endothelial cells (BOECs) from a patient carry-
ing this variant also showed mainly short, round WPB and ER retention [33]. The in-
creased VWFpp/VWF:Ag ratio measured in patients with this p.Ser1285Pro mutation 
suggests that this VWF variant is also cleared faster [22]. This may explain the differ-
ence between plasma levels of the patients and levels measured in our experimental 
system where clearance is not involved. The response to DDAVP was unfortunately 
not tested for patients with the p.Ser1285Pro mutation. However, one might speculate 
that patients will show a poor to partial response to DDAVP infusion based on our in 
vitro data and data obtained from BOECs of a VWD patient [33]. We anticipate that 
the regulated secretion in patients carrying this mutation might be quantitatively im-
paired due to retention of VWF in the ER. 
The p.Leu1307Pro variant showed severe retention of the protein in the ER, a reduced 
number of WPB and produced only round storage organelles. Basal and regulated se-
cretion of VWF were impaired as well. This phenotype was not improved when WT-
VWF was co-transfected. This is in line with data obtained from BOECs of a VWD pa-
tient heterozygous for this mutation, in which round WPB and increased ER retention 




Table 4. Summary of defects caused by single transfection of mutations in the A domain of VWF compared to WT-VWF.




A1 p.Ser1285Pro ↑ N ↓↓ N ↓ N
A1 p.Leu1307Pro ↑↑ ↓ ↓↓↓ ↓↓↓ ↓↓ Lack of HMW multimers
A1 p.Arg1374His  = N ↓↓ ↓↓ ↓ N
A2 p.Arg1583Trp  = N N N N N
A2 p.Tyr1584Cys = N ↓↓ N N N
A3 p.Val1822Gly ↑ ↓ ↓ ↓↓ ↓↓ N
‡Based on immunofluorescent images (Figure 2). N, normal; = , similar to WT-VWF.
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response obtained from a patient carrying a p.Leu1307Pro substitution in our clinic 
would define this patient as a partial responder as the VWF:RCo is lower than 50 IU/
dl after desmopressin (6 to 22 IU/dl after infusion, Table 2). This is in line with the low 
response to PMA in transfected HEK293 cells.
The p.Arg1374His variant showed a good response to stimulation with PMA in co-trans-
fection experiments (Figure 6). The data on response to DDAVP infusion in patients 
heterozygous for this mutation are conflicting [4;34]. One out of 4 patients responded 
to DDAVP in a study by Federici et al. [34]; we have previously shown a good response 
to DDAVP, raising VWF:Ag levels more than 3-fold in three family members with this 
mutation [13], while in the MCMDM-1VWD study the patient did not respond (Table 
2). Such a variation in response among patients carrying the same mutation suggests 
that the response to DDAVP is not exclusively determined by mutations in the VWF 
gene.
The p.Arg1583Trp mutation was the only variant that showed normal basal and stim-
ulated secretion of VWF as well as normal formation of elongated pseudo-WPB (Table 
4). In line with this observation, patients carrying this mutation have a mild pheno-
type and respond well to DDAVP infusion [4] (Tables 1 and 2). Alignment of the VWF 
amino acid sequence (Figure 8) shows that the arginine at position 1583 (Figure 7D) is 
poorly conserved among different vertebrate species, suggesting that the amino acid 
at this position is not critical and that substitution by tryptophan does not influence 
the structure or function of the protein. Since the expression data of p.Arg1583Trp 
are indistinguishable from WT-VWF, one might wonder whether this amino acid sub-
stitution is really pathogenic, also in the light of the fact that the VWF plasma level is 
close to normal (52 U/dl) and the FVIII/VWF ratio is approximately one, suggesting 
normal synthesis. The VWFpp/VWF:Ag ratio does not suggest increased clearance of 
the protein either [22]. 
The p.Tyr1584Cys variant (Figure 7E) has been described as a functional mutation as 
well as a polymorphism based on its prevalence [35-37]. This variant was found fre-
quently in index cases in both the Canadian type 1 VWD study as well as in the European 
MCMDM–1VWD study, and often in association with blood group O, a known modifier 
of VWF plasma levels [12,15,38]. The p.Tyr1584Cys variant has been expressed before 
in COS-7, HEK293T and AtT-20 cells, where the total protein expression reached levels 
of 75% to 90% compared to WT-VWF transfected cells [15,39]. These levels are slightly 
lower than what we observed in the current study (Table 3). However, VWF:Ag plasma 
levels also vary a lot between patients (21-80 IU/dL, Table 1). Despite the formation of 
mostly round pseudo-WPB (Figure 2B), there was no ER retention of the protein and 
the number of storage organelles as well as basal and stimulated release of VWF was 
similar to that observed for WT-VWF (Figures 2A and 6). This is in line with patient 
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In single transfection the p.Val1822Gly did not respond to PMA stimulation. However, 
PMA did induce some release of VWF in the cells expressing p.Val1822Gly upon co-ex-
pression with WT-VWF (1.3 fold increase). This is in accordance with the marginal 
response to DDAVP infusion observed in the patients (Table 2). The defects in regulat-
ed secretion of VWF may be explained by the marked decrease in WPB formation by 
p.Val1822Gly (Figure 2A). 
In summary, we have shown that naturally occurring VWD variants within the A do-
mains of VWF can cause defects in both WPB formation and regulated secretion of 
VWF. Previous data showed that the D1-D2-D’-D3-A1 subunits are required for the 
formation of elongated WPBs [6]. In our study, we show that two mutations locat-
ed within the A2 and A3 domain (p.Tyr1584Cys and p.Val1822Gly) also interfere with 
the formation of elongated WPB. Our findings show that mutations in the A2 and A3 
domain can also modulate the elongation of WPBs, as is previously suggested for the 
p.Ala1716Pro variant [10]. Interestingly, we observed that PMA-induced release of 
VWF from spherical WPBs (as observed in cells expressing pArg1374His and pTyr-
1584Cys) was not impaired. This suggests that round WPBs are equally well released 




Figure 8: Conservation of amino acids in different vertebrate species. The VWF gene was aligned using the 
HomoloGene database. Alignments of regions surrounding the studied mutations with corresponding VWF se-
quences from different vertebrate species are shown in detail. Residues highlighted in black indicate fully con-
served amino acids, whereas grey residues are highly conserved.
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WPBs containing FVIII, leading to the formation of spherical WPBs, can still release 
their cargo [40,41]. Spherical WPBs in canine endothelial cells bearing the p.Tyr87Ser 
mutation, are rapidly releasing their cargo upon stimulation with appropriate secre-
tagogues [42]. 
Overall our findings suggest that the regulated secretion upon PMA stimulation of 
transfected cells reproduces the in vivo situation (Tables 2& 4). Recent reports have 
demonstrated that BOECs isolated from VWD patients can be used to assess whether 
a patient responds to treatment with DDAVP [33,43]. However, successful isolation of 
BOECs seems to be donor-dependent and patient material may not always be available 
[33,44]. Our results indicate that HEK293 cells expressing VWF variants found in pa-
tients with VWD can be used to properly assess possible defects in regulated secretion 
of VWF. 
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Abstract
Background: One of the major determinants of von Willebrand factor (VWF) plas-
ma levels are the ABO blood groups, and individuals with blood group O have ap-
proximately 25% lower plasma levels. The exact mechanism behind this relationship 
remains unknown, although effects on clearance have been postulated. Objectives: 
Whether clearance of VWF is directly dependent on the presence of ABH antigens 
on VWF. Methods: Three type 3 von Willebrand disease (VWD) patients were infused 
with Haemate-P® and the relative loading of VWF with ABH antigens at different time 
points was measured. VWF-deficient mice were injected with purified plasma-derived 
human VWF obtained from donors with either blood group A, B or O. Results: In mice 
we found no difference in clearance rate between plasma derived A-, B- or O-VWF. 
Faster clearance of the blood group O VWF present in Haemate-P® infused in type 3 
VWD patients would have resulted in a relative increase in the loading of VWF with 
A and B antigens over time. However, we observed a 2-fold decrease of A and B anti-
gens in 2 out of 3 patients and stable loading in the third patient. Conclusion: There 
is no direct effect of ABH antigens on VWF in VWF clearance. We demonstrate that in 
a direct comparison within one individual O-VWF is not cleared faster compared to 
A- or B-VWF. Clearance differences in blood group O versus non-O individuals may 
therefore be related to the blood group status of the individual rather than the ABH 
antigen loading on VWF itself. 
Introduction
When activated upon vascular damage, von Willebrand factor (VWF) supports plate-
let adhesion and activation and initiates platelet plug formation [1]. VWF is synthe-
sized in endothelial cells and megakaryocytes and is stored in cell-specific organelles, 
respectively Weibel-Palade bodies (WPB) and α-granules [2,3]. Part of the synthesized 
VWF is secreted constitutively into the blood, where it has a half-life of about 12 hours 
[4]. 
The variation in plasma VWF levels is 66% genetically determined and the ABO blood 
group locus accounts for 30% of that variation [5]. VWF is decorated with ABO blood 
group sugars and those ABH antigens are attached to the N-linked oligosaccharide 
chains [6]. Several studies have shown that ABO blood groups are associated with 
VWF plasma levels [7;8]. Individuals with blood group O have approximately 25% low-
er VWF plasma levels. Individuals with the Bombay blood group, lacking expression 
of ABH antigens, even have lower VWF levels [9]. How ABO blood groups influence 
VWF levels exactly remains unknown. 
The VWF levels correlate with the amounts of A and B antigens present on the VWF 
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and clearance of VWF or a combination thereof. However, ABH antigens on VWF do 
not play a role in synthesis and secretion as the plasma VWF propeptide levels are 
independent of ABO blood group [12,13]. In endothelial cells derived from different 
blood group donors, the constitutive VWF secretion showed no difference, however 
those cells did not express ABH antigens on their surface nor on VWF [14]. Another 
study showed that the rise in VWF level after desmopressin treatment appears to be 
similar in patients with type 1 von Willebrand disease (VWD) with different blood 
groups, suggesting that secretion efficiency is not affected by blood group [15]. 
Nossent et al.[12] estimated, that the half-life of endogenous VWF in healthy controls 
with blood group O is almost 2 hours shorter compared with blood group non-O con-
trols. In healthy individuals the VWF half-life after DDAVP administration was also 
shorter in blood group O individuals [16]. Furthermore, the ratio in plasma between 
VWF propeptide and mature VWF, which are released in equimolar amounts, is in-
creased in individuals with blood group O compared with non-O individuals. This 
suggests faster clearance of mature VWF in blood group O individuals [12,13,17]. These 
observations clearly show that VWF plasma levels in individuals with blood group O 
are lower due to faster clearance of VWF. However, this supposition is not yet chal-
lenged in a direct comparison. All studies investigated the clearance of O-VWF in 
blood group O individuals. The question remains whether clearance differences are 
to be attributed to the blood group antigens on the VWF molecule itself or to the ABO 
blood group status of the individual that clears the VWF protein. The present study is 




VWF-deficient (VWF-/-) female mice on a C57BL/6J background (embryos original-
ly obtained from Jackson Laboratories (Bar Harbor, ME, USA) were between 8 to 12 
weeks old. Mice were housed under a 12-h light/dark cycle. Standard diet and drink-
ing water were provided ad libitum. All procedures were approved by the animal wel-
fare committee of the Leiden University (under registration #10037).
Patients
After written informed consent, VWF concentrate (Haemate-P®, CSL Behring, Mar-
burg, Germany) was infused in three type 3 VWD patients (2 females and 1 male, all 
blood group O) in a dosage of 50 units FVIII per kg body weight. Blood samples were 
collected before administration of Haemate-P®, and at 10 min, 1, 2, 4, 6, 8, and 24 
hours thereafter. The study was approved by the local ethical review committee of the 
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VWF purification 
Fresh frozen plasma from donors with blood groups A (n=3), B (n=3) or O (n=3) (San-
quin, Leiden, The Netherlands), was cryoprecipitated and precipitates were dissolved 
in elution buffer (25mM TEA, 15mM sodium citrate, 150mM NaCl, pH 7.5). Plasma 
VWF was separated by gel filtration chromatography on a Sepharose 4B column (GE 
Healthcare, Little Chalfont, UK). Collected fractions were measured for VWF antigen 
(VWF:Ag) [18]. VWF purified from donors with blood group O, containing only the 
H-antigen, is indicated as O-VWF. VWF purified from A and B donors is indicated as 
A-VWF (A-antigen present) and B-VWF (B-antigen present).
Clearance of plasma derived human VWF in mice
Female VWF-/- mice were subcutaneously injected with 50 µl Temgesic (0.1 mg/kg) 
for analgesia one hour prior to experiments. Three different human blood donors 
were used for each blood group, and five mice were used per human blood donor, so 
a total of 15 mice were used for each blood group. Fortyfive mice were injected into 
the tail vein with 200 µl of 2U/ml purified plasma derived (pd)-VWF. At 1, 15, 30, 60, 
120, 240 and 360 minutes after injection, 50 µL of citrated-blood (final concentration 
of 0.32%) was collected via tail transection and tails were subsequently cauterized. 
After centrifugation (2500g for 15min), plasma was collected and human VWF:Ag was 
measured [18]. 
Macrophage depletion in mice
Female VWF-/- mice (n=4 per group) were injected intravenously with either 200µl/
mouse clodronate liposomes (gift of Roche Diagnostics GmbH, Mannheim, Germany) 
or saline (200µl/mouse) as a control. Two days after treatment, mice were injected 
via tail injection with 200 µl Haemate-P® (5U/ml VWF:Ag) and citrated-blood was 
collected at several time points for determination of plasma VWF:Ag levels and clear-
ance rates. Macrophage depletion was confirmed by staining liver and spleen cryostat 
sections with an antibody to a specific mouse macrophage marker F4/80 (AbD Sero-
tec, Oxford, UK).
Measurement of A, B and H antigen expression on VWF
The amount of loading on VWF with A and B antigens was quantified as described 
[11]. Immobilized anti-VWF IgG (A0082, DAKO, Glostrup, Denmark) was saturat-
ed with VWF from the sample. Next, immobilized VWF is saturated with murine 
monoclonal anti-A or anti-B antibody (Immu Clone, Immucor, Rodermark, Germany). 
The amount of bound anti-A or anti-B antibody is quantified using an HRP-labelled 
goat anti-mouse IgM (Nordic Immunological laboratories, Tilburg, The Netherlands). 
The peroxidase activity of a sample was normalized against the peroxidase activity 
obtained with an A1 or B reference plasma sample, and the results were expressed as 
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VWF was measured similar to O’Donnell et al. [19]. Plates were coated with anti-VWF 
Ig (DAKO), washed and incubated for 2 hours with plasma samples (1:20, 1:40, 1:50 
and 1:100 dilution). Plates were washed and incubated for 2 hours with Lectin from 
Ulex europaeus/UEA-I-HRP (1:150 dilution, AMS Biotechnology, Abingdon, UK) and 
peroxidase activity was measured. Blood group O plasma from a healthy control was 
used as standard curve and was assigned a value of 1 U/ml. To determine the per-
centage of H antigen expressed per unit VWF, the amount of H antigen detected was 
divided by the amount of VWF:Ag present in the ELISA well and multiplied by 100.
Detection of A, B or H antigen on VWF using Western Blotting
Plasma samples were reduced using 20 mM dithiothreitol, and separated by Novex 
6% (A and B antigens) or Novex 4% (H-antigen) Tris-Glycine gel electrophoresis 
(Invitrogen, Carlsbad, CA, USA). Equal amounts of VWF protein were loaded. Gels 
were immunostained with polyclonal rabbit anti-human VWF antibody conjugat-
ed to HRP (DAKO). Duplicate lanes were immunostained with murine monoclo-
nal anti-A or anti-B antibody (Immucor) (1:10 dilution) or with Lectin from Ulex 
europaeus/UEA-I-HRP (AMS Biotechnology) (5µg/ml). Blots for detection of A and 
B antigens were subsequently incubated with a HRP-labelled goat anti-mouse IgM 
(Nordic). Staining was visualized with Supersignal WestFemto (Thermo Scientific, 
Rockford, IL, USA).
Pharmacokinetic data of infused VWD patients
In a previous study [20], ten type 1 VWD, ten type 2A VWD and eight type 3 VWD 
patients received a single i.v. VWF concentrate infusion with a median of 79 IU/kg 
VWF:RCo (32 IU/kg FVIII:C). From that study we obtained the calculated half-lives 
of VWF:RCo and VWF:Ag [20]. Another six type 3 VWD patients received a single i.v. 
VWF concentrate infusion with a median of 45 (range 25-50) IU/kg FVIII:C. Plasma 
samples were drawn at different time points and assayed for VWF:Ag and VWF:RCo 
and half-lives were calculated.
Data analysis and statistics
Analysis of pharmacokinetic data was performed using GraphPad Prism (version 
6.0, La Jolla, CA, USA). Clearance data from mice experiments were fitted to the two 
phase exponential decay equation   Y=A×e(-k1×t)+B×e(-k2×t)+Plateu to obtain A, k1, B, and 
k2.  These parameters were used to calculate mean residence time (MRT) employing 
the equation;  MRT=(A/k12+ B/k22)/(A/k1+B/k2) as previously described [21]. Clearance 
data from type 3 VWD patients were fitted to the one phase exponential decay equa-
tion Y=A×e(-kt) to obtain k. Half-lives were calculated using the first order equation; 
t½=ln2/k. Quantification of western blots was performed using Fiji (Fiji Is Just Image, 
http://fiji.sc). Statistical analyses were performed by the Student’s unpaired t-test or 
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Results
VWF clearance is not influenced by ABO blood group in mice
We first investigated whether sampling strategy has any influence on the clearance of 
VWF in VWF -/- mice. As shown in Figure 1A, no difference in decay curves of injected 
Haemate-P® was observed between mice that were sampled only once (MRT 2.2h±0.9) 
and mice that were sampled multiple times (MRT 2.0h±0.8). Further experiments 
were therefore done using the multiple sampling approach. Furthermore, the amount 
of injected Haemate-P® did not affect clearance rates (low dose VWF, MRT 2.3h±0.6 
versus high dose VWF, MRT 2.5h±0.5)(Figure 1B).
As shown in Figure 1C no significant difference was observed in clearance rate be-




Figure 1. Clearance of pd-VWF from blood groups A, B and O donors in VWF -/-mice. Panel A; In one group 
(single sampling, grey triangle) different mice (total n=12, n=3 per time point) were sampled at different time 
points after injection with 200μl Haemate-P® (5U/ml VWF:Ag); each mouse was sampled only once. In the 
second group (n=3, multiple sampling, black square) each mouse was sampled several times at different time 
points. Panel B; two different dosages (2.5U/ml and 50U/ml) of Haemate-P® were injected into VWF -/- mice 
(n=10 per dosage). Panel C; clearance profiles of human plasma derived-VWF from donors with either blood 
group A, B or O in VWF -/- mice (n= total of 15 per blood group, 5 per donor). Panel D; loading of VWF with A 
and B antigens in VWF -/- mice after injection with 200μl (10U/ml VWF:Ag) Haemate-P® [11]. Because VWF:Ag 
levels at the last two time points were below the threshold of the assay, loading was not measured for these 
time points. Data represent mean ±SD.
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When clearance rates of A-VWF and B-VWF were combined into non O-VWF (MRT 
1.6h±0.3) there was also no differences in clearance compared with O-VWF (MRT 
1.9h±0.3, p=0.2). These results suggest that in mice VWF clearance rate is not influ-
enced by ABH antigens present on VWF. In another approach, VWF-/- mice were in-
jected with Haemate-P®, a pd-VWF concentrate obtained from a pool of donors in-
cluding all ABO blood groups. Injection of Haemate-P®, and subsequent measurement 
of the changes over time in the loading of A and B antigens on VWF, facilitates the si-
multaneous investigation of differential clearance of A-, B- and O-VWF in a single test 
animal. In case ABH antigens influence clearance of VWF, the proportions of O-VWF, 
A-VWF and B-VWF in the circulating pool of VWF will change over time. Thus, the 
normalized ratio of A and B antigen on VWF (expressed as nA and nB) in the pool of 
VWF should also change over time. The loading with A and B antigen should increase 
when O-VWF is cleared faster. The loading of VWF with A- and B antigens however, 
was not significantly affected over time (p for linear trend 0.06 and 0.79 for A- and 
B-antigen respectively, Figure 1D) indicating no effect of ABH antigens on VWF clear-
ance. To investigate whether Kupffer cells mask a possible ABO dependant uptake of 
VWF by other cells in the liver, we depleted macrophages in VWF -/- mice. Depletion 
of macrophages by clodronate liposomes lead to a significant decrease in clearance 
rate of VWF (MRT 3.1h ±0.83) compared with saline treated animals (MRT 2.1h ±0.36, 
p <0.05) (Figure 2A), confirming that Kupffer cells contribute to VWF clearance. How-
ever, after depletion of Kupffer cells there was still no ABO dependent clearance ob-
served (Figure 2B-C).
Blood group O VWF is not cleared faster in VWD patients
Since our mouse model has its limitations due to possible differences in clearance 
mechanisms of VWF compared to humans, we also studied clearance of VWF in hu-
mans. As no blood group specific purified VWF is available for infusions in humans, 
we infused three type 3 VWD patients with Haemate-P® (Table 1 for patient charac-
teristics) and measured the amount of A and B antigens present on VWF. This exper-




Figure 2. Clearance of Haemate-P® in VWF -/- mice after macrophage depletion. Panel A; VWF clearance rate 
in saline (n=4, black squares) and Clodronate (n=4, grey triangles) treated animals. Panel B; loading of A (black 
bars) and B (grey bars) antigen on VWF in saline treated animals. Panel C; loading of A (black bars) and B (grey 
bars) antigen on VWF in Clodronate treated animals. Data represent mean±SD
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groups in a direct comparison in one individual. As described in the previous para-
graph, faster clearance of O-VWF would lead to increased normalized ratios of A and 
B antigen on VWF in time. However, the opposite was observed for two patients; a 
2-fold decrease in the amount of A and B antigen loading on VWF during infusion. In-
terestingly, in the third patient the loading of both A and B antigens on VWF remained 
steady over time (Figure 3A). The amount of loading with A and B antigens was also 
confirmed using the non-saturating assay as described by O’Donnell et al [10] (data 
not shown).
In principle, endogenous anti-A and anti-B antibodies could shield the antigens on 
VWF to the antibodies used in the ELISA. However, we could not detect direct antibody 
binding by adding an anti IgM antibody to captured VWF from the samples (data not 
shown). Furthermore, Western-blotting confirmed the decrease in the amount of anti-
gen loading on VWF at the latest time point for patient 2, while the amount of antigen 
loading on VWF for patient 3 remained the same (Figure  3B). The decreased loading 
therefore reflects a true decrease in VWF loaded with A and B antigens. Also the load-
ing of H-antigens on VWF was declining in time and analysis of the Western blots 
showed that the density of the bands was also decreasing in time (Figure 3C, D, Table 
2). A- and B-VWF are thus not cleared faster in our patients, leading to the reduced 
normalized ratios (Figure 3A,B) since the relative amount of O-VWF present in the 
circulation would then increase over time. These results suggest that ABH antigens 




Table 1. Patient characteristics for every time point.
Patient number Time (min) FVIII:C (IU/mL) VWF:Ag (IU/mL) VWF:RCo (IU/mL)
1 0 0.08 <0.04 <0.20
10 0.85 2.14 1.20
90 0.73 1.61 1.05
900 0.70 0.60 0.21
2 0 0.11 <0.04 <0.20
10 1.17 3.20 2.63
60 1.17 3.20 2.24
120 1.11 2.65 2.01
240 1.04 2.45 1.53
360 1.01 2.18 1.27
480 0.99 1.90 1.06
1440 0.71 0.55 0.40
3 0 <0.03 <0.04 <0.20
10 1.16 2.88 2.25
60 1.16 2.74 1.58
120 0.85 2.38 1.44
240 0.84 1.84 0.99
360 0.87 1.55 0.80
480 0.85 1.30 0.69
1440 0.70 0.18 <0.20





Figure 3. Clearance of Haemate-P® in VWD type 3 patients. Panel A;  loading of VWF with A (black bars) and 
B (grey bars) antigens at different time points. Data represent the mean loading from duplicate wells. Panel 
B; Western blot of plasma samples after reducing conditions from time points 10 min, 6 hours and 24 hours 
after infusion of patients 2 and 3. Blots were stained for VWF, A-antigen and B-antigen. Panel C; Western blot 
of plasma samples after reducing conditions from time points 10 min, 2 hours (for patient 3), 6 hours, 8 hours 
and 24 hours (for patient 2) after infusion. Blots were incubated with anti-VWF and UEA-I lectin. Due to the low 
VWF:Ag level, the latest time point for patient 3 was excluded. Equal amounts of VWF:Ag were loaded per lane 
(see also Table 2 for quantification of the western blots). Panel D; loading of VWF with H antigen at different 
time points for patient 2 (black bars) and 3 (grey bars). Due to limited availability of plasma from patient 1, this 
patient was omitted. Data represent mean±SD from 2 independent dilutions measured in duplicate.
Table 2. Density of VWF and H-antigen bands on Western blot.
Time point (min) Area Percentage Relative density* Corrected density†
VWF H-antigen VWF H-antigen VWF H-antigen
Patient 2 10 25049806 20033434 25 30 1 1 1
360 20702492 17463898 20 26 0.83 0.87 1.05
480 23908271 15613522 24 24 0.95 0.78 0.82
1440 31636454 13187108 31 20 1.26 0.66 0.52
Patient 3 10 32375999 24766806 29 35 1 1 1
120 28513342 17474078 26 26 0.88 0.74 0.84
360 27722856 10558492 25 21 0.86 0.59 0.69
480 22476170 10691593 20 19 0.69 0.53 0.77
* Time point 10 minutes is set as a standard with a relative density of 1 for both VWF and H-antigen band. Rest of bands are relative to t=10min. 
† Corrected density was calculated by dividing the relative density of H-antigen band by the relative density of VWF band.
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Clearance of Haemate-P® in blood group O vs non-O VWD patients
To investigate whether the ABO blood group status of the individual influences the 
clearance rather than the ABH antigen loading of the VWF protein per se, we stud-
ied the clearance of Haemate-P® in VWD patients with blood group O and non-O. The 
half-lives of both VWF:Ag and VWF:RCo were shorter in type 3 VWD patients with 
blood group O compared to patients with non-O (8.4h, 95%CI 3.9-12.9 vs 9.6h, 95%CI 
3.2-16.0 for VWF:Ag and 5.8h, 95%CI 3.0-8.5 vs 8.6h, 95%CI 4.3-13.0 for VWF:RCo, 
Figure 4A), however this difference was not statistically significant, probably due to 
the small group size. The same difference was also observed in type 1 (10.9h, 95%CI 
6.1-15.8 versus 16.1h, 95%CI 10.9-21.3 for VWF:Ag and 5.7h, 95%CI 3.9-7.5 versus 10.5h, 
95%CI 5.3-15.6 for VWF:RCo) and type 2A VWD patients (6.9h, 95%CI 2.0-11.8 versus 
11.0h, 95%CI 3.6-18.3 for VWF:Ag and 3.8h, 95%CI 0.7-6.9 versus 9.0h, 95%CI 4.8-13.1 
for VWF:RCo) (Figure 4B,C). These preliminary results support our hypothesis that 
blood group O individuals clear VWF faster than blood group A or B individuals inde-
pendent of the blood group status of VWF.
Discussion
In this study we investigated the assumed faster clearance of VWF from individuals 
with blood group O. Since we cannot measure possible differences in clearance rates 
of human VWF from different donors simultaneously in humans, we first investigated 
whether we could detect a clearance difference in VWF -/- mice. This mouse model has 
advantages since it allowed us to 1) measure simultaneous VWF clearance of different 




Figure 4. Half-lives of VWF:Ag and VWF:RCo in blood group O vs non-O VWD patients. Pharmacokinetic data 
obtained from patients with type 3 VWD (n=14, panel A), type 1 VWD (n=10, panel B) and type 2A VWD (n=10, 
panel C) who were previously infused with Haemate-P® were analysed for the VWF half-life. Patients were 
divided in blood group O or blood group non-O. Individual patients are plotted. Black bars indicate mean ±SD.* 
p <0.05, ** p < 0.01.
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fied from individuals with either blood group A, B or O. However, in VWF -/- mice we 
did not observe differences in the clearance of purified human A-, B- or O-VWF. We 
also did not observe the expected increase in the relative amount of A and B antigen 
loading on VWF in VWF -/- mice injected with Haemate-P®.  In Haemate-P® infused 
type 3 VWD patients we could also not observe the expected increase.
Mice have genes homologous to the human A-, B- and H-transferase genes. Howev-
er, the enzymatic activity is much lower than the human homologues [22]. The ex-
pression of the genes is limited to a few tissues [23]. Clearance of VWF in mice might 
therefore not be dependent on the ABH antigens present on VWF, either because the 
VWF clearance system is different than in humans or because mice might not recog-
nize human ABH antigens on VWF. This could explain why we did not observe a faster 
clearance of O-VWF. However, although the enzymatic activity is lower, mice do ex-
press the transferase genes. It is therefore more likely that the VWF clearance system 
in mice is able to recognize human ABH antigens present on VWF. This is supported 
by results from a study of Wolofsky et al. who observed increased phagocytosis of in-
fected human blood group O erythrocytes compared to infected blood group A and B 
erythrocytes in mice [24]. 
Mouse ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 
1 motif, member 13) does not cleave human VWF very efficiently [25], so whether pro-
teolysis has an influence on ABO dependent VWF clearance could not be answered. 
Increased susceptibility to ADAMTS13 proteolysis of O-VWF has been postulated as a 
mechanism for increased clearance of O-VWF. However, basal VWF levels are similar 
in normal and ADAMTS13 -/- mice [26]. Additionally, wild type VWF and the p.Ser-
1618Pro VWF variant, which results in more susceptibility to ADAMTS13 cleavage, had 
similar clearance rates in a rat model [27]. It is therefore unlikely that (potential) in-
creased ADAMTS13 susceptibility of O-VWF would lead to an accelerated clearance.
Given the limitations of the mouse model, we also investigated the assumed faster 
clearance of O-VWF in patients with type 3 VWD. By infusion of Haemate-P® we were 
able to study clearance of VWF loaded with A, B and H antigens simultaneously in one 
individual, excluding any variability between subjects and variation over time. To our 
surprise, loading of VWF with A and B antigens decreased over time. This decrease 
could not be explained by simple shielding of antigens in vivo. Faster removal of A- 
and B-VWF compared to O-VWF would lead to a decreased ratio, although this would 
be contradictory to the assumed faster clearance of O-VWF. However, the amount of 
H-antigen present on VWF also decreased during clearance. The decrease in A, B and 
H-antigen loading indicates that either the A, B and H-antigens are removed from the 
VWF molecule or heavily glycosylated VWF is cleared faster, leading to the reduced 
amounts of loading. All three patients have blood group O, and whether interaction 
between endogenous Anti-A and Anti-B antibodies and the antigens on VWF could in-
fluence the clearance of VWF, by subsequent clearance of the whole complex or by re-
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antibody binding to antigens on VWF in our plasma samples, nor could we demon-
strate antibody binding to ABH antigens on VWF by incubating VWF deficient plasma 
from different blood group donors with Haemate-P®. The ideal experimental set-up 
to tackle this problem would be infusing a VWD type 3 patient with blood group AB, 
thereby excluding possible antibody-antigen interaction, however this type of patient 
is very rare [28], and was not available. 
In 2 infused patients we observed a 2-fold decrease in A and B antigen loading, but 
in the other patient we did not observe such a strong decrease in antigen loading. We 
have no reasonable explanation for the discrepancy between patients 1 and 2 versus 
patient 3. There is no difference in the amount of A- and B-antibodies present, as anti-
body titers between the three patients are comparable, nor have the patients received 
different batches of Haemate-P®. 
Taking together the results, we could not demonstrate the assumed faster clearance 
of O-VWF. It could be that the association between ABO blood group and plasma VWF 
levels is not just via an effect on VWF clearance but could include individual differ-
ences, for example receptor mediated uptake of VWF [29]. Mannucci et al. [30], found 
that their recombinant VWF product, which lacks the ABH antigens, had a similar 
pharmacokinetic profile compared with human pd-VWF in patients with VWD. This 
findings support our results that ABH antigens on VWF  itself do not affect clearance. 
Nevertheless, there is overwhelming evidence suggesting increased VWF clearance 
in individuals with blood group O [12,13,16,17]. However, all those studies investigated 
the clearance of O-VWF in a blood group O individual and A-VWF in a blood group A 
individual. Since we demonstrated that within one individual O-VWF is not cleared 
faster compared to A- or B-VWF, we postulate that the ABO blood group dependent 
differences in VWF clearance depend on the ABO blood group status of the individual 
and not on the ABH antigens on VWF per se. Since VWF is the carrier protein of factor 
VIII (FVIII) and clearance of FVIII is largely dependent on VWF, clearance of (infused) 
FVIII will most likely also be dependent of the blood group status of the individual. 
This hypothesis is supported by our preliminary results of a shorter half-life in blood 
group O individuals, independent of the ABO blood group of the circulating VWF. 
However more pharmacokinetic data is required to substantiate this assumption. 
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Abstract
The ratios between von Willebrand factor propeptide (VWFpp) or FVIII coagulant ac-
tivity (FVIII:C) and VWF antigen (VWF:Ag) reflect synthesis, secretion and clearance 
of VWF. We aimed to define the pathophysiology of 658 types 1, 2 and 3 von Wille-
brand disease (VWD) patients with VWF levels ≤30 U/dL from the “Willebrand in the 
Netherlands” (WiN-)study using the VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios. We 
also evaluated the use of VWFpp in the classification and diagnosis of VWD. Based on 
the ratios, reduced VWF synthesis was observed in 18% (67/380) of type 1 patients and 
in only 2% (5/240) of type 2 patients. A significant proportion of type 3 patients had 
detectable VWFpp (14/37, 41%). These patients had a lower bleeding score than type 3 
patients with complete absence of both VWF:Ag and VWFpp: 14.0 vs. 19.5, p=0.025. 
The majority of these patients had missense mutations associated with rapid VWF 
clearance, whereas “true” type 3 patients were homozygous for null alleles. In con-
clusion, VWFpp identified severe type 1 VWD with very low VWF levels in patients 
who had previously been classified as type 3 VWD. This study underlines the clinical 
significance of the VWFpp assay in the diagnosis and classification of VWD.
Introduction
Von Willebrand factor (VWF) is a large multimeric glycoprotein that mediates platelet 
adhesion and aggregation at sites of vascular injury, and serves as the carrier of factor 
VIII (FVIII) to prevent its premature clearance [1,2]. Synthesis of VWF is restricted 
to endothelial cells and megakaryocytes [3], where it is formed as a precursor pro-
tein, pre-proVWF, with a signal peptide, a propeptide and a mature subunit [4]. After 
translocation to the endoplasmic reticulum the signal peptide is cleaved, and the pro-
VWF undergoes extensive post-translational modifications, including dimerization in 
the endoplasmic reticulum and multimerization in the Golgi system [5,6]. The VWF 
propeptide (VWFpp) is subsequently removed from the mature VWF, however it stays 
noncovalently bound [7]. Part of VWF is secreted constitutively into the plasma and 
the remaining part is stored in Weibel-Palade bodies in the endothelium or α-granules 
in megakaryocytes [8.9]. After release into the circulation, the VWFpp and the mature 
VWF completely dissociate [8]. 
Plasma VWF concentrations represent a balance between synthesis, secretion and 
clearance from the circulation. VWF and VWFpp are secreted equimolarly, but are 
cleared independently with estimated half-lives of 8-12 hours for VWF and 2 hours for 
VWFpp [10,11]. The ratio between VWFpp and VWF antigen (VWF:Ag) can therefore be 
used to assess the rates of synthesis, secretion and clearance of VWF [10,12,13]. In ad-
dition to VWFpp, the ratio between FVIII coagulant activity (FVIII:C) and VWF:Ag can 
also be used to assess VWF synthesis and clearance [14]. Since FVIII and VWF circulate 
in blood as a complex and are cleared together, their half-lives are strongly related 
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mon inherited bleeding disorder [16,17]. Low VWF levels are caused by reduced VWF 
synthesis or secretion, increased VWF clearance, or a combination thereof [18,19]. Re-
cently, Eikenboom et al. have shown that the VWFpp/VWF:Ag and FVIII:C/VWF:Ag 
ratios represent the pathophysiology of VWD and correspond to different VWF gene 
mutations in type 1 VWD [20]. However, it is still unknown whether these ratios can 
also provide insight into the pathophysiological mechanism in types 2 and 3 VWD. 
VWD patients are classified as type 1, 2 or 3 VWD according to their remaining lev-
el of functional VWF [16,21]. Type 1 VWD is characterized by partially reduced VWF 
levels, while type 3 VWD show completely absent VWF plasma levels. In type 2 VWD, 
functionally abnormal variants of VWF are synthesized. Type 2 VWD is subclassified 
as 2A, 2B, 2M or 2N, based on the type of functional defect in VWF [16,21]. In some 
patients it is difficult to classify VWD correctly, as the available diagnostic laboratory 
tests do not provide adequate information to distinguish between VWD (sub)types. In 
addition, these laboratory assays are less sensitive in measuring extremely low VWF 
and FVIII levels and are therefore less reliable.
In this large nationwide cross-sectional Willebrand in the Netherlands (WiN)-study, 
we aimed to define the pathophysiology of type 1, 2 and 3 VWD using the VWFpp/
VWF:Ag and FVIII:C/VWF:Ag ratios irrespective of the VWF gene mutation. In addi-




In the nationwide cross-sectional “Willebrand in the Netherlands” (WiN-)study 804 
VWD patients who had previously been diagnosed with types 1, 2 or 3 VWD, were in-
cluded [23-25]. The inclusion criteria for the WiN-study were (1) hemorrhagic diath-
esis or a family history of VWD and (2) historically lowest VWF levels ≤30 U/dL (VW-
F:Ag and/or VWF:RCo) and/or FVIII:C levels ≤40 U/dL. Patients were excluded if they 
were known to have other hemostatic disorders resulting in hemorrhagic diathesis. 
The Medical Ethical Committees at all participating centers approved this study, and 
all participants gave informed consent.
For the current study, only patients from whom plasma was obtained were selected 
(n=681). Exclusion criteria were pregnancy (n=7) and the recent use of desmopressin 
or replacement therapy at the time of blood sampling (n=16). Therefore, a total of 658 
VWD patients were included in the current study. 
Assessment of bleeding symptoms
All patients completed a questionnaire regarding bleeding episodes, treatment of 
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previously described by Tosetto [28], we used information on the severest life-time 
event of each of twelve specific bleeding symptoms. To avoid prophylaxis-bias, bleed-
ing symptoms were not scored if patients had received prophylactic desmopressin or 
prophylactic replacement therapy before a surgical intervention, dental extraction or 
delivery [24,29]. However, if bleeding did occur despite prophylactic treatment, this 
bleeding was scored according to the Tosetto BS.
Laboratory measurements
Patients’ plasma was obtained at inclusion in the study. Venous whole blood was col-
lected in 0.105M sodium citrate tubes and centrifuged twice at 2200x g for 10 minutes 
at room temperature and stored at -80°C. VWF:Ag, VWF activity (VWF:Act), FVIII:C, 
VWF binding to FVIII (VWF:FVIIIB), and VWF multimers were determined centrally 
at the Erasmus University Medical Center, Rotterdam, as described [24]. VWFpp was 
measured centrally at the Leiden University Medical Center, Leiden. This assay was 
also used in the previous paper from Eikenboom et al. [20], and was measured at the 
same center. VWFpp antigen was determined with an ELISA using antibodies from 
Sanquin (Amsterdam, the Netherlands) as described [10,20]. First microtiter plates 
were coated with antibody CLB-Pro 35 overnight at 4°C, then blocked with 1% Bovine 
Serum Albumin (BSA) at room temperature for 2 hours. Next the diluted samples were 
incubated for 2 hours at 37°C. VWFpp was detected with peroxidase-conjugated anti-
body CLB-Pro 14.3. Pooled normal plasma was used to create a standard curve. At the 
time of the study, no international standard was available for VWFpp and therefore 
the plasma pool was arbitrarily set at 100 U/dL. Details on the blood-sampling proce-
dure and laboratory measurements at inclusion in the study have been described in 
more detail by de Wee et al [24]. 
Definitions
Determination of VWD type was based on the current ISTH guidelines [16], using cen-
trally measured plasma concentrations of VWF:Ag, VWF:Act and FVIII:C; VWF mul-
timer patterns; VWF:FVIIIB assay; and locally performed ristocetin-induced platelet 
aggregation (RIPA) tests [24]. 
Type 1 VWD patients had a VWF:Act/VWF:Ag ratio ≥0.70, whereas type 2 patients 
had a ratio <0.70. If type 2 patients had normal multimers they were classified as 2M. 
Type 2A or 2B VWD patients showed abnormal multimers. If the locally performed 
RIPA test showed increased VWF affinity for platelets, patients were classified as type 
2B. Type 2N patients had a FVIII:C/VWF:Ag ratio <0.70, and VWF:FVIIIB <60%. Type 
3 VWD was defined as having both VWF:Ag and VWF:Act levels <5 IU/dL, irrespective 
of FVIII:C level. 
The normal range (2.5th to 97.5th percentile) used for VWFpp was 82-173 U/dL, for the 
VWFpp/VWF:Ag ratio 0.8-2.2, and for the FVIII:C/VWF:Ag ratio 0.6-1.9, as reported 
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Statistical methods 
Descriptive statistics for categorical data are presented as numbers with percentages 
(n, %). As data were non-normally distributed, continuous variables are presented 
as median with 25-75% interquartile ranges [IQR]. For comparison of proportions, 
chi-squared tests were used. The Kruskal-Wallis test was used to test differences in 
VWF:pp, VWFpp/VWF:Ag ratio and FVIII:C/VWF:Ag ratio between types 1, 2A, 2B, 
2M, 2N and 3 VWD. Mann-Whitney U-test were applied to detect differences between 
types and to compare bleedings score between groups. Statistical analyses were 
performed with SPSS for Windows, version 21.0 (SPSS Inc, Chicago, USA). A p-value 
<0.05 was considered statistically significant.
Results
A total of 658 VWD patients were included in the current analyses, 381 of whom had 
type 1 VWD, 240 type 2 VWD, and 37 type 3 VWD, according to the current ISTH guide-
lines [16]. Baseline characteristics are presented in table 1.
VWF parameters and ratios per type of VWD
In type 1 patients, median VWFpp was 91 U/dL [IQR 68-116], median VWFpp/VWF:Ag 
ratio 2.2 [IQR 1.7-3.1] and median FVIII:C/VWF:Ag ratio 1.8 [IQR 1.4-2.3] (Figure 1A and 
table 2). This is in accordance with previously published data by Eikenboom et al.[20]. 
In type 2 patients, median VWFpp was 104 U/dL [81-136], which was higher than in 




Table 1. Baseline characteristics
Characteristics VWD Patients (n=658)
Age (years), median (range) 43.5 (1-83)
Male sex, n (%) 251 (38)








Blood group O, n (%)* 398(61)
VWF:Ag (IU/dL), median [IQR] 29[18-45]
VWF:Act (IU/dL), median 
[IQR]
22 [8-53]
FVIII:C (IU/dL), median [IQR] 51 [32-73]
Bleeding score, median [IQR]† 11 [6-16]
*4 missing, †32 missing





Figure 1: Ratio’s per type of VWD A: VWFpp levels, VWFpp/VWF:Ag ratios and FVIII:C/VWF:Ag ratios are shown 
for type 1 VWD and type 2 VWD patients. For a better presentation of the graphic VWFpp/VWF:Ag ratio, one 
type 1 VWD patient with both a high VWFpp/Ag ratio (33.7) and a FVIII:C/VWF:Ag ratio of 3.4 was omitted. B: 
For all patients with type 2A, 2B, 2M and 2N VWD the VWFpp levels, VWFpp/VWF:Ag ratios and FVIII:C/VWF:Ag 
ratios are shown. The central horizontal line represents the median. The upper and lower horizontal lines show 
the 25-75% interquartile ranges. The dash lines illustrate the normal ranges (2.5th to 97.5th percentile) for VWFpp 
(82-173 U/dL), for VWFpp/VWF:Ag ratio (0.8-2.2), and for FVIII:C/VWF:Ag ratio (0.6-1.9).  
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FVIII:C/VWF:Ag ratio 1.6 [1.2-2.0] in the type 2 patients. The VWFpp/VWF:Ag ratio 
was higher in type 2 VWD than in type 1 VWD (p<0.001) and the FVIII:C/VWF:Ag ratio 
was lower in type 2 VWD compared with type 1 VWD (p<0.001) (table 2 and Figure 1A). 
This difference in VWFpp, VWFpp/VWF:Ag and FVIII:C/VWF:Ag between type 1 and 
2 VWD was also observed after exclusion of type 2N patients (all p<0.001): median 
VWFpp in type 2A, 2B and 2M VWD was 103 U/dL [81-135], median VWF:pp/VWF:Ag 
was 4.6 [3.4-6.2], and median FVIII:C/VWF:Ag was 1.6 [1.3-2.1].
VWF parameters and ratios per subtype of type 2 VWD
In VWD 2B patients, median VWFpp was significantly higher than in 2A patients or 
2M patients: 137 U/dL [IQR 106-157] vs. 99 U/dL [79-123] or 93 U/dL [IQR 75-119], both 
p<0.001 (Figure 1B and table 2). VWFpp/VWF:Ag ratio was increased in 2A, 2B and 
2M patients based on the normal range (0.8-2.2)[20]; 4.5 [3.3-6.2] in 2A, 4.6 [3.7-5.8] 
in 2B, and 4.8 [3.1-6.2] in 2M VWD. Type 2B patients had significantly lower FVIII:C/
VWF:Ag ratios than 2A or 2M patients (1.3 [1.1-1.5] vs. 1.7 [1.3-2.2]or 1.9 [1.6-2.1], both 
p<0.001). Median VWFpp and median VWFpp/VWF:Ag ratio were similar between 
type 2N and type 1 VWD. Type 2N patients had a significantly decreased FVIII:C/VW-
F:Ag ratio compared with type 1, 2A, 2B and 2M VWD (all p<0.001), as expected by the 
decreased FVIII binding affinity in type 2N.
Pathophysiological mechanisms in type 1 VWD
An increased VWFpp/VWF:Ag ratio (> 2.2) defines accelerated clearance of VWF and 
an increased FVIII:C/VWF:Ag ratio (>1.9) correlates with reduced VWF synthesis 
(Figure 2A). The pathophysiological mechanisms of type 1 VWD were variable with 
increased clearance of VWF in 23% of type 1 patients (89/380), reduced synthesis of 
VWF in 18% (67/380), and a combination of these in 23% (86/380). In 36% (138/380) 
of type 1 patients other pathophysiological mechanisms may play a role, as VWFpp/




Table 2. VWF parameters and ratios per type of VWD
Type of 
VWD














median [IQR] median [IQR] median [IQR] median [IQR] median [IQR] median [IQR] median [IQR]
1* 381 38 [23-53] 46 [24-72] 67 [49-88] 91 [68-116] 1.2 [1.0-1.4] 2.2 [1.7-3.1] 1.8 [1.4-2.3]
2 240 24 [16-34] 8 [4-16] 37 [27-48] 104 [81-136] 0.4 [0.2-0.5] 4.5 [3.2-6.0] 1.6 [1.2-2.0]
2A 157 22 [14-32] 8 [3-15] 37 [27-47] 99 [79-123] 0.4 [0.2-0.5] 4.5 [3.3-6.2] 1.7 [1.3-2.2]
2B 42 28 [23-40] 8 [6-14] 39 [28-48] 137 [106-157] 0.3 [0.2-0.4] 4.6 [3.7-5.8] 1.3 [1.1-1.5]
2M 27 24 [16-30] 5 [3-13] 42 [31-52] 93 [75-119] 0.3 [0.1-0.4] 4.8 [3.1-6.2] 1.9 [1.6-2.1]
2N 14 34 [28-44] 45 [29-54] 19 [13-28] 111 [71-157] 1.2 [1.0-1.5] 2.7 [2.0-4.4] 0.6 [0.4-0.7]
3 37 1 [0-4] 0 [0-1] 3 [1-9] 0 [0-60]** NA NA NA
*Median and 25-75% interquartile range (IQR) of VWFpp level and ratios in type 1 VWD patients are in accordance with the results from 
Eikenboom et al. [20] **VWFpp levels below the assay detection limit (<4 U/dL) were considered 0 (n=25). Abbreviations: VWF = von Willebrand 
factor, VWD = von Willebrand disease, n = number, VWF:Ag = VWF antigen, VWF:Act = VWF activity, FVIII:C = factor VIII coagulant activity, VWFpp 
= von Willebrand factor propeptide, IQR = 25-75% interquartile range, NA = not applicable





Figure 2: Pathophysiological mechanisms per type of VWD A: Scatter plots of FVIII:C/VWF:Ag (x-axis) versus 
VWFpp/VWF:Ag (y-axis) for type 1 VWD and type 2A, 2B, 2M and 2N VWD. The yellow area represents the pa-
tients with increased clearance, the purple area the patients with reduced synthesis, the green area the patients 
with a combination of both mechanisms, and the white area represents the absence of these pathophysiological 
mechanisms. For a better presentation of the graphics: one type 1 VWD patient with a very high VWFpp/Ag ratio 
(33.7), and two type 1 VWD patients with high FVIII:C/VWF:Ag ratios (8.4 and 9.7) were omitted. B: Proportion of 
VWD patients with increased clearance (yellow), reduced synthesis (purple), combination of increased clearance 
and reduced synthesis (green), and none of these mechanisms (white). X = not present.
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Pathophysiological mechanisms in type 2 VWD variants
Based on increased VWFpp/VWF:Ag or FVIII:C/VWF:Ag ratios, the majority of type 
2A VWD was characterized by an increased clearance of VWF (93/158, 59%), followed 
by a combination of increased clearance and reduced synthesis (50/158, 32%). In only 
five (of 158, 3%) patients with 2A VWD, reduced synthesis of VWF predominated. In 
ten (of 158, 6%) 2A patients, the VWD was characterized by neither increased clear-
ance nor reduced synthesis. Ninety-five percent (40/42) of type 2B patients showed 
an increased VWFpp/VWF:Ag ratio with a normal FVIII:C/VWF:Ag ratio, suggesting 
that 2B VWD is completely characterized by an increased clearance of normally syn-
thesized and secreted VWF. The pathophysiological mechanisms of type 2M VWD 
were an increased clearance in almost half of the patients (13/27, 48%) and a combina-
tion of increased clearance and reduced synthesis in the other half (12/27, 44%). None 
of the 2M patients had an increased FVIII:C/VWF:Ag ratio, indicating that 2M VWD 
is not characterized by reduced synthesis solely. Ten (of 14, 71%) 2N patients had an 
increased VWFpp/VWF:Ag ratio, indicating that apart from reduced FVIII binding the 
type 2N VWD is also characterized by increased clearance (Figure 2). 
Type 3 VWD patients
Thirty-seven patients with VWF:Ag and VWF:Act <5 IU/dL were classified as type 3 
VWD, according to the current ISTH guidelines [16]. VWFpp was undetectable in 59% 
of the (22/37) type 3 patients, which confirms the definition of type 3 VWD with com-
plete absence of VWF. We therefore designated these patients: “true type 3 VWD pa-
tients”. In all other type 3 patients (15/37, 41%), VWFpp was detectable with a median 




Table 3. Characteristics of type 3 VWD patients with and without VWFpp
Type 3 VWD patients
Characteristics without VWFpp  
n=22




Male sex, n (%)





22 (2-60) 35 (4-65) 0.636
9 (41) 7 (47) 0.729
8 (36) 12 (80) 0.009
0 [0-0] 72 [37-94] <0.001
0 [0-1] 4 [2-4] <0.001
0 [0-0] 1 [0-3] 0.036
2 [1-3] 9 [8-13] <0.001
Multimers absent 19 (86) 3 (20) <0.001
abnormal 3 (14) 12 (80)
Bleeding score
Mutations identified†
19.5 [11.3-23.8]* 14.0 [7.0-17.0] 0.025
10 out of 12 homozygous 
or compound heterozygous 
for null alleles
14 patients genotyped, 10 of whom 
had a mutation that is associated with 
increased clearance
*2 missing, †11 missing. Levels and bleeding score are presented as median and 25-75% interquartile range [IQR]. Age is presented as median 
and range. Abbreviations: VWD = von Willebrand disease; VWFpp = von Willebrand factor propeptide; VWF:Ag = von Willebrand factor antigen; 
VWF:Act = von Willebrand factor activity; FVIII:C = factor VIII coagulation activity. VWFpp, VWF:Ag, VWF:Act and FVIII:C levels were measured 
centrally at time of inclusion in the study. 
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Compared with the “true” type 3 VWD patients with complete absence of both VWFpp 
and VWF:Ag, type 3 patients with detectable VWFpp had higher VWF:Ag levels (0 vs. 
4 IU/dL, p<0.001), higher VWF:Act levels (0 vs. 1 IU/dL, p=0.036), and higher FVI-
II:C levels (2 vs. 9 IU/dL, p<0.001). The frequency of blood group O was significantly 
higher in the type 3 patients with detectable VWFpp than in the “true” type 3 patients 
(12/15 vs. 8/22, p=0.009). 
In 12/22 “true” type 3 patients, the VWF gene was sequenced. Ten of whom were ho-
mozygous or compound heterozygous for a null allele (p.R2535X, p.N2546Y, p.Y1570X, 
p.S330KfsX4, p.D1333EfsX43, and deletion of exons 17-25). Of the 15 patients with 
detectable VWFpp, the VWF gene mutation was known in 14. Ten of whom had mis-
sense mutations in regions associated with rapid clearance of VWF (p.R1205H and 
p.S1285P) or mutations that are considered to rapidly clear VWF from the circulation 
(p.Y1584C and p.Y1146C)[12,18,30,31]. Additionally, three were compound heterozy-
gous for a null allele and an unknown defect on the other allele.
Bleeding phenotype, VWFpp and pathophysiological mechanism
Bleeding score was significantly higher in the “true” type 3 patients with undetect-
able VWFpp than in those with detectable VWFpp level: 19.5 [11.3-23.8] vs. 14.0 [7.0-
17.0], p=0.025 (table 3). In patients with type 1 VWD, the BS was not associated with 
the pathophysiological mechanisms of VWD, i.e. increased clearance, reduced syn-
thesis, combination of increased clearance and reduced synthesis, or none of these 
mechanisms: median BS 10.0 vs. 9.0 vs. 8.5 vs. 9.0 respectively (Figure 3A). Howev-
er, all type 2 patients with increased clearance, reduced synthesis or combination, 
had significantly higher BS than type 2 patients with none of these pathophysiologic 
mechanisms (p=0.010). Median BS in type 2 patients with increased clearance (13.0 
[9.0-17.5], p=0.001) or a combination of increased clearance and reduced synthesis 
(13.0 [8.0-16.3], p=0.007) was significantly higher than in those with normal ratios: 
(7.5 [5.5-10.8]). Median BS in type 2 VWD characterized by reduced synthesis was 17.0 
[8.0-26.0] vs. 7.5 [5.5-10.8] in those with normal ratios (p=0.051) (Figure 3B). 
Discussion
In the present study from the WiN-cohort, we present as first that VWFpp improved 
the discrimination of true type 3 VWD patients with a total absence of both VWF:Ag 
and VWFpp, and VWD patients with extremely rapid VWF clearance leading to very 
low VWF plasma levels. Moreover, the ratios of VWF:Ag with VWFpp or FVIII:C differ 
between type 1 and 2 VWD. Type 2 VWD was mainly characterized by an increased 
clearance of VWF and type 1 VWD had a more heterogeneous pathophysiology. Finally, 
low VWFpp was associated with higher BS in type 3 and type 2 VWD.
VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios have been shown to identify type 1 VWD 
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VWF levels, i.e. increased clearance and reduced synthesis of VWF [12,20,32]. We 
confirmed this in our study and showed that the pathophysiology of type 1 VWD is 
diverse, as our type 1 patients showed a mixture between VWF synthesis and clear-
ance defects using the VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios. Almost two fifth 
of patients did not have increased ratios. Probably VWD in these patients results from 
other not yet identified mechanisms. This confirms the heterogeneity of type 1 VWD 
and the various causes of low VWF levels.
We hypothesized that as a result of our inclusion criteria (historically lowest VWF 
levels <30 U/dL), we selected more type 1 patients with accelerated clearance of VWF 
or reduced synthesis, and therefore patients with higher ratios. However, the VWFpp 
levels and ratios thereof in our type 1 patients are in agreement with a previous study 
in type 1 VWD patients [20]. This is remarkable as in the MCMDM-1VWD study also 
milder cases were included. Regression to the mean or the effect of aging on VWF and 
FVIII levels may have been observed [27]. 
110
chapter
6 Figure 3: Bleeding score per pathophysiological mechanisms for type 1 and 2 VWD Bleeding score according 
to different pathophysiological mechanisms of VWD for (A) type 1 VWD and (B) type 2 VWD. Boxplots show 
median, 25-75% interquartile ranges and minimum and maximum score.
Proefschrift_Binnenwerk_Dafna_Groeneveld_final.indd   110 8/13/15   11:33 AM
209658-L-bw-Groeneveld
We observed a higher VWFpp/VWF:Ag ratio in type 2 VWD patients compared with 
type 1 VWD patients. However, type 1 patients had a significantly higher FVIII:C/VW-
F:Ag ratio, revealing reduced synthesis as a pathophysiological mechanism of VWD in 
type 1, but rarely or not in type 2 VWD. This also suggests that these ratios may dis-
criminate between type 2 en type 1 VWD, which has been stated before [33]. 
The main pathophysiological mechanism of type 2 VWD is increased VWF clearance, 
as the majority of type 2A, 2B and 2M patients showed an increased VWFpp/VW-
F:Ag ratio. In addition, a small proportion of type 2 patients showed a combination 
of reduced VWF survival and reduced synthesis, but this was only seen in 2A and 2M 
VWD. The effect of proteolysis of VWF on clearance has been argued [3,30,34,35].  We 
found no differences between 2A VWD with defects in multimerization and enhanced 
ADAMTS-13-mediated proteolysis, and 2M VWD with normal multimer patterns. Be-
cause of small sample size these findings should be interpreted with care. Our data 
indicate that 2B VWD is completely characterized by a normal synthesis and an in-
creased clearance of VWF, which has been shown before in 18 type 2B VWD patients 
[36]. It has been suggested that the mutant VWF is cleared faster in these patients due 
to the spontaneous binding of VWF to platelets [17,19,37,38]. Our results also showed 
that the mutant type 2N VWF is cleared faster than normal VWF.
To the best of our knowledge, this is the first study to assess VWFpp in VWD patients 
with VWF:Ag and VWF:Act <5 IU/dL, the diagnostic criteria used in the current ISTH 
classification for type 3 VWD [16]. We showed that VWFpp is detectable in half of 
the type 3 VWD patients, indicating that VWF is actually produced but very rapidly 
cleared from the circulation in these patients. Our findings suggest that these type 3 
VWD patients should actually reclassify as severe type 1 VWD patients. We therefore 
conclude that VWFpp can discriminate between “true” type 3 VWD with complete ab-
sence of both VWF:Ag and VWFpp, and severe type 1 VWD with extremely low VWF 
levels. A significant proportion of these severely affected type 1 VWD patients had 
blood group O, which may have contributed to the low VWF levels in these patients. 
Distinguishing between true type 3 VWD and severe type 1 VWD is of clinical impor-
tance as VWD patients with lack of VWF but detectable VWFpp have different clinical 
characteristics than those with a complete absence of both VWF and VWFpp. 
Because VWF:Ag and FVIII:C levels are associated with bleeding phenotype in VWD 
[24,28,39], it may be expected that VWFpp also associates with bleeding phenotype 
in VWD patients: indirectly through its association with VWF:Ag or by binding to ma-
ture VWF in the circulation [40]. Interestingly, we found that the presence of VWF-
pp in patients with VWF:Ag levels <5 IU/dL correlates with a milder bleeding pheno-
type. We also observed that increased clearance, reduced synthesis and a combination 
thereof associates with higher bleeding scores in type 2 patients.
Mutation analysis of the VWF gene has been advised in type 2N VWD, type 2B VWD, 
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widely available. Looking at the molecular background of the type 3 VWD patients, 
we observed homozygosity and compound heterozygosity for null alleles in the true 
type 3 VWD patients with complete absence of VWF:Ag and VWFpp. In the type 3 
VWD patients with detectable VWFpp, missense mutations in the D3 and D4 domain 
of the VWF gene were identified that are associated with accelerated clearance of VWF 
(p.R1205H; p.S1285P) [12,18,30]. Therefore assessing VWFpp may substitute for VWF 
gene analyses as it identifies carriers of two null alleles and thus “true” type 3 VWD. In 
addition, the MCMDM-1VWD study has recently shown that a high VWFpp/VWF:Ag 
ratio predicts the detection of VWF gene mutations in type 1 VWD patients [20]. Addi-
tionally, patients with mutations in regions of the VWF gene associated with reduced 
VWF survival, can be identified with the VWFpp/VWF:Ag ratio [12,18,30]. Based on 
our results and the current literature, we believe that measurement of VWFpp should 
be implemented as a standard diagnostic in VWD for patients with low VWF levels and 
may render mutation analysis of the VWF gene unnecessary. 
VWFpp measurement is of clinical importance because its ratio with VWF:Ag predicts 
reduced VWF survival and may therefore predict desmopressin response. In patients 
with increased VWF clearance, VWF disappears rapidly after desmopressin adminis-
tration. The desmopressin response in these patients is probably sufficient for hemo-
stasis in case of minor bleeding, but inadequate in case of major bleeding or surgery 
because they lack a sustained response [13,18,42]. The FVIII:C/VWF:Ag ratio can also 
help in the classification of VWD patients, as those patients with an increased FVI-
II:C/VWF:Ag mainly classify as type 1 VWD. With the current novel insights into the 
pathophysiology and molecular biology of VWD the classification of VWD should be 
reviewed in the near future.
In conclusion, VWFpp discriminates between true type 3 VWD patients with complete 
lack of VWF and severe type 1 VWD patients with very low VWF levels. An increased 
FVIII:C/VWF:Ag ratio may help identify type 1 VWD patients. This study shows the 
clinical significance of the VWFpp assay; it is of added value for the classification of 
VWD, for the assessment of the bleeding phenotype, for genetic counseling, and it also 
has therapeutic consequences.
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Abstract
Objective: It has recently been shown that von Willebrand factor (VWF) can act as a 
negative regulator of angiogenesis. VWF is stored in endothelial cells in Weibel-Pal-
ade bodies (WPB) together with angiopoietin-2, osteoprotegerin and galectin-3. These 
proteins are known to mediate angiogenesis. We hypothesized that defects in VWF, 
potentially leading to impaired or loss of WPB formation, result in dysregulated re-
lease of angiogenic mediators in the circulation. Approach and Results: We meas-
ured plasma levels of VEGF, angiopoietin-1 and 2, osteoprotegerin and galectin-3 in 
380 type 1, 239 type 2 and 36 type 3 von Willebrand Disease (VWD) patients and 100 
healthy controls . VWD patients had higher angiopoietin-1 and lower angiopoietin-2 
levels compared with controls. VEGF levels were also higher in VWD patients and  de-
pendent upon VWF levels in plasma. These levels were higher in type 3 compared to 
type 1 patients. Type 1 and 2 VWD patients had lower angiopoietin-2 levels compared 
with controls, while type 3 VWD patients had similar angiopoietin-2 levels as con-
trols. Type 3 VWD patients had higher osteoprotegerin levels compared with controls. 
Conclusions: Patients with VWD have various disturbances in angiogenic markers in 
plasma. However, defects in VWF, leading to impaired or absent formation of WPB in 
VWD patients, do not consistently lead to dysregulated release of other WPB compo-
nents. The variations in angiogenic mediators may contribute to the development of 
vascular malformations, such as angiodysplasia that are frequently observed  in VWD 
patients.
Introduction
Von Willebrand factor (VWF) is mainly produced in endothelial cells, although a small 
fraction of the total VWF pool is synthesized in megakaryocytes [1-3]. Upon formation 
of the multimeric VWF structure, the protein is either constitutively secreted into the 
blood, or stored in cell-specific organelles. In endothelial cells VWF is stored in the 
Weibel-Palade bodies (WPB)[4]. VWF is essential for the formation of these WPBs, 
because absence of VWF leads to the loss of WPB formation [5]. Cells that normally do 
not express VWF form pseudo-WPB when transfected with VWF [6,7].
Although VWF is best known for its role in hemostasis [1,8], other functions have 
been identified in recent years, indicating that this protein is involved in multiple 
vascular processes (reviewed in [9]). Vascular malformations in von Willebrand dis-
ease (VWD) patients, most frequently angiodysplasia in the gastrointestinal tract, 
have repeatedly been reported [10,11]. These malformations can be responsible for 
severe, intractable bleeding which is often not responsive to VWF replacement ther-
apy and thus represent a significant unmet clinical challenge [12]. The pathological 
mechanism underlying vascular malformations in VWD is still largely unexplained. 
Recently it has been shown that VWF can act as a negative regulator of angiogenesis 
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in a Vascular Endothelial Growth Factor Receptor (VEGFR)-2 dependent process. In-
creased angiogenesis induced by VWF knockdown in endothelial cells was associated 
with increased angiopoietin-2 (Ang-2) release into the medium. Blood Outgrowth En-
dothelial Cells (BOECs) of type 1 and 2 VWD patients confirmed that low VWF levels 
lead to increased angiogenesis in vitro [13].
The angiogenic mediators Ang-2, osteoprotegerin (OPG), galectin-3 (Gal-3) 
are synthesized in endothelial cells and stored in the WPB together with VWF [14-16]. 
Angiopoietin-1 (Ang-1) and Ang-2 work together with Vascular Endothelial Growth 
Factor-A (VEGF) to mediate angiogenesis. Ang-2 is an antagonist of Ang-1 and both 
angiopoietins bind to the TIE-2 receptor on endothelial cells [17]. Increased levels of 
Ang-2 results in destabilized vessels, while increased VEGF levels can lead to vascular 
malformations in humans [18]. OPG, a soluble decoy receptor for both receptor ac-
tivator of nuclear factor-kappaB ligand (RANKL) and tumor necrosis factor-related 
apoptosis inducing ligand (TRAIL), is a positive regulator of microvessel formation, 
promoting both endothelial cell sprouting and proliferation [19]. Gal-3 modulates 
VEGF-mediated angiogenesis by binding to integrin αVβ3 on endothelial cells, sub-
sequently activating the signalling pathways that promote the growth of new vessels 
[20].  Since VWF is essential for the formation of WPB, other WPB components such as 
Ang-2, OPG and Gal-3 are dependent on VWF for their storage and secretion. We hy-
pothesize that reduced levels or defects in VWF, which can lead to impaired WPB for-
mation or complete loss of WPB, result in dysregulated release of other components 
of the WPB. The aim of this study was therefore to investigate plasma levels of angio-
genic mediators in patients with various types of VWD in order to obtain more insight 
in the development of vascular malformations frequently observed in these patients. 
Materials and Methods
Patients and controls
Stored plasma samples from the nationwide cross-sectional study among VWD 
patients in the Netherlands, the ‘Willebrand in the Netherlands’ (WiN) study [21-23] 
were used for this study. Patients diagnosed with type 1, 2 and 3 VWD who fulfilled 
the following inclusion criteria were initially included: (i) hemorrhagic symptoms or 
a family history of VWD; and (ii) historically lowest levels of VWF ≤ 30 U/dL (VWF:Ag 
and/or VWF:RCo) and/or FVIII:C  ≤ 40 U/dL.  Exclusion criteria for the current study 
were: patients who (i) were pregnant at time of inclusion, (ii) had received blood 
products, (iii) had received DDAVP infusion 72 hours prior to inclusion. Healthy indi-
viduals, who participated in the ATTAC study [24], for which VWF:Ag and blood group 
were known, were included to obtain reference values, and matched for age, sex and 
blood group. A total of 100 controls were included in this study. The Medical Ethi-
cal Committees at all participating centers approved this study and written informed 
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Laboratory Measurements
Details regarding the blood sampling procedure, questionnaires and laboratory meas-
urements of VWF:Ag and VWF:Act have been described in more detail by De Wee et 
al.[22], Sanders et al.[23] and De Bruijne et al.[24] VWFpp was measured as previously 
described [25]. At inclusion, peripheral venous blood was collected in tubes contain-
ing 3.2% (0.105 M) trisodium citrate. Subsequently, patient samples were centrifuged 
twice at 2,200 x g for 10 minutes at room temperature, control samples were centri-
fuged at 2000 x g for 10 minutes and plasma was additionally centrifuged at 20.000 
x g for 10 minutes. Citrated platelet-poor plasma was aliquoted and stored at –80°C. 
Angiopoietin-1 levels were measured using the Human Angiopoietin-1 DuoSet ELISA 
kit (DY923, R&D Systems Europe, Abingdon, Oxon, UK).  Angiopoietin-2 levels were 
measured using the Human  Angiopoietin-2 DuoSet ELISA kit (DY623),  galectin-3 lev-
els with the Human Galectin-3 Duoset ELISA kit (DY1154), osteoprotegerin with the 
Human Osteoprotegerin/TNFRSF11B DuoSet ELISA kit (DY805), and VEGF levels with 
the Human VEGF DuoSet ELISA kit (DY293B, all R&D systems). 
Statistical Analysis
Because data were not normally distributed, plasma levels are presented as median 
and 25-75% IQR. The Kruskal-Wallis test was used to test differences between types 1, 
2A, 2B, 2M, 2N, 3 VWD and the control group. The Mann-Whitney U test was then used 
to detect differences between the groups. Correlations between different parameters 
were determined by Spearman correlation coefficient. A spearman rs of <0.20 was 
regarded as very weak, 0.20-0.39 as weak, 0.40-0.59 as moderate and ≥ 0.6 as a strong 
correlation. Statistical analyses were performed with SPSS for Windows, version 22.0 
(SPSS Inc, Chicago, USA). A p-value <0.05 was considered statistically significant. 
Results
A total of 804 moderate and severe VWD patients participated in the WiN-study. 
From 681 patients plasma samples were obtained, 26 patients were excluded because 
of pregnancy (n=7), recent use of desmopressin or replacement therapy (n=17) or in-
sufficient plasma sample (n=2). Therefore a total of 655 VWD patients were included 
in this study; 380 patients were classified as type 1 VWD, 239 as type 2 VWD and 36 
as type 3 VWD according to the 2006 classification [26]. Fifteen patients who were 
initially diagnosed with type 3 VWD, had VWFpp levels >5 U/dL, and as a consequence 
these patients were included in the type 1 VWD group for the current analysis. Patient 
characteristics are given in Table 1.
Angiogenic mediators according to age, VWF:Ag levels and VWD
Both in VWD patients and controls OPG and VWF:Ag levels correlated with age. In 
VWD patients VEGF, OPG and Gal-3 levels correlated significantly with VWF:Ag levels 
(r= -0.129, r= 0.089, r= 0.083) (Table 2). Considering all VWD patients together, 









Table 1. Baseline characteristics
Characteristics VWD Patients (n=655) Controls  
(n = 100)
Age (years), median (range) 44 (1-83) 43 (18-56)
Male sex, n (%) 250 (38) 38 (38)








Blood group O, n (%)* 396 (61) 56 (56)
VWF:Ag (IU/dL), median [IQR] 29 [18-45] 91 [77-125]
VWF:CB (IU/dL), median [IQR] 22 [7-51] 108 [88-139]
VWF:Act (IU/dL), median [IQR] 23 [8-52]
FVIII:C (IU/dL), median [IQR] 51 [32-73]
Bleeding score, median [IQR]† 11 [6-16]
Bleeding in last year, n (%) ‡
Yes 180 (31)
GI bleeding 9 (5)
No 420 (69)
*6 missing, †32 missing, ‡ 46 missing. VWF:Ag, von Willebrand factor: Antigen; VWF:CB, von Willebrand factor: Collagen 
Binding activity; VWF:Act, von Willebrand factor: Activity; FVIII:C, factor VIII coagulation activity; GI, gastrointestinal.
Table 2. Correlations between parameters
Relation Group Spearman r P value
VEGF and VWF:Ag Patients -0.129 0.001
OPG and VWF:Ag Patients 0.089 0.023
Gal-3 and VWF:Ag Patients 0.083 0.033
VEGF and Age Patients -0.28 <0.001
OPG and Age Patients 0.382 <0.001
Gal-3 and Age Patients 0.26 <0.001
OPG and Age Controls 0.294 0.003
VWF:Ag and Age Patients 0.276 <0.001
VWF:Ag and Age Controls 0.203 0.043
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(median 5 [0-17] pg/ml) than healthy controls (0.14 [0.03-0.34] ng/ml, p=0.0002 and 
0 [0-10] pg/ml, p<0.0001). Ang-2 levels were lower in VWD patients (0.12 [0-0.26] 
ng/ml) than in controls (0.20 [0.12-0.33] ng/ml, p<0.0001), while OPG and Gal-3 
levels did not differ between patients and controls (Table 3).
Median Ang-1 levels were higher in type 1 (0.89 [0.51-1.54] ng/ml, p<0.0001), type 2 
(0.95 [0.5-1.66] ng/ml, p<0.0001) and type 3 (1.32 [0.79-1.97] ng/ml, p<0.0001) VWD 
patients than in healthy controls (0.14 [0.03-0.34] ng/ml) (Table 3). In contrast, me-
dian levels of Ang-2 were lower in type 1 (0.1 [0-0.24] ng/ml, p<0.0001) and type 2 
VWD patients (0.14 [0-0.29] ng/ml, p=0.003) than in healthy controls (0.20 [0.12-
0.33] ng/ml). Type 3 VWD patients had comparable Ang-2 levels (0.16 [0.04-0.29] ng/
ml, p=0.17) as controls (Table 3). Median VEGF levels were higher in type 1, 2 and 3 
VWD patients compared with healthy individuals (4 [0-15] pg/ml, p<0.001 for type 1 
patients, 4 [0-21] pg/ml, p<0.001 for type 2 patients and 16 [7-52] pg/ml, p<0.0001 for 
type 3 patients vs 0 [0-10] pg/ml for controls) (Table 3). 
Type 3 VWD patients tended to have higher Ang-1 levels than type 1 VWD patients (me-
dian 1.32 [0.79-1.97] ng/ml vs 0.89 [0.51-1.54] ng/ml, p=0.07)(Table 3). Ang-2 levels 
were lower in type 1 VWD patients compared with type 2 VWD patients (0.1 [0-0.24] 
ng/ml vs 0.14 [0-0.29] ng/ml, p=0.04) (Table 3). In addition, type 3 VWD patients had 
the highest VEGF levels compared with both type 1 (16 pg/ml vs 4 pg/ml, p=0.0014) 
and type 2 VWD patients (16 pg/ml vs 4 pg/ml, p=0.006) (Table 3). OPG levels did not 
differ between type 1, 2 or 3 VWD patients and controls, although there was a trend 
towards higher levels in the type 3 VWD (1.28 [0.98-1.86] ng/ml) compared with type 




Table 3. Angiogenic parameters in VWD patients and controls.
Angiogenic mediator Controls (n=100) All Patients 
(n=655)
Type 1 (n=395) Type 2 (n=239) Type 3 n=21)
Ang-1 0.14 0.91 0.89 0.95 1.32
[ng/ml] (0.03-0.34) (0.51-1.56)a (0.51-1.54)a (0.50-1.66)a (0.79-1.97)a
Ang-2 0.20 0.12 0.10 0.14 0.16
[ng/ml] (0.12-0.33) (0-0.26)a (0-0.24)a,1 (0-0.29)c (0.04-0.29)
VEGF 0 5 4 4 16
[pg/ml] (0-10) (0-17)b (0-15)a,2 (0-21)b,2 (7-52)a
OPG 1.04 1.1 1.10 1.10 1.28
[ng/ml] (0.77-1.29) (0.85-1.48) (0.85-1.44) (0.84-1.56) (0.89-1.86)
Gal-3 2.12 2.0 2.06 1.95 1.68
[ng/ml] (1.6-2.76) (1.28-2.77) (1.36-2.78) (1.2-2.78) (0.93-2.70)
Variables are expressed as medians (IQR). a p<0.0001, b p<0.001, c p<0.01 compared with controls. 
1 p<0.05 compared with type 2. 2p<0.01 compared with type 3.
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and controls (1.0 [0.77-1.29] ng/ml, p=0.02) (Table 3). Also Gal-3 levels did not differ 
between type 1, 2 or 3 VWD patients and healthy controls, although the type 3 VWD 
patients had slightly lower plasma levels (1.68 [0.93-2.7] ng/ml) compared with con-
trols (2.12 [1.6-2.76] ng/ml, p=0.07) and type 1 and 2 VWD patients (2.06 [1.36-2.78] 
ng/ml, p=0.12 and 1.95 [1.2-2.78] ng/ml, p=0.26 respectively) (Table 3).
Angiogenic markers according to subtypes of type 2 VWD
Since type 2 VWD patients have different qualitative defects in their VWF, there might 
be diverse consequences on the various WPB components in the different VWD type 2 
subtypes. Type 2 VWD patients were subdivided based on the ISTH subtype classifica-
tion [26]. Our study had 156 type 2A, 43 type 2B, 26 type 2M and 14 type 2N patients. 
As shown in Table 4, compared with controls type 2A, 2B, 2M and 2N VWD patients 
had higher Ang-1 levels (p<0.0001). The median Ang-1 levels are higher in the type 
2A (1.04 [0.61-1.78] ng/ml, p=0.0012) and 2M VWD (1.11 [0.65-1.69] ng/ml, p=0.02) 
compared with type 2B VWD (0.70 [0.27-1.1] ng/ml). Ang-1 levels were slightly lower 
in the type 2N VWD group (0.74 [0.35-1.41] ng/ml), but this difference did not reach 
statistical significance (Table 4). Ang-2 levels were only significantly lower in type 2A 
(0.14 [0.02-0.30] ng/ml, p=0.005) patients compared with controls (0.2 [0.12-0.33] 
ng/ml)(Table 4). Although there was no difference in Ang-2 levels within the type 2 
VWD group, the type 2B VWD patients (0.21 [0.03-0.34] ng/ml) had slightly high-
er levels compared with the other type 2 VWD patients (Table 4). VEGF levels were 
higher in type 2A (4 [0-18] pg/ml, p=0.0048), 2M (9 [0-28] pg/ml, p=0.0038) and 2N 
(7 [1.5-58] pg/ml, p=0.016) patients compared with controls (0 [0-10] pg/ml), but not 
in type 2B patients (3 [0-26] pg/ml, p=0.054). VEGF, OPG and Gal-3 levels did not dif-




Table 4. Angiogenic parameters in type 2 VWD patients and controls.






Type 2M (n=26) Type 2N (n=14)
Ang-1 0.14 0.95 1.04 0.70 1.11 0.75
[ng/ml] (0.03-0.34) (0.50-1.66)a (0.61-1.78)a,1 (0.27-1.10)a (0.65-1.69)a,2 (0.35-1.41)a
Ang-2 0.20 0.14 0.14 0.21 0.02 0.11
[ng/ml] (0.12-0.33) (0-0.29)c (0.02-0.30)c (0.03-0.34) (0-0.32)d (0.02-0.40)
VEGF 0 4 4 3 9 7
[pg/ml] (0-10) (0-21)b (0-18)c (0-26) (0-28)c (2-58)
OPG 1.04 1.10 1.12 1.09 0.95 1.43
[ng/ml] (0.77-1.29) (0.84-1.56) (0.84-1.56) (0.84-1.59) (0.61-1.19) (0.94-1.75)
Gal-3 2.12 1.95 1.98 1.67 2.4 1.48
[ng/ml] (1.6-2.76) (1.2-2.78) (1.27-2.78) (0.99-2.39) (1.68-3.23) (0.99-3.43)
Variables are expressed as medians (IQR). a p<0.0001, b p<0.001, c p<0.01, d p<0.05 compared with controls.  
1 p<0.01, 2 p<0.05  compared with type 2B.
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VEGF levels are dependent upon VWF levels in plasma 
In order to study the association between VWF:Ag levels and the angiogenic mark-
ers,  we divided the VWD patients into 4 groups based on their VWF:Ag level; <10 
(n=79), 10-20 (n=115), 21-30 (n=154), and >30 IU/dL (n=306). As shown in Figure 1A, 
patients with VWF:Ag levels below 10 IU/dL had higher VEGF levels (14 pg/ml, IQR 
[4-42]) compared with patients with VWF:Ag levels between 10-20 IU/dL (5 [0-18] 
pg/ml, p=0.0006), patients with VWF:Ag levels between 21-30 IU/dL (3 [0-16] pg/ml, 
p<0.0001) and patients with VWF:Ag levels >30 IU/dL (4 [0-14] pg/ml, p<0.0001). If 
only patients with type 1 and 2 with VWF:Ag levels <10 IU/dl were considered, also 
these patients had the highest VEGF levels (Figure 1B,C). For the type 2 patients this 
was still observed after exclusion of type 2B patients (data not shown). Ang-1, Ang-2, 
OPG and Gal-3 levels did not differ between the subgroups based on VWF:Ag levels 
(data not shown). 
Increased VWF clearance and impaired VWF synthesis
The ratio between VWF propeptide (VWFpp) and VWF:Ag (VWFpp/VWF:Ag) can 
be used to assess VWF clearance, while the ratio between FVIII coagulant activity 
(FVIII:C) and VWF:Ag (FVIII:C/VWF:Ag) can be used to assess VWF synthesis [27]. A 
high VWFpp/VWF:Ag ratio indicates increased clearance of VWF and a high FVIII:C/
VWF:Ag ratio decreased synthesis of VWF. Since Ang-2, OPG and Gal-3 are stored to-
gether with VWF inside the WPB, we investigated if increased VWF clearance and/or 
impaired VWF synthesis influences the plasma levels of the other WPB components. 
Within the type 1 VWD group we divided the patients into normal synthesis (n=219) 




Figure 1. VEGF plasma levels in relation to VWF:Ag levels. All patients were divided into four groups based on 
their VWF:Ag level; < 10U/dL, 10 - 20U/dL, 21 - 30U/dL and > 30U/dL.  Panel A shows VEGF plasma levels of all 
patients (< 10U/dL  n=79, 10 - 20U/dL n=115, 21 - 30U/dL  n=154, > 30U/dL  n=306). In panel B only patients with 
type 1 VWD are plotted (n=34, n=50, n=79, n=232), in panel C only patients with type 2 VWD are plotted (n=24, 
n=65, n=75, n=74). Box plots show median values and interquartile ranges. Whiskers show Tukey hinges; black 
circles are outliers. Asterisks denote significant deviations, * P≤0.05, ** P≤0.01, ***P≤0.001, ****P≤0.0001.
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and FVIII:C/VWF:Ag ratios as described by Eikenboom et al. [27]) or moderately and 
severely impaired synthesis (n=121 and 55) or increased clearance (n=137 and 58)
(Figure 2). Median Ang-2 levels were higher in patients with very fast VWF clear-
ance (arbitrary defined as a VWFpp/VWF:Ag ratio above 5) (0.16 [0.06-0.42] ng/ml), 
compared with patients with normal (0.09 [0-0.22] ng/ml, p=0.0021) or moderately 
increased clearance (0.09 [0-0.24] ng/ml, p=0.018) (Figure 2A). OPG and Gal-3 levels 
were similar in patients with normal and increased clearance of VWF (Figure 2B-C). 
Although not significant, Ang-2 levels were lower in patients with normal VWF syn-
thesis (ratio of FVIII:C/VWF:Ag ≤1.9) compared with impaired VWF synthesis (ratio 
above 1.9)(Figure 2D). OPG levels were similar between patients with normal and im-
paired VWF synthesis (Figure 2E). Patients with normal VWF synthesis had signifi-
cantly higher Gal-3 levels (2.15 [1.56-2.86] ng/ml) compared with patients with mod-
erately impaired synthesis (1.91 [1.28-2.67] ng/ml, p=0.045) and severely impaired 




Figure 2. Plasma levels of WPB components Ang-2, OPG and Gal3 in relation to VWF synthesis and clear-
ance. VWFpp/VWF:Ag was used as a parameter for VWF clearance rate (A-C). Within the type 1 VWD group 
(n=395), patients were categorized in three groups:  VWFpp/VWF:Ag ratio of  ≤ 2.2 (n=200), 2.21 – 5 (n=137) and 
> 5 (n=58). Panel A shows levels of Ang-2, panel B shows OPG levels and panel C shows Gal-2 levels. The FVIII:C/
VWF:Ag ratio was used as a parameter for VWF synthesis (D-F). Type 1 VWD patients were categorized into 
three groups based on their FVIII:C/VWF:Ag ratio:  < 1.9 (n=219) , 1.9 – 3 (n=121) and > 3 (n=55). Panel D shows 
levels of Ang-2, panel E shows OPG levels and panel F shows Gal-2 levels. The cutoffs are based on the upper 
limit of normal range as described by Eikenboom et al. [27]. Box plots show median values and interquartile 
ranges. Whiskers show Tukey hinges; black circles are outliers. Asterisks denote significant deviations, * P≤0.05, 
** P≤0.01.
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Angiogenic mediators and lack of Height Molecular Weight (HMW) Multimers 
Angiodysplasia is mostly reported in type 2A, 2B [28-30] and type 3 VWD [10] pa-
tients, i.e. in patients lacking HMW multimers. Patients were divided into normal 
VWF multimer pattern (total n=339, type 1=300, type 2M =25, type 2N=14) or lacking 
the HMW multimers (total n=111, type 2A=76, type 2B=35) based on multimer analysis. 
We observed higher Ang-2 levels in the subgroups of VWD patients lacking the HMW 
multimers (0.14 [0.02-0.29] ng/ml) compared with those with normal multimeric 
pattern (0.09 [0-0.24] ng/ml, p=0.02) (Figure 3B). Although not significant, also Ang-
1 levels are increased in patient lacking the HMW multimers (0.89 [0.51-1.47] ng/ml vs 
0.99 [0.60-2.15] ng/ml, p=0.09), while Gal-3 levels were lower in these patients (2.0 
[1.3-2.8] ng/ml vs 1.73 [1.2-2.58], p=0.0733) (Figure 3A, E). VEGF and OPG levels were 
comparable between the two patient groups (Figure 3C-D).   
Angiogenic mediators and gastrointestinal bleeding
To investigate whether dysregulation of angiogenic mediators could contribute to 
vascular malformations leading to gastrointestinal bleedings, we analysed patients 




Figure 3. Plasma levels of angiogenic mediators in relation to VWF multimer pattern. Patients with normal 
VWF multimer pattern (Total n=339; type 1 = 300, type 2M = 25, type 2N = 14) and patients who lack the high 
molecular weight (HMW) multimers (Total n=111; type 2A = 76, type 2B = 35) are plotted for their plasma levels 
of (A) Ang-1, (B) Ang-2, (C) VEGF, (D) OPG and (E) Gal-3. Box plots show median values and interquartile ranges. 
Whiskers show Tukey hinges; black circles are outliers. Asterisks denote significant deviations, * P ≤ 0.05.
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bleedings elsewhere (n=180) and patients without bleedings in the year before inclu-
sion (n=420). We observed higher Ang-2 levels in patients who bled (0.15 [0.01-0.29] 
ng/ml) compared with patients who did not experience bleedings (0.09 [0-0.25] ng/
ml, p=0.03). Due to a lack of power, considering the small group of VWD patients with 
gastrointestinal bleedings we could not detect other  differences between those with 
and without GI bleeding.  
Discussion
VWF is a negative regulator of (in vitro) angiogenesis [13] and is stored in WPBs in 
endothelial cells. Besides VWF also other angiogenic mediators are stored within the 
WPBs. In this study we investigated plasma levels of angiogenic mediators in patients 
with VWD in order to obtain more insight in the development of vascular malfor-
mations frequently observed in patients with VWD. We observed that several of the 
measured angiogenic mediators are significantly different in VWD patients compared 
to healthy controls. Also within the VWD patient groups variations in these levels 
were observed. 
We found higher Ang-1 and VEGF plasma in patients with VWD, with the highest 
levels in type 3 patients, which is in line with a previously published study [31]. VEGF 
is the best characterized pro-angiogenic endothelial growth factor [32,33]. At high 
concentrations however, VEGF induces an irregular vasculature with fragile and 
frequently hemorrhagic vessels, reminiscent of angiodysplasia [34] and increased 
VEGF levels have been reported in patients presenting with angiodysplasia and in 
patients with hereditary hemorrhagic telangiectasia [35,36]. Higher VEGF levels 
in VWD patients could therefore contribute to vascular malformations frequently 
seen in these patients [12]. However, care should be taken interpreting the increased 
VEGF and Ang-1 plasma levels. Since platelets store a large amount of Ang-1 and 
VEGF, circulating levels of these proteins may be biased by platelet count, in vivo 
platelet activation and unintentional platelet activation during blood collection [37]. 
Centrifugation steps were slightly different between patients and controls and we 
cannot exclude that this might have led to differences in ex vivo platelet activation. 
Since the first step of centrifugation is similar between patients and controls, and 
most platelets are discarded after this step, potential ex vivo activation is presumably 
comparable between patients and controls. Nonetheless, plasma collection was 
identical for all VWD patients, and thus within the VWD group this is not an issue. 
Platelet counts were not documented in this study, but most VWD patients have normal 
platelet numbers [36]. It has been shown that megakaryocytopoiesis is modified by the 
enhanced VWF-GPIbα interactions in patients with type 2B VWD [38], and VEGF and 
Ang-1 levels could be influenced by the abnormal megakaryocytopoiesis. However, 
when type 2B patients were excluded from the type 2 groups for analysis, differences 
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of VEGF in VWD patients could be a consequence of perturbed intracellular and 
extracellular pathways leading to increased VEGF expression in the absence of VWF 
[12,39]. This may also explain why patients with the lowest VWF:Ag levels (type 3 
VWD patients and patients with a VWF:Ag <10 IU/dL) have the highest VEGF levels.
We speculated that defects in VWF, potentially leading to impaired or absent WPB for-
mation, enhanced the release of other components of the WPB. In accordance with 
this hypothesis we found higher Ang-2 and OPG levels in type 3 VWD patients com-
pared with type 1 and 2 VWD patients. However, the opposite was observed for Gal-3 
levels; Gal-3 levels were the lowest in type 3 VWD patients. In VWF deficient mice Gal-
3 levels were also reduced compared with wild-type mice [14], confirming the results 
observed in our type 3 VWD patients. In VWF deficient mice the reduced Gal-3 levels 
were corrected following hydrodynamic gene transfer of VWF, indicating that VWF 
contributes to the regulation of Gal-3 plasma levels. In the circulation Gal-3 is bound 
to VWF [14,40] and in the absence of VWF, Gal-3 co-precipitated with FVIII [40]. In 
type 3 VWD patients FVIII levels are very low (FVIII:C 1 IU/dL, IQR 1-3 in our group), 
because the half-life of free FVIII is very short compared with VWF-bound FVIII. In 
the absence of VWF, levels of circulating Gal-3 could be lower because complex forma-
tion with VWF, which may promote the circulatory lifespan of Gal-3, cannot occur or 
complex formation with free FVIII in the absence of VWF, promotes faster clearance. 
The decreased Ang-2 levels observed in VWD patients compared with controls is con-
tradictory to previous published results obtained from cultured endothelial cells from 
VWD patients [12,41]. The difference could be explained by lack of a clearance mech-
anism in the culture experiments. Since Ang-2 levels were measured in supernatants 
of cultured cells, clearance of Ang-2, which could play a role in vivo, is not affected 
in those experiments. Furthermore, Ang-2 levels were only measured in VWF siR-
NA-treated human umbilical vein endothelial cells, and levels in BOECs from VWD 
patients were unfortunately not reported. Both Ang-1 and Ang-2 bind to the TIE-2 
(Tyrosine kinase with Immunoglobulin-like and EGF-like domains-2) receptor on en-
dothelial cells [17,42] and activation of TIE-2 by Ang-1 binding induces intracellular 
signalling pathways leading to down-regulation of Ang-2 production in endothelial 
cells [42]. This interaction however, does not occur in cultured endothelial cells be-
cause Ang-1 is absent in culture experiments.
The pathological mechanism underlying angiodysplasia in VWD is still largely unex-
plained. We observed higher Ang-2 levels in patients who had bleedings compared 
with patients who did not experience bleedings, but due to the small group of patients 
(n=9) with gastrointestinal bleedings we could not detect further significant differ-
ences. Higher Ang-2 levels, combined with lower Ang-1 levels could contribute to the 
formation of fragile vessels seen in angiodysplasia, but more patients with a recent 
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With regard to the WPB components Gal-3, Ang-2 and OPG, the functional consequenc-
es of their binding to VWF have been investigated to a limited extent, if at all. Being in 
complex with VWF may prevent the interaction with their natural ligand via sterical 
hindrance, as is the case for FVIII.  However, information is scarce on this issue, and 
it would be interesting to examine the shared functional effects between VWF and its 
binding partners. Since endothelial cells contain several other VWF-binding proteins 
with pro- and anti-angiogenic properties that we did not study, such as galectin-1, 
connective tissue growth factor and insulin-like growth factor binding protein-7, it 
is very likely that VWF plays an exceedingly complex role in regulating angiogenesis 
at different levels. Characterisation of the molecular pathways through which VWF 
regulates angiogenesis can provide novel therapeutic targets for the treatment of an-
giodysplastic gastrointestinal bleeding, since prophylaxis is less successful at reduc-
ing gastrointestinal blood loss than it is for reducing blood loss at different sites in the 
body [43]. 
In conclusion, VWD patients have several abnormalities in the levels of angiogenic 
mediators in plasma compared to controls. Impaired formation or loss of WPB in VWD 
patients leads to both increased and decreased plasma levels of angiogenic mediators 
compared with healthy individuals. The dysregulation between these angiogenic me-
diators could contribute to the vascular malformation frequently observed in these 
patients.
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Abstract
Endothelial von Willebrand factor (VWF) has been shown to negatively regulate 
angiogenesis. Blood Outgrowth Endothelial Cells (BOECs) isolated from von Wille-
brand disease (VWD) patients showed enhanced in vitro angiogenesis compared with 
healthy control BOECs. Characterisation of the angiogenic response of BOECs from 
VWD patients is limited and differences between the different types of VWD have not 
been investigated in detail. The aim of this study was to further explore the poten-
tial pathogenic role of VWF mutations in regulating angiogenesis. We isolated BOECs 
from 4 healthy individuals, 10 patients with VWD and 1 heterozygous carrier of a type 
2N mutation and measured cell migration and tube formation. Migration velocity 
and total tube formation was similar between VWD patients and controls in general. 
BOECs from the type 3 VWD patient and one type 2B patient showed increased mi-
gratory velocity and tube formation. Directionality was impaired in 8 out of 10 VWD 
BOECs and the ability to form tubes was limited to early passage numbers, but not 
for BOECs from healthy controls. In conclusion, BOECs from VWD patients did not 
have enhanced in vitro angiogenesis compared with healthy controls, but individual 
patients showed both increased and decreased angiogenic potential. Almost all VWD 
patients showed impaired directional migration. BOECs can be a useful tool for ex vivo 
assessment of endothelial cell function in patients with different types of VWD. But 
limitations, such as early loss of angiogenic capacity, should be taken into account 
when studying BOECs from VWD patients.
Introduction
Von Willebrand factor (VWF) is best known for its three classical hemostatic func-
tions; (i) as a carrier protein for coagulation factor VIII, (ii) binding to exposed col-
lagen upon vascular damage and (iii) as a mediator of the recruitment of platelets to 
sites of vascular injury [1]. A decreased concentration or abnormal function of VWF is 
responsible for von Willebrand disease (VWD), the most common inherited bleeding 
disorder [2]. A reduced concentration of structurally normal VWF is classified as type 
1 VWD. Qualitatively abnormal variants of VWF are classified as type 2 VWD (with 
subgroups 2A, 2B, 2M and 2N), while a complete deficiency of the VWF protein is 
classified as type 3 VWD [3]. Von Willebrand factor (VWF) is mainly produced in en-
dothelial cells, while a small contribution comes from synthesis in megakaryocytes 
[4,5]. Synthesized VWF is either constitutively secreted into the blood, or stored in 
cell-specific organelles. VWF is stored in in the alpha-granules in platelets, while in 
endothelial cells it is stored in the Weibel-Palade bodies (WPB)[6].
Until recently, there was limited access to endothelial cells (EC) from VWD patients 
and this has been a barrier to better understand the cellular pathophysiology of VWD. 
Studies on cellular effects of VWF mutants have been carried out mainly in non-EC 
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as they do not entirely mimic the endothelial cell milieu. While VWF storage and 
secretion can be assessed with VWF transfections in cell types such as HEK293 [7-
9], these cells do not have the typical endothelial characteristics, such as expression 
of endothelial cell markers and the capacity of forming capillary-like structures in 
matrigel. Blood Outgrowth Endothelial Cells (BOECs) provide a useful system to study 
the storage and secretion of VWF in patients with VWD. BOECs can be derived from 
human peripheral blood mononuclear cells [10]. In culture, these BOECs have the 
typical endothelial cobblestone morphology, express endothelial cell markers such 
as CD34, VWF, vascular endothelial (VE)-cadherin and platelet endothelial cell adhe-
sion molecule (PECAM)[11], and are capable of forming capillary-like structures on 
Matrigel [12]. BOECs from several type 1 and 2 VWD patients have been successfully 
isolated and used to study the storage and secretion of VWF in VWD disease [13,14]. 
In recent years it has become clear that VWF has a versatile function beyond hemo-
stasis. Endothelial VWF has been implicated in pathophysiological processes, such as 
tumor metastasis, cell proliferation and inflammatory processes [15]. Starke et al [16], 
demonstrated that endothelial VWF is also a negative regulator of angiogenesis. VWF 
knockdown in HUVECs led to increased in vitro angiogenesis. BOECs isolated from 
type 1 and 2 VWD patients showed increased migration and tube formation compared 
with BOECs isolated from healthy individuals [16]. Whether this also holds for type 3 
VWD BOECs is unknown, since successful isolation has not been reported yet. Char-
acterisation of the angiogenic characteristics of BOECs from VWD patients is still very 
limited and differences between the different types of VWD have not been investigat-
ed in detail. The aim of this study was to further explore the potential pathogenic role 
of VWF mutations in regulating angiogenesis. To this end, we isolated BOECs from 
type 1, 2 and 3 VWD patients and characterized their angiogenic capacity.
Methods
Patients and Controls
BOECs were successfully isolated from the following individuals: 1) Four type 1 VWD 
patients heterozygous for the mutations p.Arg1205His, p.Arg1205His/p.Arg924Gln, 
p.Tyr1584Cys, p.Cys2693Tyr. 2) Four type 2B VWD patients heterozygous for the mu-
tations p.Arg1308Cys (two patients), p.Val1316Met and p.Pro1337Leu. 3) One VWD pa-
tient with an unidentified mutation leading to a type 2A phenotype. 4) An asympto-
matic heterozygous carrier of the type 2N mutation p.Arg854Gln. 5) One type 3 VWD 
patient compound heterozygous for the p.Arg2535* mutation and a second unknown 
mutation. 6) Four healthy individuals. Plasma VWF:Ag levels were measured as pre-
viously described [17]. Angiopoietin-2 plasma levels were measured using the Human 
Angiopoietin-2 DuoSet ELISA kit (DY623, R&D Systems Europe, Abingdon, Oxon, UK). 
The study protocol was approved by the Leiden University Medical Center ethics re-
view board. Written informed consent was obtained from all participating subjects 
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BOECs isolation, characterisation and culture
BOECs were isolated and cultured as previously described [14]. Briefly, 80ml of pe-
ripheral blood from each participant was drawn in 10ml citrated tubes (S-Monovette, 
Sarstedt, Nümbrecht, Germany). Citrated blood was diluted 1:1: with phosphate buff-
ered saline (PBS) and buffy coat mononuclear cells were isolated by gradient centrif-
ugation over Ficoll-Paque PLUS (GE Healthcare, Diegem, Belgium) at 800 x g for 30 
minutes, washed twice with PBS. Cell pellets were resuspended in EGM-2 medium 
(Lonza, Breda, The Netherlands) supplemented with 20% fetal calf serum (Gibco, Life 
Technologies, Grand Island, NY, USA) and a cocktail of growth factors (EGM-2 bullet 
kit, Lonza, Breda, The Netherlands). The cells were seeded onto 6-well tissue culture 
plates pre-coated with rat tail collagen type 1 (BD, Biosciences, Bedford, Massachu-
setts, USA). Culture medium was refreshed daily until the first colony appeared. Me-
dium was then refreshed every 2 days. Cells were used for experiments at passages 2 
to 8 unless stated otherwise.
FACS analysis
BOECs were washed once with PBS containing 1% bovine serum albumin and 0.01% 
sodium azide and were incubated with primary antibody or isotype control for 30 
minutes at room temperature in the dark. Primary mouse monoclonal antibodies 
(all purchased from BD Biosciences) against human CD14-APC, human CD45-PE/cy5, 
human CD31 (PECAM), human KDR-PE and human CD144 (VE-Cadherin)-APC were 
used. A secondary antibody conjugated to Alexa Fluor 488 was used to label CD31. In 
separate tubes, cells were incubated with isotype controls. Samples were fixed in 1% 
paraformaldehyde and analyzed by FACS (LSRII, BD Biosciences). Data were analyzed 
using FACSDiVa software (BD Biosciences).
Confocal immunofluorescence microscopy
BOECs were grown on collagen coated coverslips. Confluent cells were fixed, permea-
bilized and stained essentially as previously described[8]. Polyclonal sheep antihuman 
antibody VWF-FITC (ab8822, Abcam, Cambridge, UK), monoclonal antibody CD62P 
(Clone AC1.2, BD Biosciences), polyclonal rabbit antihuman β-catenin antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), polyclonal mouse antihuman NOS type III 
antibody (BD Biosciences), and polyclonal rabbit antihuman protein disulfide isomer-
ase (PDI) antibody A66 (obtained from prof. I. Braakman, Department of Chemistry, 
Utrecht University, The Netherlands) were used to visualize VWF, P-selectin, β-cat-
enin, eNOS and PDI respectively. Alexa 488 and Alexa 594-conjugated secondary anti-
bodies were purchased from Invitrogen (Carlsbad, CA, USA). Samples were analysed 
by Leica SL confocal laser scanning microscopy with a 40x and 63x oil objective (Leica 
Microsystems).
In vitro Matrigel Assay
Matrigel assays were performed according to the manufacturer’s instructions. 
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ty-eight-well tissue culture plates were coated with 150µl/well matrigel for 30min 
at 37°C. BOECs from both VWD patients and from healthy donors were cultured for 
4 hours in EGM-2 medium. Cells were subsequently seeded onto matrigel (BD Bio-
sciences) coated wells at 50.000 cells per well in a 48-well plate in EGM-2 medium. 
Twenty-four hours after seeding images were taken by Leica DM IL LED inverted mi-
croscopy equipped with the Leica DFC295 digital camera (Leica Microsystems). Char-
acterisation of the capillary-like structures was analyzed using the online software 
program WimTube (Wimasis Image Analsysis, Ibidi GmbH, München, Germany)[18]. 
BOECs at different stages of cell passage were used to investigate the behaviour of 
the cells during prolonged culture. Three independent experiments in duplicate were 
performed for each BOEC.
Wound-healing Assay
BOECs were grown in complete EGM-2 medium supplemented with 20% fetal calf se-
rum until a confluent monolayer was formed in a 24-well plate coated with collagen, 
washed twice with PBS and further migration experiments were performed in EGM-2 
medium. Actinomycin D (2ng/ml) (Sigma, St Louis, MO, USA) was added to the cells 
to inhibit proliferation in order to exclude bias related to proliferative effects. A thin 
‘wound’ was introduced by scratching the bottom of the well with a pipette tip. Cul-
ture plate was placed in a Leica DMI6000 inverted microscope equipped with an envi-
ronmental chamber for the control of temperature, CO2 concentration, and humidity. 
Images were taken every hour using a Leica DF350FX CCD camera, until 24 hours af-
ter scratching. Images were analyzed using Fiji (ImageJ, National Institutes of Health, 
Bethesda, Maryland, USA). The cell covered area (µm2) was measured for every image 
and subsequently the increase of cell-covered area per time interval was calculated. 
For the cell front migration velocity the total area was multiplied by the increase of 
cell-covered area, and this number was divided by the time interval. The result is the 
normalized cell front migration velocity in µm/h. This ratio was converted to µm/
min. Three independent experiments in duplicate were performed for each BOEC. 
For individual cell migration, images were analysed using the Fiji manual tracking 
plug-in (ImageJ). Chemotaxis and Migration tool (Ibidi) was used to plot trajectories 
and calculate individual cell migration velocities. According to tracking instructions, 
around 25-30 individual cells in one well were tracked to calculate the individual cell 
migration velocity and average directionality. The average directionality is calculated 
by dividing the mean Euclidean distance (the shortest linear distance travelled from 
starting to end point of a tracked cell) of all tracked cells by the mean accumulated 
distance of all tracked cells. A value of 1 equals a straight-line migration from start to 
endpoint.
Statistics
Variables are expressed as means (with standard deviations, SD) or medians [with 
interquartile range, IQR]. Continuous data were tested for normality and analyzed by 
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P values of 0.05 or less were considered statistically significant. Statistical analysis 
was performed using GraphPad Prism, version 6.00 for Windows (GraphPad Software 
Inc, La Jolla, CA, USA).
Results
Isolation of BOECs from different VWD patients
We isolated circulating progenitor cells from patients with VWD and healthy controls 
and cultured them to expand BOECs. BOECs were successfully isolated from 10 VWD 
patients (4 with type 1, 5 with type 2 and 1 with type 3), 1 carrier of type 2N VWD and 
4 healthy controls (Table 1). All patients had reduced plasma VWF:Ag levels compared 
with healthy controls. The type 3 VWD patient had VWF:Ag levels below the detection 
limit of the assay. Plasma levels of angiopoietin-2, an angiogenic protein that is stored 
within Weibel-Palade bodies together with VWF, were significantly lower in the VWD 
patients (mean ± SD, 0.85 ± 0.53 ng/ml) compared with healthy donors (2.1 ± 1.4 ng/
ml, p=0.02)(Table 1).
Characterisation of type 3 VWD BOEC
We successfully isolated BOECs from a type 3 VWD patient. The BOECs were de-
rived from a type 3 VWD patient compound heterozygous for a nonsense mutation 
p.Arg2535* and an unknown mutation on the other VWF allele. Plasma VWF:Ag levels 
were below the detection limit of 5 U/dl, no VWF multimers could be visualized on 
multimer gel, and the inheritance pattern in the family was autosomal recessive con-




Table 1. Characteristics of investigated subjects
Control /Patient nr Amino acid change Nucleotide change VWD Type* VWF:Ag U/dL Ang-2 ng/ml
1** n/a n/a n/a 80 1.188
2** n/a n/a n/a 110 1.277
3** n/a n/a n/a 91 4.085
4** n/a n/a n/a 120 1.821
1 Unknown Unknown 2A 62 0.840
2** p.Arg854Gln c.2561G>A 2N 73 1.053
3 p.Arg1205His c.3864G>A 1 15 0.832
4 p.Arg1205His/p.Arg924Gln c.3864G>A and c.2271G>A 1 11 0.412
5 p.Arg1308Cys c.3922C>T 2B 21 0.588
6 p.Arg1308Cys c.3922C>T 2B 26 0.485
7 p.Val1316Met c.3946G>A 2B 36 0.525
8 p.Pro1337Leu c.4010C>T 2B 47 2.017
9** p.Tyr1584Cys c.4751A>G 1 48 0.417
10*** p.Arg2535 stop codon/unknown c. 7603C>T 3 <5 1.631
11** p.Cys2693Tyr c.8078G>A 1 46 0.525
n/a, not applicable; VWD, von Willebrand disease; VWF:Ag, von Willebrand factor antigen; U/dL, units per decilitre; Ang-2, angiopoietin-2. * VWD 
type according to the 2006 classification [3]. **BOECs from these controls, patients and heterozygous type 2N carrier have been described in 
detail by Wang et al.[14] ***BOEC from a compound heterozygous type 3 patient for whom the mutation on the second allele is unknown.





Figure 1. Phenotypic and functional analysis of a type 3 VWD BOEC. (A) Cobblestone-like morphology under 
bright field microscopy of BOECs isolated from a type 3 VWD patient compound heterozygous for the p.Arg2535* 
mutation and a second unknown mutation. (B) FACS analysis demonstrate that BOECs were negative for 
monocyte markers CD14 and CD45, but positive for endothelial cell markers CD31 (PECAM), KDR (VEGFR) and 
CD144 (VE-Cadherin). Isotype controls are shown as grey lines. (C)  Fluorescence microscopy of type 3 BOECs 
(upper images) and BOECs from a healthy control (lower images). Left panel: co-staining for eNos (endothelial 
nitric oxide synthase, green) and ß-Catenin (red). Middle panels: co-staining for VWF (green) and PDI (red). 
Right panels: co-staining for VWF (green) and P-selectin (red). White arrows indicate diffuse P-selectin staining. 
Images were taken by Leica SL confocal laser scanning microscopy with a 40x or 63x/1.40 NA oil objective. (D) 
BOECs formed capillary-like structures in Matrigel. (E) BOECs were able to migrate and closed the open area in 
a wound healing assay within 20 hours.
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cobblestone morphology (Figure 1A). Further characterisation by FACS analysis con-
firmed that these BOECs are endothelial cells as they expressed the classic endothelial 
cell markers VE-cadherin (CD144), KDR (VEGFR2) and PECAM (CD31)(Figure 1B). On 
the other hand, these cultured cells were negative for the monocyte markers CD45 and 
CD14 (Figure 1B). Confocal microscopy revealed that these cells also express β-catenin 
and to some extent endothelial nitric oxide synthase (eNOS)(Figure 1C, left image, 
top). In BOECs from healthy individuals we could demonstrate the elongated WPB 
with co-localization of VWF with P-selectin (Figure 1C, right image, bottom). VWF 
was not detectable in BOECs from this type 3 VWD patient, and staining for P-selectin 
was faint and rather diffuse with the presence of some small granules, which are most 
likely lysosomes. Therefore no apparent WPB were detected in the endothelial cells 
isolated from this patient (Figure 1C, middle and right images, top). BOECs from the 
type 3 VWD patient were functional endothelial cells as they were capable of forming 
capillary-like structures in Matrigel coated wells (Figure 1D), as well as migrate and 
close a wound in a wound-healing assay (Figure 1E).
Migration behaviour of BOECs from VWD patients 
The median cell front migration velocity did not differ between BOECs of controls 
(median [IQR], 0.46 [0.39-0.56] µm/min) and BOECs of VWD patients overall (0.37 
[0.27-0.48] µm/min)(Table 2 and Figure 2A). However, BOECs from patient with the 




Table 2. Migratory characteristics of BOECs from controls and VWD patients
BOEC Cell front migration 
velocity  (µm/min)







Control 1 0.38 ± 0.10 0.46 ± 0.10 527 ± 109 398 ± 102 0.75
Control 2 0.51 ± 0.06 0.43 ± 0.07 431 ± 109 288 ± 122 0.66
Control 3 0.41 ±0.08 0.46 ± 0.08 677 ± 161 496 ± 139 0.73
Control 4 0.58 ± 0.0009 0.51 ± 0.12 448 ± 110 323 ± 120 0.71
2A-1  
(Unknown)
0.25 ± 0.03c 0.40 ± 0.14 620 ± 228 374 ± 276 0.56
Carrier of 
p.Arg854Gln
0.41 ± 0.013 0.47 ± 0.08 802 ± 198a 350 ± 155 0.45
p.Arg1205His 0.32 ± 0.08 0.40 ± 0.09 668 ± 134c 351 ± 129 0.51
p.Arg1205His/
p. Arg924Gln
0.35 ± 0.06 0.45 ± 0.11 559 ± 106 320 ± 108 0.58
p.Arg1308Cys-1 0.41 ± 0.002 0.45 ± 0.13 647 ± 185 291 ± 198 0.43
p.Arg1308Cys-2 0.37 ± 0.06 0.42 ± 0.11 567 ± 150 267 ± 126 0.47
p.Val1316Met 0.27 ± 0.002c 0.46 ± 0.10 553 ± 168 343 ± 165 0.61
p.Pro1337Leu 1.29 ± 0.58c 0.60  ± 0.13a 352 ± 61c 314 ± 65 0.81
p.Tyr1584Cys 0.48 ± 0.12 0.43 ± 0.11 710 ± 245b 386 ± 211 0.55
p.Arg2535*/ 
unknown1
0.74 ± 0.019b 0.58 ± 0.11a 568 ± 159 399 ± 147 0.70
p.Cys2693Tyr 0.23 ± 0.04b 0.46 ± 0.17 780 ± 335a 411 ± 176 0.55
All data indicate mean ± SD. † Around 25-30 individual cells were tracked for each BOEC. †† The euclidean distance is the direct (linear) distance 
between starting point and end point of a cell track. ††† The directionality is calculated by dividing the mean euclidean distance of the tracked cells 
by the mean accumulated distance. A value of 1 equals a straight-line migration from start to endpoint. 1 BOEC from a compound heterozygous 
type 3 patient for whom the mutation on the second allele is unknown. a p<0.001, b p<0.01, c p<0.05 compared with controls.
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velocity than healthy control BOECs (Table 2). On the other hand, BOECS from some 
patients (2A-1, p.Val1316Met, and p.Cys2693Tyr) had significantly lower cell front mi-
gration velocity compared with BOECs from healthy individuals (Table 2). We did not 
observe a difference in the cell front migration velocity between type 1 (0.34 [0.25-
0.45] µm/min) and type 2 (0.39 [0.27-0.63] µm/min) VWD patients. Compared to the 
median cell front migration velocity of type 1 and 2 VWD patients, the BOECs from the 
type 3 VWD patient migrated faster (Figure 2A). The addition of actinomycin D, which 
inhibits proliferation without inducing cell death, in the wound-healing assay rules 
out that proliferative effects are responsible for the observed differences. Live-cell 
imaging of the cells showed that cells did not proliferate during the wound-healing 
assay. 
Since cells can also migrate in other directions than the (open) wounded area, we also 
measured the velocity rate of individual cells by tracking cells during migration. In-
dividual cell migration velocity did not differ between controls (0.46 [0.44-0.50] µm/
min) and patients overall (0.45 [0.42-0.47] µm/min)(Table 2 and Figure 2B). However 
in accordance with the cell front migration velocity, individual cells from the patient 
with the p.Pro1337Leu mutation (mean±SD, 0.60 ±0.13 µm/min) and the type 3 VWD 
patient (0.58 ±0.11 µm/min) also migrated significantly faster compared with individ-
ual cells from healthy individuals (0.47 ±0.03 µm/min, p <0.001). While BOECs from 
patients with the 2A, the p.Val1316Met and the p.Cys2693Tyr mutation had signifi-
cantly slower cell front migration velocity, individual cells migrated with comparable 
rates as control BOECs (Table 2 and Figure 2B). The impaired migration velocity of the 
front layer was due to a loss of directionality towards the wounded area (Table 2). The 




Figure 2. Migration behavior of BOECs from healthy individuals and VWD patients. BOECs were grown until 
they formed a confluent monolayer. A wound was introduced by scratching the bottom of the well with a pipette 
point. Images of migrating cells were taken every hour using a live-cell imaging microscope set-up for up to 
24 hours after scratching. (A) Collective migration of the front cell layer for BOECS from healthy individuals 
and VWD patients. Around 25-30 individual cells were tracked using the manual tracking plug-in of the ImageJ 
software Fiji to measure individual cell migration velocity (panel B) and directionality (panel C). Directionality 
is calculated by dividing the Euclidean distance by the accumulated distance. Black bars indicate the medians 
with IQR. * p < 0.05.
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compared with healthy controls (0.72 [0.67-0.75], p=0.03). Type 1 VWD patients (0.55 
[0.52-0.57]) also had impaired directionality compared with controls (0.72 [0.67-
0.75], p=0.03). Although the median directionality of BOECs from type 2 patients was 
even lower this did not reach statistical significance (0.52 [0.45-0.66], p=0.11)(Table 2 
and Figure 2C). Individually, BOECs from VWD patients showed impaired directional 
migration towards the open wound area in most cases. Only BOECs from the patient 
with the p.Pro1337Leu mutation and type 3 VWD patient showed comparable direc-
tional migration compared with healthy controls (Table 2 and Figure 3). 
Capacity to form capillary-like structures of BOECs from VWD patients
We investigated the angiogenic properties of BOECs from VWD patients in an in vitro 
tube formation assay on growth-factor reduced Matrigel. This assay measures the 
ability of endothelial cells to form structures which involves endothelial cell adhe-
sion, migration and eventually tubule formation. Total tube length was similar be-
tween BOECs isolated from VWD patients overall (3.1 [2.3-3.6] cm) and BOECs iso-
lated from healthy individuals (3.3 [3.0-3.3] cm) (Table 3 and Figure 4A). However 
BOECs from the patients with the p.Pro1337Leu and p.Tyr1584Cys mutations and type 
3 VWD patient showed significantly increased total tube length compared with con-
trols, while BOECs from patients with the p.Arg1205His,p.Arg1205His/p.Arg924Gln, 
p.Arg1308Cys-2, p.Cys2693Tyr mutation showed significantly decreased total tube 
length compared with BOECs from healthy donors (Table 3). This decrease in total 
tube length was accompanied by a decrease in branching points and loops and these 
BOECS also formed less tubes compared to control BOECs. On the other hand, BOECs 
that formed more tubes compared with control BOECs, also had a smaller average tube 
length than control BOECs (Table 3). The number of branching points, total tubes and 
the average length of a tube did not differ between BOECs from VWD patients overall 
and BOECs from healthy individuals (Figure 4B-D and Table 3). Although we could not 
detect statistically significant differences, type 1 VWD patients had lower total tube 
length, less branching points and formed less tubes than type 2 VWD patients and 
the type 3 VWD patient, while their average tube length was slightly higher. (Table 3, 
Figure 4A-C). 
BOECs from VWD patients lose their angiogenic capacity earlier
BOECs from both healthy individuals and VWD patients gradually lost their capaci-
ty to form capillary-like tubules on Matrigel (Figure 5). However, while BOECs from 
healthy individuals were still capable of forming tubes at passage number 10 and be-
gan gradually losing their capacity around passage 15, BOECs from VWD patients lost 
their capacity to form capillary-like tubules much earlier on. The ability to form capil-
lary-like tubules began to decrease at around passage 7 and 8 for BOECs isolated from 
VWD patients (Figure 5). Interestingly, BOECs isolated from the type 3 VWD patient 
with the p.Arg2535* mutation quickly lost their ability to form tubules on Matrigel 
(Figure 5, lower panel). While the capacity to form capillary-like tubules was declin-
ing for VWD BOECs, their migration velocity remained similar for up to passage num-









Figure 3. Trajectory plots of individual cell migration of BOECs. Around 25-30 individual cells were tracked 
using the manual tracking plug-in and recorded data was analyzed using the chemotaxis and migration tool from 
Ibidi. Trajectory plots of BOECs show individual cells migrating into a wounded area. The starting point of each 
cell trajectory is plotted at the center of the graph and the wounded area is upwards of the horizontal line which 
goes through zero on the y-axis. Upwards movement of cells indicates direction towards the wound, downwards 
movement of cells indicates direction away from the wound. Black dots indicate cells that are moving upwards 
to the wounded area, red dots indicate cells that are moving downwards away from the wounded area.





Figure 4. Characterization of capillary network formation of BOECs from controls and VWD patients. 
BOECs from healthy donors and VWD patients were seeded onto Matrigel coated wells and images were taken 
after 24 hours. Total length of all tubes (panel A), the number of branching points (Panel B), the number of tubes 
formed (Panel C) and the average length of the tubes (Panel D) was characterized with the WimTube online 
Software from Ibidi. Individual patient and control BOECs are plotted. Data represent the mean value of three 
independent experiments done in duplicate. The black bars indicate the medians with IQR.

















Control 1 21 ± 4 2.91 ± 0.34 89 ± 19 27 ± 9 170 ± 36 174 ± 23 8.46 ± 2.99 1427 ± 413
Control 2 26 ± 8 3.31 ± 0.23 113 ± 15 41 ± 12 208 ± 40 163 ± 23 4.86 ± 0.74 986 ± 142
Control 3 29 ± 5 3.26 ± 0.39 106 ± 23 41 ± 13 185 ± 38 180 ± 18 5.78 ± 1.50 1068 ± 164
Control 4 22 ± 4 3.31 ± 0.20 111 ± 15 36 ± 9 217 ± 23 153 ± 7 5.76 ± 0.80 1240 ± 136
2A-1  
(Unknown)
29 ± 3 3.43 ± 0.41 126 ± 25 38 ± 10 245 ± 52d 142 ± 15d 5.93 ± 1.27 1204 ± 140
Carrier of 
p.Arg854Gln
33 ± 1d 3.38 ± 0.20 120 ± 13 42 ± 5 216 ± 25 158 ± 16 4.59 ± 0.16 954 ± 54
p.Arg1205His 12 ± 3b 1.40 ± 0.36a 38 ± 13a 10 ± 7b 73 ± 17a 193 ± 19d 6.42 ± 4.62 1028 ± 226
p.Arg1205His/
p. Arg924Gln
12 ± 0c 2.49 ± 0.01c 73 ± 0d 19 ± 1d 153 ± 4 163 ± 5 8.88 ± 1.68 1545 ± 183
p.Arg1308Cys-1 23 ± 2 3.12 ± 0.20 105 ± 9 27 ± 8 203 ± 15 154 ± 5 5.69 ± 1.46 1219 ± 254
p.Arg1308Cys-2 13 ± 2c 2.31 ± 0.20a 63 ± 6c 9 ± 2b 150 ± 9 153 ± 4 6.28 ± 2.57 1199 ± 444
p.Val1316Met 30 ± 0 3.03 ± 0.04 53 ± 11 15 ± 1 100 ± 21 181 ± 6 4.77 ± 0.76 871 ± 65
p.Pro1337Leu 30 ± 6 4.61 ± 0.46a 218 ± 35a 82 ± 23a 399 ± 76a 117 ± 13a 2.63 ± 0.51d 797 ± 73d
p.Tyr1584Cys 29 ± 4 4.05 ± 0.09a 157 ± 2a 48 ± 3 327 ± 17a 128 ± 8b 4.89 ± 0.50 1223 ± 105
p.Arg2535*/ 
unknown1
28 ± 5 3.63 ± 0.11d 134 ± 7d 53 ± 2d 232 ± 12 157 ± 5 4.10 ± 0.32 908 ± 75
p.Cys2693Tyr 16 ± 2c 2.20 ± 0.26a 60 ± 9b 16 ± 2c 120 ± 17c 185 ± 11 10.65 ± 3.08c 1528 ± 344d
† All data indicate mean ± SD. 1 BOEC from a compound heterozygous type 3 patient for whom the mutation on the second allele is unknown. a p<0.0001, 
b p<0.001, c p<0.01, d p<0.05 compared with controls.
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Discussion
Characterisation of the angiogenic capacity of BOECs from VWD patients is still lim-
ited and potential differences in angiogenic capacity between the different types of 
VWD have not been investigated in detail. In this study we aimed to further explore 
the potential pathogenic role of VWF mutations in regulating angiogenesis by study-
ing BOECs. We isolated BOECs from healthy individuals, a carrier and patients with 
type 1, 2 and 3 VWD and characterized their angiogenic capacity by cell migration 
and Matrigel assays. Taken all patients together, we did not observe a difference in 
in vitro angiogenesis between BOECs from VWD patients and BOECs from healthy do-
nors with regards to migration velocities or tube formation. Several BOECs showed 
decreased angiogenic potential (less tube formation and slower migration velocity) 




Figure 5. Capillary formation of BOECs from control and VWD patients at different passage numbers. 
BOECs from healthy control and VWD patients were seeded on Matrigel coated wells and images were taken 
after 24hours. Upper pictures are representative results of tube formation in BOECs from healthy control at 
passage number 5, 13 and 15. Middle pictures are capillary formation of BOECs from a patient with the p.Pro-
1337Leu mutation at passage numbers 2, 5 and 8. Lower pictures are from BOECs derived from the type 3 VWD 
patient compound heterozygous for the p.Arg2535* mutation at passage numbers 2, 4 and 5. White scale bar 
indicates 200 µm.  
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p.Pro1337Leu mutation and the type 3 VWD patient had significantly increased mi-
gration velocity and increased tube formation compared with control BOECs (for a 
summary see Table 4). Although not statistically significant, type 2 VWD BOECs and 
the type3 VWD BOEC had higher angiogenic capacity than BOECs isolated from type 
1 VWD patients. The directionality of BOECs from VWD patients overall was signif-
icantly impaired compared with healthy controls. Only 2 VWD patients had normal 
directional migration. Interestingly, the potential to induce tube formation was de-
clining in BOECs from VWD patients over subsequent cell passages, and especially the 
type 3 VWD BOEC clone lost its ability to form capillary-like structures in vitro at an 
early passage number.
Knockdown of VWF with siRNA in HUVECS led to a loss of directional migration in 
the study of Starke et al. [16] BOECs from our type 3 VWD patient, which did not ex-
press any detectable VWF, did not have impaired directional migration. However, we 
do observe loss of directionality in most of the other BOECs from our VWD patients 
compared with BOECs from healthy individuals. Only 2 out of 11 patients had normal 
directionality. Starke et al. [16] unfortunately did not report on the directionality of the 
BOECs they isolated from their VWD patients, so we cannot compare results between 
BOECs. In our wound-healing assay BOECs from VWD patients did not migrate faster 
than BOECs from healthy controls. This is in contrast to the reported data from Starke 
et al. [16], which showed increased migration compared with healthy controls. How-
ever, they also showed that BOECs from VWD patients had increased proliferation. We 
added actinomycin D to the medium in our wound-healing assay to inhibit prolifera-
tion of the BOECs, without inducing apoptosis of the cells. The increased proliferative 
and migratory effects seen by Starke et al, suggests that the results observed in their 
study were most likely related to alterations of the proliferative rather than migrato-
ry phenotype. Furthermore, BOECs from their VWD patients showed increased total 




Table 4. Summary of angiogenic characteristics of BOECs harbouring VWF mutations.
BOEC Cell front velocity† Individual cell velocity Directionality Tube formation
2A-1 (Unknown) ↓↓ = ↓ =
Carrier of p.Arg854Gln = = ↓ =
p.Arg1205His = = ↓ ↓↓
p.Arg1205His/p.Arg924Gln = = ↓ ↓
p.Arg1308Cys-1 = = ↓ =
p.Arg1308Cys-2 = = ↓ ↓
p.Val1316Met ↓↓ = ↓ =
p.Pro1337Leu ↑↑ ↑ = ↑↑
p.Tyr1584Cys = = ↓ ↑
p.Arg2535*/ unknown1 ↑ ↑ = ↑
p.Cys2693Tyr ↓↓ = ↓ ↑
† Based on Tables 2 and 3, = is comparable, ↓ is mild decrease, ↓↓ is severely decrease, ↑ is mild increase and ↑↑ is substantially increase 
compared with healthy control BOECs. 1 BOEC from a compound heterozygous type 3 patient for whom the mutation on the second allele is 
unknown.
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total tube formation in BOECs from VWD patients in general, although some patients 
had significantly increased tube formation. This discrepancy between their results 
and our data could reflect individual differences between the chosen healthy donors 
and/or the included VWD patients. The variation in their assays in both their control 
and VWD group is large, and while we do see a large variation between our VWD pa-
tients, the variation among our healthy controls is small.
While the VWF production in BOECs is stable for at least 10 passages in culture[14], 
the ability of BOECs to form tubular structures on Matrigel was declining earlier in 
patients with VWD. This reduced angiogenic response is most likely not the result of 
potentially progressive decrease in VWF production, since the reduced angiogenic re-
sponse was already noticeable around passage 7-8. Furthermore, BOECs from the type 
3 VWD patient were capable of forming numerous tubes on Matrigel at early passages 
when VWF was already absent. The reduced capacity of forming capillary-like struc-
tures might be attributable to decreased expression of other angiogenic proteins like 
VE-Cadherin, VEGF, Galectin-3 or αvβ3 [19-22]. The tube formation assay covers sev-
eral processes involved in angiogenesis such as adhesion, migration, protease activity 
and tube formation. The migratory ability of the BOECs did not decline as fast as the 
tube formation, and this suggests that the impaired tube formation is attributable to 
other processes beyond the migratory response.  
Although we could not observe a significant difference between type 1 and 2 VWD pa-
tients, our data suggests that BOECs from type 1 VWD patients have lower angiogenic 
capacity than BOECs from type 2 and 3 VWD patients. The angiogenic capacity varied 
significantly between VWD patients, although variation within the same patient in 
independently performed assays was small. Variability may be overcome by isolating 
BOECs from a larger number of patients and controls. This might be a solution when 
investigating differences between the different VWD types in general. However, for 
investigating effects of specific VWF mutations this will not be feasible, as the number 
of patients carrying a specific mutation is generally limited.
We succeeded in isolating BOECs from a type 3 VWD patient, and BOECs obtained 
from this patient showed enhanced angiogenic capacity. Interestingly, we could not 
detect cellular presence of VWF, and P-selectin staining was faint and diffuse, indi-
cating lack of WPB formation. This is in line with previous data obtained from BOECs 
isolated from type 3 VWD dogs [23]. Our study included only one type 3 VWD patient, 
and BOECs from more type 3 VWD patients should be isolated to substantiate the ob-
served increased angiogenic capacity. Unfortunately, several attempts to establish 
BOECs from another type 3 VWD patient were unsuccessful. To date success in isolat-
ing BOECs from patients with type 3 VWD is limited, but published data shows that 
there is variation in the cellular VWF presence in BOECs isolated from the several type 
3 VWD patients [24,25]. While BOECs from our patient showed a complete absence 
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staining of VWF in type 3 VWD BOECs inside and outside the endoplasmic reticulum 
[24,25]. The presence of diffuse VWF in some type 3 VWD BOECs may influence the 
angiogenic capacity of those BOECs and it would be interesting to study angiogenesis 
in BOECs from type 3 VWD patients with different VWF genotypes and phenotypes.
In conclusion, we did not observe an increased angiogenic potential in BOECs from 
VWD patients compared with healthy controls, but individual patients showed both 
increased and decreased angiogenic potential. BOECs from VWD patients provide an 
easily accessible model to investigate the pathogenic role of VWF in regulating angi-
ogenesis in VWD. However, the loss in angiogenic phenotype at later passages should 
be taken into account when performing angiogenesis assays with BOECs from VWD 
patients.
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Introduction
Almost 90 years ago, the first case of what is now known as von Willebrand disease 
(VWD), was published in a Finish scientific journal [1,2]. Prof. dr. Erik von Willebrand 
described in this journal his first case of an inheritable bleeding disorder. Almost 30 
years later, Nilsson and co-workers concluded that the impaired clot formation was 
due to the lack of a plasma factor, the von Willebrand factor (VWF)[3,4]. VWF is best 
known for its three classical hemostatic functions: (i) as a carrier protein for coagu-
lation factor VIII, (ii) binding to exposed collagen upon vascular damage and (iii) as 
a mediator of the recruitment of platelets to sites of vascular injury [5]. However, in 
recent years it has become clear that VWF has a versatile function beyond hemosta-
sis, and has been implicated in several pathophysiological processes, such as tumor 
metastasis, angiogenesis, cell proliferation and inflammatory processes [6]. So, apart 
from its evident role in hemostasis, it has recently become clear that VWF is a much 
more complex multifaceted protein then initially thought. Several aspects – from syn-
thesis, secretion and clearance, to functions in the circulation – of this protein have 
been studied and the results are described in this thesis. 
Part 1: Aspects of synthesis and secretion of VWF
VWD is the most common inherited bleeding disorder and is characterized by reduced 
plasma VWF levels or functionally abnormal VWF [7,8]. VWD is divided into three 
groups based on the type of defect. Type 1 VWD is characterized by a partial quan-
titative loss of VWF, while type 3 VWD corresponds to a virtually complete loss of 
VWF. Type 2 VWD is encompasses all qualitative dysfunctions of VWF and is sub-
divided into 4 subtypes: 2A, 2B, 2M and 2N. Low plasma levels in VWD patients are 
the result of mutations in the VWF gene that lead to decreased synthesis, impaired 
secretion, increased clearance or a combination thereof. However, in approximately 
30 to 40 % of the index cases no (causative) mutations were found [9-11], suggesting 
that other factors outside the VWF gene can determine VWF plasma levels. In Chapter 
2 we gave an overview of factors that can influence VWF plasma levels. Factors such 
as ABO blood group [12], platelet α2β1 polymorphisms [13], age [12,14], and hormonal 
alterations [15,16] have major influences on VWF plasma levels and/or the bleeding 
phenotype of patients. This illustrates that VWD is a complex multifactorial disease, 
with inter-relating genetic and environmental components contributing to the var-
iable phenotype of the disease. So despite the growing understanding of the patho-
physiology of VWD, the diagnosis is often still difficult because of the many factors 
influencing VWF levels. 
The VWF molecule contains a large number of cysteine residues which all form either 
intrachain or interchain disulfide bonds. Intrachain disulfide bonds are important for 
the VWF monomer structure, while interchain disulfide bonds are essential for the 
formation of the high molecular weight multimers (HMW)[17]. Cysteine mutations 
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via www.vwf.group.shef.ac.uk). Most cysteine mutations lead to a loss of intrachain 
disulfide bonds and are associated with low VWF plasma levels. Interestingly, the 5 
identified cysteine mutations that are involved in interchain disulfide bonds (p.Cy-
s1099Tyr, p.Cys2771Ser/Tyr and p.Cys2773Arg/Ser) are associated with normal VWF 
plasma levels. These distinct effects of the two types of cysteine mutations made us 
hypothesize that impaired intrachain or interchain disulfide bond formation in VWF 
may have different effects on the biogenesis of Weibel-Palade bodies (WPB), the en-
dothelial cell-specific storage organelles for VWF. By analyzing formation of pseu-
do-WPB upon expression of VWF variants with disrupted intrachain (p.Cys1130Phe 
and p.Cys2671Tyr) or interchain (p.Cys2773Ser) disulfide bond formation in Chapter 
3, we concluded that natural mutations of cysteines involved in the formation of inter-
chain disulfide bonds do not affect the storage in WPB and secretion of VWF, whereas 
mutations of cysteines forming intrachain disulfide bonds will lead to reduced VWF 
storage and secretion due to endoplasmic reticulum retention.
Some type 1 VWD patients are known to have a reduced response to DDAVP treat-
ment [18]. Interestingly, most of the VWF mutations identified in those patients with 
reduced response were located within the A1-A3 domains. As the DDAVP-induced in-
crease in plasma VWF is due to exocytosis of WPB, the formation of WPB in those 
patients might be impaired by VWF mutations. However, expression studies of var-
iants located in the A domains of VWF are limited. We therefore characterized in 
Chapter 4 the biosynthesis of six VWF mutations, located in the VWF A1-A3 domains, 
which were found in families diagnosed with VWD. We found that all mutants, except 
the p.Arg1583Trp, showed impaired formation of pseudo-WPB when transfected in 
HEK293 cell. In addition, two mutations (p.Leu1307Pro and p.Val1822Gly) also showed 
reduced numbers of pseudo-WPB and increased endoplasmic reticulum retention. 
Regulated secretion upon stimulation of transfected cells reproduced the in vivo sit-
uation, indicating that HEK293 cells expressing VWF variants found in patients with 
VWD can be used to properly assess defects in regulated secretion. The effects of the 
mutations p.Ser1285Pro, p.Leu1307Pro and p.Tyr1584Cys on WPB formation and regu-
lated secretion as seen in transfection experiments with HEK293 cells were confirmed 
in the Blood Outgrowth Endothelial Cells (BOECs) derived from the corresponding pa-
tients [19].
Part 2: Aspects of clearance of VWF
As mentioned in Chapter 2, one of the major determinants of VWF plasma levels are 
the ABO blood groups. VWF is one of the few plasma proteins that is decorated with 
ABO blood group sugars. Those ABH antigens are attached to the N-linked oligosac-
charide chains of VWF [20]. Individuals with blood group O have approximately 25% 
lower VWF plasma levels compared to non-O individuals [21]. Individuals with the 
Bombay blood group phenotype, who lack expression of the ABH antigens, even have 
lower plasma levels than individuals with blood group O [22]. The exact mechanism 
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although effects on clearance have been postulated [23]. We therefore examined in 
Chapter 5 whether clearance of VWF depends on the ABH antigens present on the 
VWF molecule. By purifying human VWF from blood group A, B and O donors, we 
were able to study the clearance of VWF containing the different blood groups in VWF 
deficient mice. However, we observed no difference in clearance rate between A, B or 
O human plasma-derived VWF. In our human model, we infused three type 3 VWD 
patients with a VWF concentrate (Haemate-P®). Haemate-P® contains VWF from do-
nors with all blood groups, which allowed us to study the clearance of A-VWF, B-VWF 
and O-VWF simultaneously in one individual. Faster clearance of O-VWF present in 
infused type 3 VWD patients would result in a relative increase in the loading of VWF 
with A and B antigens over time. Interestingly, we found that the loading of VWF with 
A,B and H antigens decreased 2-fold during clearance of VWF in 2 out of 3 patients, in 
the third patient the loading remained the same. Those changes in ABH antigen load-
ing of VWF were confirmed by Western blot. Based on the results from our mouse- 
and human model we concluded that there is no direct effect of ABH blood group anti-
gens on VWF in VWF clearance. We demonstrated that in a direct comparison within 
one individual O-VWF is not cleared faster compared to A- or B-VWF. Preliminary 
results on the pharmacokinetic data of type 3 VWD patients with blood group O and 
non-O that were infused with Haemate-P®, seems to substantiate our new hypothesis 
that it is the blood group O status of the individual himself that determines the faster 
clearance of the VWF molecule, and that this is independent of the ABO blood group 
antigens on VWF. 
Faster clearance of the VWF protein is one of the mechanisms leading to decreased 
VWF plasma levels and subsequently bleeding phenotypes. Mature VWF and VWF 
propeptide (VWFpp) are released in equimolar amounts in the circulation, but the 
half-lives differ. The ratio between these two parameters can therefore be used to dis-
criminate between normal and accelerated VWF clearance. While VWFpp and VWF 
are cleared differentially, FVIII is in complex with VWF and therefore their half-lives 
are related. The ratio between FVIII coagulant activity (FVIII:C) and VWF:Ag (FVIII:C/
VWF:Ag) can be used to identify defects in VWF synthesis. The FVIII:C/VWF:Ag is in-
creased when VWF synthesis is reduced but the ratio remains 1 when VWF is cleared 
faster [24]. Opposing results are obtained for VWFpp/VWF:Ag, which will remain un-
changed with reduced synthesis, but will increase with reduced half-life of VWF. Us-
ing the VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios, we have investigated in Chapter 
6 the pathophysiological mechanisms involved in type 1, 2 and 3 VWD in patients in-
cluded in the Willebrand in the Netherlands (WiN) cohort [25]. We found that in type 
1 VWD both reduced synthesis (increased FVIII:C/VWF:Ag) and accelerated clearance 
(increased VWFpp/VWF:Ag) contribute to the pathophysiological phenotype in these 
patients. This is in line with previously published data in a large European cohort of 
type 1 VWD patients [24]. Interestingly, in type 2B patients increased clearance was 
frequently observed, probably because type 2B VWF spontaneously binds to platelets 
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to lower VWF:Ag levels but normal VWFpp levels. Another, unexpected, finding was 
the measurable level of VWFpp in a large group of type 3 VWD patients, while their 
VWF:Ag level was below the Type 3 VWD criteria of 5 IU/dL. The measurable amount 
of VWFpp indicates that these patients do synthesize VWF, but the mature VWF is 
probably cleared so fast that the VWF:Ag level remains very low. Indeed in most of 
these patients mutations were found that are known to cause accelerated clearance 
such as the p.Arg1205His and p.Ser1285Pro mutations [26]. For the clinical therapy 
of these patients this will not be of that much importance, since patients will receive 
the same VWF concentrates, but it might be important for genetic counseling and as 
a diagnostic tool the VWFpp can discriminate between ‘true’ type 3 VWD and Type 1 
VWD in which the VWF is cleared very fast. 
Part 3: Aspects of VWF beyond hemostasis
Besides playing an important role in hemostasis, VWF also seems to be a negative reg-
ulator of angiogenesis [27], the formation of new blood vessels from preexisting ones. 
VWF is stored in WPBs in endothelial cells. But besides VWF, also other proteins are 
stored in the WPB. Several of these proteins are known to be involved in angiogenesis, 
like angiopoietin-2 (Ang-2), galectin-3 (Gal-3) and osteoprotegerin (OPG). Since VWF 
is essential for the formation of WPBs, these factors rely on VWF for their storage in 
the WPB and secretion into the circulation. We therefore speculated in Chapter 7 that 
disturbed WPB formation and/or exocytosis due to VWF mutations, would lead to a 
dysregulated secretion of angiogenic mediators. Using the WiN cohort (see Chapter 
6) plasma samples of types 1, 2 and 3 VWD patients were analyzed for their angiopoie-
tin-1 (Ang-1), Ang-2, Gal-3, OPG and vascular endothelial growth factor (VEGF) levels. 
Compared with controls, VWD patients had higher Ang-1 and VEGF levels and lower 
Ang-2 levels. Type 1 and 2 patients had lower Ang-2 levels compared with controls, 
while type 3 VWD patients had higher OPG levels compared with controls. VEGF levels 
were strongly dependent upon VWF levels in plasma, and were the highest in patients 
with type 3 VWD. Patients with VWD have thus various disturbances in angiogenic 
markers in plasma. However, defects in VWF, leading to impaired or absent formation 
of WPB in VWD patients, do not consistently lead to dysregulated release of other 
WPB components. The variations in angiogenic mediators may contribute to the de-
velopment of vascular malformations, such as angiodysplasia that can occur in VWD.
From the literature it was shown that endothelial VWF regulates in vitro angiogenesis 
[27]. BOECs isolated from type 1 and 2 VWD patients showed enhanced angiogenesis 
compared with BOECs isolated from healthy individuals. Whether this also holds for 
type 3 VWD BOECs is unknown, since successful isolation has been reported to a lim-
ited extent. Characterization of the angiogenic capacity of BOECs from VWD patients 
is still limited and differences between the different types of VWD have not been in-
vestigated in detail. We therefore examined in Chapter 8 the angiogenic capacity of 
BOECs from patients diagnosed with type 1 (n=4), type 2 (n=6) and type 3 (n=1) VWD 




Proefschrift_Binnenwerk_Dafna_Groeneveld_final.indd   164 8/13/15   11:33 AM
209658-L-bw-Groeneveld
the pathogenic role of VWF mutations in regulating angiogenesis. Considering all 11 
VWD patients, migration velocity and total tube formation was similar between VWD 
patients and controls. However, BOECs from the type 3 VWD patient and one type 2B 
patient showed enhanced angiogenic capacity. Directional migration was impaired in 
9 out of 11 VWD patients. We also observed that the angiogenic response of BOECs 
from VWD patients was limited to early passage numbers. While BOECs from VWD 
patients can be a useful tool for ex vivo assessment of endothelial cell function in pa-
tients with different types of VWD, limitations (such as earlier loss of angiogenic ca-
pacity) should be taken into account when studying BOECs from VWD patients.
Future perspectives
In recent years it has become evident that VWF is much more than just a coagula-
tion factor which supports platelet adhesion and protecting coagulation factor VIII 
from premature clearance, and has been implicated in multiple pathological process-
es ranging from inflammatory diseases to cancer. The studies presented in this thesis 
explored several aspects of VWF from synthesis, secretion and clearance of the pro-
tein to functions beyond hemostasis.
Although the general assumption is that VWF plasma levels in individuals with blood 
group O is lower as a result of enhanced clearance of the protein, our data described 
in Chapter 5 suggest that this is not entirely true. Our hypothesis that the blood group 
O individuals clear the VWF protein faster but that this is independent of the blood 
group antigens on VWF, is substantiated by preliminary results obtained from phar-
macokinetic data of VWF concentrate infused in VWD patients. Faster clearance of 
the VWF protein in blood group O individuals suggests that their clearance mecha-
nism might be different than in individuals with blood group A, B or AB. One of the 
limitations in our study was the fact that all three VWD patients had blood group O. 
We cannot exclude the possibility that endogenous antibodies against A and B anti-
gens interacted with the A and B antigens on VWF. Studies on infusions with recombi-
nant VWF products, which are now used in clinical trials [28], in type 3 VWD patients 
with different blood groups should be carried out to exclude the possible interaction 
of naturally occurring Anti-A and Anti-B antibodies present in the circulation of indi-
viduals with antigens present on VWF. Experiments regarding uptake and endocyto-
sis of VWF by macrophages or other cells involved in VWF clearance isolated from dif-
ferent blood group donors might give more insight whether VWF is more efficiently 
cleared by macrophages from blood group O donors than non-O donors. Those studies 
will advance our knowledge about the mechanism(s) of VWF clearance, which might 
lead to a more personalized treatment of VWD patients in the future.
VWF has been described as a ‘molecular bus’, carrying other proteins in the circula-
tion.  Besides FVIII also other ligands have been shown to be associated with VWF in-
cluding but not limited to ADAMTS-13, P-selectin, insulin-like growth factor binding 
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the WPB components galectin-3, angiopoietin-2 and osteoprotegerin, the function-
al consequences of their binding to VWF have been investigated to a limited extent, 
if at all. Being in complex with VWF may prevent the interaction with their natural 
ligand via sterical hindrance, as is the case for FVIII.  However, knowledge is scarce 
on this issue, and it would be interesting to investigate the shared functional effects 
between VWF and its binding partners. Since endothelial cells contain several other 
VWF-binding proteins with pro- and anti-angiogenic properties that we did not study 
in Chapter 7, such as galectin-1, connective tissue growth factor and insulin-like 
growth factor binding protein-7, it is likely that VWF plays an exceedingly complex 
role in regulating angiogenesis at different levels. It remains to be determined wheth-
er the effect of VWF on angiogenesis is qualitative or quantitative, but it seems likely 
that its role is somehow linked to angiodysplasia seen in a subset of VWF patients. 
Angiodysplasia may result from vascular malformations resulting from the dysreg-
ulated release in VWD patients. Patients with VWD demonstrated elevated levels of 
VEGF and high levels of VEGF can lead to the formation of fragile capillaries, with dis-
rupted structure reminiscent of angiodysplasia. The elevated VEGF and Ang-1 levels, 
may therefore contribute to vascular complications such as angiodysplasia that occur 
frequently in VWD patients. Angiodysplasia is most frequently observed in patients 
lacking the high molecular weight (HMW) VWF multimers (types 2A, 2B and 3), but 
so far no evidence has been described for a specific role of HMWM in the cellular mod-
els of angiogenesis. However, extracellular pathways have been identified by which 
VWF controls angiogenesis, and thus it is possible that HMW multimers may affect 
the interaction of VWF with endothelial cells. In Chapter 8 we characterized the an-
giogenic capacity of BOECs isolated from VWD patients, including type 2 and 3 VWD. 
Although our group of patients was small, our results suggests that BOECs from type 
2 VWD patients and the type 3 patient have enhanced angiogenic capacity compared 
with BOECs from type 1 VWD patients. Future studies will be required to determine 
the exact role of VWF multimers in angiogenesis. Three-dimensional microvessel 
systems have been developed to study angiogenesis in vitro. The recent development 
of microfluidic vascular networks, allows us to study many aspects of microvascular 
function [29,30]. Seeding BOECs, isolated from VWD patients, into these synthetic 
vessels would permit us to study the angiogenic response of endothelium of a VWD 
patient and the role of (functionally) defective VWF in regulating angiogenesis in dif-
ferent types of VWD in much more detail.  Furthermore, BOECs can for example be 
seeded into these microvessels with and without perivascular cells to investigate local 
interactions with these cells, which is an important step in angiogenesis. In-depth 
characterization of the molecular pathways through which VWF regulates angiogen-
esis will provide novel therapeutic targets for the treatment of angiodysplastic gas-
trointestinal bleedings in VWD patients where VWF concentrates are not sufficient. 
Since the discovery of VWF, significant progress has been made in our fundamental 
knowledge of both the disease and the protein. But it appears that we only have seen 
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protein. Even its classic role in hemostasis is not completely understood. Therapeu-
tic inhibitors of VWF-mediated platelet adhesion and activation may inhibit the pro-
gression of inflammatory diseases like atherosclerosis, hepatosteatosis and ischemic 
stroke. With regard to the non-hemostasic functions of VWF, many opportunities also 
remain to be explored. The combination of data obtained from both clinical and fun-
damental research on VWF will no doubt contribute in increasing our knowledge of 
this versatile protein and VWF-related research has a bright future ahead. The studies 
described in this thesis and the suggested future research will advance our knowledge 
about the biogenesis of VWF and its functions beyond hemostasis. This knowledge 
might eventually lead to a personalized treatment for VWD and its complications in 
the future. Back in 1926, Dr. von Willebrand certainly did not fully grasp what great 
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Introductie
Bijna 90 jaar geleden werd de eerste casus van wat nu bekend staat als ziekte van 
von Willebrand (VWD) gepubliceerd in een Fins wetenschappelijk tijdschrift [1,2]. 
Prof. dr. Erik von Willebrand beschreef in dit tijdschrift zijn eerste casus van een er-
felijke bloedingsziekte. Ongeveer 30 jaar later concludeerden Nilsson en collega’s dat 
de verminderde stolselvorming ontstond door het ontbreken van een plasma factor; 
de von Willebrand factor (VWF)[3,4]. VWF is het best bekend voor wat betreft zijn 
drie klassieke hemostatische functies: (i) als dragereiwit voor stollingsfactor VIII, (ii) 
binding aan blootgesteld collageen bij vasculaire schade en (iii) als mediator bij het 
aantrekken van bloedplaatjes naar plekken van vasculaire schade [5]. De afgelopen 
jaren is duidelijk geworden dat VWF een veelzijdig eiwit is dat behalve bij hemostase, 
ook betrokken is bij verscheidene pathofysiologische processen, zoals tumormetas-
tase, angiogenese, cel proliferatie en ontstekingsprocessen [6]. Dus, afgezien van de 
duidelijke rol in hemostase, is recent duidelijk geworden dat VWF een veel complexer 
en veelzijdiger eiwit is dan aanvankelijk gedacht werd. Verschillende aspecten - van 
synthese, secretie en klaring tot functies in de circulatie - van dit eiwit zijn bestudeerd 
en de resultaten zijn in dit proefschrift opgeschreven.
Deel 1: Synthese en secretie aspecten van VWF
VWD is de meest voorkomende erfelijke bloedingsziekte en wordt gekenmerkt door 
verlaagde plasma VWF niveaus of functioneel abnormale VWF [7,8]. VWD is onderver-
deeld in drie groepen op basis van het type defect. Type 1 VWD wordt gekenmerkt 
door een gedeeltelijk kwantitatieve afname van VWF, terwijl type 3 VWD gekenmerkt 
wordt met een (bijna) volledige afwezigheid van VWF. Type 2 VWD omvat alle kwal-
itatieve disfuncties van VWF en is onderverdeeld in 4 subtypen: 2A, 2B, 2M en 2N. 
Lage plasmaspiegels bij patiënten met VWD zijn het gevolg van mutaties in het VWF 
gen die leiden tot verminderde synthese, verminderde secretie, verhoogde klaring of 
een combinatie daarvan. In ongeveer 30 tot 40% van de indexpatiënten wordt geen 
(oorzakelijke) mutatie gevonden [9-11], wat suggereert dat andere factoren buiten het 
VWF gen de plasmaspiegels kunnen bepalen. In hoofdstuk 2 geven we een overzicht 
van de factoren die VWF plasmaspiegels kunnen beïnvloeden. Factoren zoals ABO 
bloedgroep [12], bloedplaatjes α2β1 polymorfisme [13], leeftijd [12,14], en hormonale 
veranderingen [15,16] hebben grote invloed op VWF plasmaspiegels en / of bloed-
ingsfenotype van de patiënten. Dit illustreert dat VWD een complexe multifactoriële 
ziekte is waar genetische- en omgevingsfactoren bijdragen aan het variabele fenotype 
van de ziekte. Dus ondanks het groeiende inzicht in de pathofysiologie van VWD, is 
de diagnose vaak nog moeilijk vanwege de vele factoren die van invloed zijn op VWF 
plasmaspiegels.
Het VWF molecuul bevat een groot aantal cysteïneresiduen die ofwel intramoleculaire 
of intermoleculaire disulfidebruggen vormen. Intramoleculaire disulfidebruggen zijn 
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gen essentieel zijn voor de vorming van de hoogmoleculaire multimeren (HMW)[17]. 
Cysteïne mutaties in VWF zijn vaak geïdentificeerd in patiënten met VWD (VWF da-
tabank, te raadplegen via www.vwf.group.shef.ac.uk). Het merendeel van de cysteïne 
mutaties leidt tot een verlies van intramoleculaire disulfidebruggen en zijn geasso-
cieerd met lage VWF plasmaspiegels. Opvallend is dat de 5 geïdentificeerde cysteïne 
mutaties die betrokken zijn bij intermoleculaire disulfidebruggen (p.Cys1099Tyr. 
p.Cys2771Ser/Tyr and p.Cys2773Arg/Ser) zijn geassocieerd met normale VWF plas-
maspiegels. Deze verschillende effecten van de twee soorten cysteïne mutaties deed 
ons veronderstellen dat een verminderde intramoleculaire of intermoleculaire di-
sulfidebrugvorming in VWF verschillende effecten op de biogenese van Weibel-Pal-
ade bodies (WPB), de endotheel specifieke opslagorganellen voor VWF, kan hebben. 
Door het analyseren van de vorming van pseudo-WPB door expressie van VWF var-
ianten met verstoorde intramoleculaire (p.Cys1130Phe en p.Cys2671Tyr) of intermo-
leculaire (p.Cys2773Ser) disulfidebruggen in hoofdstuk 3, hebben we geconcludeerd 
dat natuurlijke mutaties van cysteïnen, betrokken bij de vorming van interchain di-
sulfidebruggen de opslag in WPB en secretie van VWF niet beïnvloeden, terwijl mu-
taties van cysteïnen die de intramoleculaire disulfidebruggen verstoren tot vermind-
erde opslag en secretie VWF leiden door retentie in het endoplasmatisch reticulum.
Het is bekend dat sommige patiënten met VWD type 1 een verminderde respons op 
DDAVP behandeling laten zien [18]. Interessant is dat de VWF mutaties die in deze 
patiënten zijn geïdentificeerd allen binnen de A1-A3 domeinen van VWF liggen. 
Aangezien de DDAVP geïnduceerde toename van plasma VWF door exocytose van 
WPB komt, kan de vorming van WPB bij deze patiënten zijn aangetast door de mu-
taties. Expressie studies met varianten in de A-domeinen van VWF zijn beperkt. 
Daarom hebben we in hoofdstuk 4 de biosynthese van zes VWF mutaties in de VWF 
A1-A3 domeinen gekarakteriseerd, die zijn gevonden in families die gediagnosticeerd 
zijn met VWD. We vonden dat alle mutanten, behalve de p.Arg1583Trp, een vermin-
derde vorming van pseudo–WPB vertoonden. Bovendien vertoonden 2 mutanten (p.
Leu1307Pro en p.Val1822Gly) ook een verminderd aantal pseudo-WPB en verhoogde 
retentie in het endoplasmatisch reticulum. Gereguleerde secretie van VWF na stimu-
latie van getransfecteerde HEK293 cellen reproduceert de in vivo situatie. Dit geeft aan 
dat het systeem met HEK293 cellen die VWF varianten tot expressie brengen die zijn 
gevonden in patiënten met VWD, goed kan worden gebruikt om defecten in geregu-
leerde secretie te bestuderen. De effecten die we zagen van de mutanten p.Ser1285Pro 
, p.Leu1307Pro en p.Tyr1584Cys op pseudo-WPB vorming en gereguleerde VWF se-
cretie met HEK293 cellen werden bevestigd in de endotheelcellen (Blood Outgrowth 
Endothelial Cells) van de overeenkomstige patiënten [19].
Deel 2: Aspecten van VWF klaring 
Zoals vermeld in hoofdstuk 2, zijn de ABO bloedgroepen één van de belangrijkste 
determinanten van VWF plasmaspiegels. VWF is een van de weinige plasmaeiwitten 
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N-gekoppelde oligosacharide ketens van VWF. Individuen met bloedgroep O hebben 
ongeveer 25% lagere VWF plasma niveaus in vergelijking met non-O individuen [21]. 
Personen met het Bombay bloedgroep fenotype, die geen ABH antigenen hebben, heb-
ben zelfs lagere plasmaspiegels dan mensen met bloedgroep O [22]. Het exacte mech-
anisme achter de relatie tussen ABO bloedgroep en VWF niveau is onbekend, hoew-
el effecten op de klaring worden vermoed [23]. Daarom hebben we in hoofdstuk 5 
onderzocht of klaring van VWF afhankelijk is van de ABH antigenen aanwezig op het 
VWF molecuul. Door het zuiveren van humaan VWF van bloedgroep A, B en O donor-
en, waren we in staat om de klaring van VWF met de verschillende bloedgroepen in 
VWF deficiënte muizen te bestuderen. We zagen echter geen verschil in klaring tus-
sen A, B of O humaan plasma-gezuiverd VWF. In ons humane model, hebben we drie 
type 3 VWD patiënten een VWF concentraat (Haemate-P®) intraveneus toegediend. 
Haemate-P® bevat VWF van donoren met alle bloedgroepen, wat ons in staat stelde 
om A-VWF, B-VWF en O-VWF gelijktijdig te bestuderen in één individu. Snellere klar-
ing van O-VWF aanwezig in de Type 3 VWD patiënten na infusie zou moeten leiden 
tot een relatieve toename van de belading van VWF met A- en B antigenen in de tijd. 
Opvallend genoeg vonden wij dat de belading van VWF met A en B antigenen vermin-
derde tijdens de klaring van VWF in 2 van de 3 patiënten en in de derde patiënt bleef 
de belading gelijk. De afname van A en B antigeen belading van VWF werd bevestigd 
door Western blot. Op basis van de resultaten van ons muis - en menselijke model zijn 
we tot de conclusie gekomen dat er geen direct effect is op de klaring van VWF van 
ABH bloedgroepantigenen op VWF. We hebben aangetoond dat in een directe vergeli-
jking binnen één individu O-VWF niet sneller geklaard wordt in vergelijking met A- of 
B-VWF. Preliminaire resultaten over de farmacokinetische gegevens van infusies van 
Haemate-P® bij bloedgroep O en non-O type 3 VWD patiënten, lijken onze nieuwe hy-
pothese te onderbouwen dat het de bloedgroep O status van het individu zelf is waar-
door het VWF molecuul sneller klaart, maar dat dit onafhankelijk is van de ABO bloed 
groep antigenen op VWF. 
Snellere klaring van VWF is een van de mechanismen die leiden tot lagere VWF plas-
maspiegels en vervolgens bloedingsfenotypes. VWF en VWF propeptide (VWFpp) 
worden uitgescheiden in equimolaire hoeveelheden in de circulatie, maar de half-
waardetijden verschillen. De ratio tussen deze twee parameters kan daarom gebruikt 
worden om onderscheid te maken tussen normale en versnelde klaring van VWF. 
Terwijl VWFpp en VWF differentieel worden geklaard, vormt stollingseiwit FVIII 
daarentegen een complex met VWF en dus zijn hun halfwaardetijden gerelateerd. 
De ratio tussen FVIII stollingsactiviteit (FVIII:C) en VWF:Ag (FVIII:C/VWF:Ag) kan 
gebruikt worden voor het identificeren van defecten in VWF synthese. De FVIII:C/
VWF:Ag is verhoogd wanneer VWF synthese verminderd is, maar de verhouding blijft 
1 wanneer VWF sneller wordt geklaard. Tegengestelde resultaten worden verkregen 
voor VWFpp/VWF:Ag, die met verminderde synthese ongewijzigd blijft, maar zal 
toenemen met verminderde halfwaardetijd van VWF [24]. Met behulp van de VW-
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zocht wat de pathofysiologische mechanismen zijn bij type 1, 2 en 3 VWD patiënten in 
de Willebrand in Nederland (WIN) cohort [25]. We vonden dat in type 1 VWD zowel 
verminderde aanmaak (verhoogde FVII:C/VWF:Ag) als versnelde klaring (verhoogde 
VWFpp/VWF:Ag) bijdragen aan het pathofysiologische fenotype bij deze patiënten. 
Dit is in lijn met eerder gepubliceerde data uit een grote Europese cohort van type 1 
patiënten [24]. Interessant is dat in de type 2B patiënten verhoogde klaring frequent 
werd waargenomen. Dit is waarschijnlijk te wijten aan het feit dat type 2B VWF spon-
taan bindt aan bloedplaatjes in de circulatie. Het VWF-bloedplaatjes complex wordt 
geklaard uit de circulatie, wat leidt tot lagere VWF:Ag levels maar normale VWFpp 
niveaus. Een andere, onverwachte, bevinding was het meetbare niveau van VWFpp in 
een grote groep van type 3 VWD patiënten, terwijl hun VWF:Ag onder het criterium 
van 5 IU/dL lag. De meetbare hoeveelheid VWFpp geeft aan dat deze patiënten wel 
degelijk VWF synthetiseren en uitscheiden, maar dat het VWF waarschijnlijk zo snel 
geklaard wordt dat het VWF:Ag niveau zeer laag blijft. Inderdaad vonden wij bij de 
meeste van deze patiënten mutaties die bekend zijn met versnelde klaring zoals de 
p.Arg1205His en p.Ser1285Pro mutaties [26]. Voor de klinische behandeling zal dit 
echter niet van zoveel belang zijn, aangezien patiënten allen VWF concentraat zullen 
krijgen indien nodig, maar voor genetische counseling kan het waardevol zijn en het 
VWFpp kan als diagnostisch hulpmiddel het onderscheid maken tussen ‘echte’ type 
3 VWD patiënten en type 1 VWD patiënten bij wie het VWF heel snel geklaard wordt.
Deel 3: Aspecten van VWF naast hemostase
Naast dat het een belangrijke rol in de hemostase speelt, lijkt VWF ook een negatieve 
regulator van (in vitro) angiogenese [27], de vorming van nieuwe bloedvaten uit reeds 
bestaande vaten. VWF is opgeslagen in WPBs in endotheelcellen. Maar naast VWF 
worden ook andere eiwitten opgeslagen in de WPB. Van meerdere van deze eiwitten 
is bekend dat ze betrokken zijn bij angiogenese, zoals angiopoietine-2 (Ang-2), ga-
lectin-3 (Gal-3) en osteoprotegerin (OPG). Omdat VWF essentieel is voor de vorming 
van WPBs, zijn deze factoren afhankelijk van VWF voor hun opslag in de WPB en de 
secretie in de circulatie. We speculeerden dan ook in hoofdstuk 7 dat verstoorde WPB 
formatie en/of exocytose door VWF mutaties, zou leiden tot een ontregelde secretie 
van andere angiogene mediatoren. Met behulp van het WiN cohort (zie hoofdstuk 
6) zijn 655 plasma monsters van type 1, 2 en 3 VWD patiënten geanalyseerd op hun 
angiopoietin-1 (Ang-1), Ang-2, Gal-3, OPG en vasculair endothelial growth factor 
(VEGF) niveaus. Vergeleken met controles, hebben patiënten hogere Ang-1 en VEGF 
concentraties. Type 1 en 2 patiënten hadden lagere Ang-2 niveaus, terwijl type 3 VWD 
patiënten hogere OPG concentraties hadden in vergelijking met controles. VEGF 
niveaus waren sterk afhankelijk van VWF plasmaspiegels, en waren het hoogst bij 
patiënten met type 3 VWD. Patiënten met VWD hebben dus diverse veranderingen 
in angiogene markers in het plasma. Mutaties in VWF, die leiden tot een verstoorde 
vorming van WPB, leiden echter niet consequent tot ontregelde secretie van andere 
WPB componenten. De variaties in angiogene mediatoren kunnen bijdragen aan de 
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Uit recent onderzoek is gebleken dat endotheel VWF in vitro angiogenese reguleert 
[27]. BOECs geïsoleerd uit bloed van type 1 en 2 VWD patiënten vertoonden verhoogde 
angiogenese in vergelijking met BOECs geïsoleerd van gezonde individuen. Of dit ook 
geldt voor type 3 VWD BOECs is onbekend, omdat succesvolle isolatie nog nauweli-
jks is gepubliceerd. Karakterisering van de angiogene capaciteit van BOECs van VWD 
patiënten is nog zeer beperkt en verschillen tussen de verschillende typen VWD zijn 
nog niet in detail onderzocht. Daarom hebben we in hoofdstuk 8 de angiogene ca-
paciteit van BOECs van patiënten met type 1 (n=4), type 2 (n=6) en type 3 (n=1) VWD 
onderzocht om verder te onderzoeken of BOECs als endotheelcel model te gebruiken 
zijn om zo de pathogene rol van VWF mutaties in het reguleren van angiogenese te 
bestuderen. De migratie snelheid en de totale tube formatie was vergelijkbaar tussen 
alle VWD patiënten en controles. Echter, BOECs van de type 3 VWD patiënt en één type 
2B VWD patiënt vertoonden meer angiogene capaciteit dan controle BOECs. De direc-
tionaliteit van de migratie was aangetast in 9 van de 11 VWD patiënten. Tevens zagen 
we dat de angiogene respons van BOECs van VWD patiënten beperkt was tot vroege 
passagenummers. Hoewel BOECs van VWD patiënten een nuttig instrument kunnen 
zijn voor ex vivo bepaling van endotheliale cel functie bij patiënten met verschillende 
typen VWD, dient er ook rekening gehouden te worden met beperkingen (zoals vroeg 
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